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ABSTRACT  
 
Chronic  myeloid  leukaemia  (CML)  is  a  clonal  myeloproliferative  disorder  of  the 
haemopoietic  stem  cell,  defined  by  the  Philadelphia  chromosome  (Ph)  -  the 
outcome  of  a  balanced,  reciprocal  translocation  between  the  long  arms  of 
chromosomes 9 and 22. The novel fusion oncogene generated on chromosome 
22 as a result of this translocation is called BCR-ABL. In the majority of patients, 
this oncogene transcribes a 210-kDa constitutively active protein tyrosine kinase, 
often referred to as p210
BCR-ABL, which is necessary for the transformation of the 
disease. The introduction of the orally available, tyrosine kinase inhibitor (TKI) - 
imatinib mesylate (IM) - marked a major advance in CML treatment in terms of 
efficacy and tolerability and has now become the first line of therapy. IM acts by 
competing  with  ATP  to  block  ABL-kinase  activity,  resulting  in  the  selective 
apoptosis induction of BCR-ABL
+ cells. However, despite the success of IM as 
standard therapy for CML, only a small proportion of patients obtain a complete 
molecular response, where they become negative for BCR-ABL transcripts by RT-
PCR.  It  is  hypothesised  that  this  minimal  residual  disease  is  the  result  of  a 
primitive quiescent subpopulation of leukaemic cells, which may be the cause for 
relapse  at  a  later  date.  Another  major  clinical  concern  is  the  observation  of 
molecular resistance in IM-treated patients. Proposed mechanisms of resistance 
include BCR-ABL amplification, decreased intracellular IM concentrations caused 
by drug efflux proteins such as multi drug resistance-1 and the development of 
point  mutations  within  the  ABL-kinase  domain.  In  an  attempt  to  overcome  IM-
resistance,  a  second  generation  of  BCR-ABL  inhibitors  has  been  developed. 
Dasatinib  (BMS-354825,  Sprycel)  is  a  TKI  developed  for  the  treatment  of  IM-
resistant or -intolerant patients with Ph
+ leukaemias, which has a 325-fold greater 
potency  than  IM  against  cells  expressing  wild-type  BCR-ABL,  and  is  effective   3 
against all IM-resistant BCR-ABL mutants tested in vitro, except T315I. Previously, 
we showed that dasatinib induced durable inhibition of BCR-ABL and impressive 
clearance  of  Ph
+ cells,  however,  the  primitive  quiescent  cell population  did not 
appear to undergo apoptosis even after several days TKI exposure. Therefore, it 
was still not clear  whether early CML progenitor cells depend on BCR-ABL for 
their growth and survival. In this study we have attempted to determine whether 
CML stem cells are dependent on BCR-ABL TK activity for their survival and/or 
proliferation using dasatinib treatment and aimed to characterise the cells which 
survived drug exposure. We found that 10% of the CML cells were able to survive 
the dasatinib treatment. We also showed that maximal BCR-ABL TK inhibition was 
achieved in the surviving CML cells, both in the bulk population of cells and the 
more problematic primitive stem cell population. Those cells which survived the 
dasatinib treatment were found to be primitive, residing mainly in the undivided cell 
fraction  and  the  very  early  cell  divisions.  Since  these  BCR-ABL  TK-inhibited, 
resistant cells were also able to grow when re-cultured in cytokines and form long- 
term culture-initiating cell (LTC-IC) colonies; these data suggested that ~10% of 
primitive  CD34
+  CML  cells  are  not  addicted  to  BCR-ABL  TK  activity  for  their 
survival. This also suggested that these primitive, resistant CML cells appeared to 
survive and proliferate by BCR-ABL-independent mechanisms. Therefore, the next 
experiments were then designed to investigate the cellular process of autophagy 
as a potential means of primitive CML cell survival. Analysis of the properties of 
CD34
+ CML cells which remained viable following dasatinib treatment, revealed 
the  existence  of  cytoplasmic  autophagic  structures  determined  by  electron 
microscopy  and  significantly  increased  autophagosome-asociated  LC3-II, 
particularly in the cells cultured without growth factors (GF)s. This suggested that 
autophagy is induced following GF deprivation of CML cells and is significantly 
increased  within  these  cells,  upon  BCR-ABL  inhibition  following  dasatinib   4 
treatment.  Furthermore,  we  also  found  that  the  inhibition  of  autophagy  greatly 
potentiated the effect of TKI treatment on the reduction of primitive CML progenitor 
cells, in terms of the effective eradication of functionally defined colony forming 
cells and LTC-ICs. 
 
Overall, this thesis has shown for the first time that the most TKI-resistant primitive 
CML  cells  are  likely  to  be  independent  of  BCR-ABL  TK  activity  for  their 
proliferation  and/or  survival.  Furthermore,  we  have  shown  that  these  resistant 
CML stem cells rely on the BCR-ABL independent autophagy process for survival 
in response to stressful conditions, such as, GF deprivation and TKI treatment. 
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ALBA   human albumin solution  
ALDH     aldehyde dehydrogenase  
ALL     acute lymphoblastic leukaemia  
alloSCT   allogeneic stem cell transplantation  
A-loop   activation loop 
AML     acute myeloid leukaemia  
AMP    adenosine monophosphate  
AMPK   AMP-kinase  
AP     accelerated phase  
Ara-C    cytosine arabinoside 
ATP     adenosine triphosphate 
Bad     Bcl-2-associated death promoter 
BAF    bafilomycin A1 
Bap    BRCA1-associated protein 
BC     blast crisis 
Bcl     B-cell lymphoma 
BCA     bicinchoninic acid 
BCR-ABL   breakpoint cluster region-abelson 
BIT    bovine serum albumin/insulin /transferrin  
BM    bone marrow 
BRCA1   breast cancer 1 
BSA    bovine serum albumin 
C-C     coiled-coil 
CCR    complete cytogenetic response 
CFC     colony-forming cell 
CFSE     carboxyfluorescein diacetate succinimidyl ester  
CHR     complete haematological response 
CIS     cytokine-induced SH2-containing 
CLP     common lymphoid progenitors 
CML    chronic myeloid leukaemia 
CMP     common myeloid progenitors 
CMR    complete molecular response 
COOH   carboxy 
CP     chronic phase 
CQ     chloroquine  
CrkL    Crk-like 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO   dimethyl sulfoxide 
Dok     docking protein  
DT     diphtheria toxin 
EDTA   ethylenediaminetetraacetic acid 
eIF4E     eukaryoytic initiation factor 4E 
ELISA   enzyme-linked immunosorbent assay 
EM     electron microscopy  
ERK     extracellular signal-regulated kinase 
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1. INTRODUCTION 
 
1.1 Haemopoietic stem cells and normal haemopoiesis 
Haemopoiesis  is  the  process  of  blood  cell  formation  within  an  organism  and 
results in the development and differentiation of haemopoietic stem cells (HSCs) 
(1,  2).  In  adult  mammals,  HSCs  are  predominantly  found  in  the  bone  marrow 
(BM),  with  the  majority  being  relatively  short-lived  within  the  circulation  (3).  In 
order to maintain the haemopoietic system, it is necessary for the BM to produce 
up to 10
13 cells per day (4). Terminally differentiated cells are incapable of further 
growth themselves and therefore, to  prevent the  depletion of the BM stem cell 
pool, they must be replaced through the development and proliferation of HSCs.  
 
A  key  criterion  which  defines  an  HSC  is  the  ability  to  replicate  symmetrically, 
through  the  mitotic  process  of  self-renewal.  This  results  in  the  generation  of 
progeny  that  are  identical  copies  of  the  HSC  and  allows  the  BM  cellularity  to 
remain in a constant steady state.  Multipotency is a further criterion which defines 
an HSC, with a single cell being able to give rise to a number of differentiated cell 
types.  In  order  to  achieve  this,  the  stem  cell  also  replicates  asymmetrically, 
producing one copy of itself and a second which is able to differentiate (5, 6). It is 
estimated that one stem cell is capable of producing approximately 10
6 mature 
blood cells after around twenty cell divisions.  
 
The  haemopoietic  system  is  often  assessed  using  a  transplantation  assay, 
whereby the transplantation of a single HSC from the BM into a lethally irradiated 
animal can rescue the entire haemopoietic system (7-9). On the basis of these 
experiments using murine haemopoietic cells, transplanted HSCs can be further   27 
classified  into  three  distinct  populations:  long-term  HSCs  (LT-HSC)  which  are 
capable of producing all blood cell types indefinitely and generate progeny that 
demonstrate  similar  potentiality  on  secondary  transplant;  short-term  HSCs  (ST-
HSC) which reconstitute the myeloid and/or lymphoid compartments for a limited 
period  of  time;  and  multipotent  progenitor  (MPP)  cells  which  have  little  or  no 
detectable ability to self-renew (10, 11).  These MPP cells then commit either to 
the lymphoid or myeloid lineage by differentiating to common lymphoid progenitors 
(CLP) (12) or common myeloid progenitors (CMP) (13), which are able to give rise 
to cells which are functionally mature (Figure 1-1).  
 
At steady state, only a small proportion of HSCs reconstitute the haemopoietic 
system, as it is believed that HSCs cycle infrequently, with the majority of cells 
existing in a quiescent state, or G0 stage of cell cycle (14, 15). This infrequent 
proliferation is important for the maintenance of tissue homeostasis and allows 
time to repair any DNA damage which may arise from life-long HSC self-renewal 
(16).   
 
The fate of the HSC to self-renew, differentiate or remain quiescent is thought to 
be  controlled  by  signals  from  their  microenvironment,  commonly  known  as  the 
stem cell niche (17). The BM haemopoietic niche utilises signals from osteoblasts 
and mesenchymal stromal cells (18), to secrete factors like stromal cell-derived 
factor-1  (SDF-1)  (CXCL12),  which  activate  the  CXCR4  receptor  expressed  on 
HSCs. This instructs circulating HSCs to home to and engraft in the BM (19) and 
thereby maintains HSC quiescence and potential for self-renewal (20-22). Loss of 
this mechanism would typically result in the stem cell leaving the niche to either 
divide, differentiate or apoptose (23). 
   28 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1 The haemopoietic hierarchy model 
Only LT-HSC and ST-HSC have the capacity for self-renewal, which is lost 
once  the  cell has become an  MPP. These give rise  to the CLP and CMP, 
which undergo several proliferation and differentiation steps to give rise to 
mature, terminally differentiated progeny. [LT-  long term, ST - short term, 
HSC-  haemopoietic  stem  cell,  CMP-  common  myeloid  progenitor,  CLP- 
common lymphoid progenitor, MPP- multi-potent progenitor] 
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The CD34 molecule is a 115-kDa type I transmembrane glycoprotein, which is 
strongly  expressed  on  human  HSCs  and  shows  a  progressive  decline  in 
expression as these cells undergo differentiation (24). Studies suggest that CD34 
may play a role in cell adhesion and signal transduction in HSC and progenitor 
cells, although despite its importance, its exact function and regulation are still not 
completely  understood  (25).  Since  its  discovery,  CD34  has  become  the  most 
widely  used  marker  to  obtain  enriched  populations  of  human  HSCs  and 
progenitors for research or clinical use. However, the total CD34
+ population is 
heterogeneous and it is thought that the frequency of the true HSC population is 
low (<0.5% in total BM and 1-10% of all CD34
+ cells (26)). HSCs do not express a 
variety of surface markers which are associated with terminal differentiation. The 
lack of expression of these markers can, therefore, be used to distinguish the most 
primitive cells from differentiated cells within a total haemopoietic cell population. 
For example, the type II transmembrane glycoprotein, CD38, which was originally 
described as a lymphoid cell surface differentiation marker (27), is expressed at 
intermediate to high levels on >90% of CD34
+ cells. These CD34
+38
+ cells are 
able to give rise to a transient repopulation of irradiated mice (28). By contrast, 
CD34
+38
-  haemopoietic  cells  are  capable  of  continuous,  multi-lineage 
reconstitution  following  transplant  into  irradiated  mice  (29),  indicating  that  true 
HSC exist only  within  this  rare cell population. Therefore,  a  population  of cells 
enriched for HSC can be identified by cell surface phenotype - CD34
+lin
-CD38
- 
(30). Alternative strategies for HSC enrichment include positive selection of cells 
that express surface markers, such as CD133 (31, 32), in combination with CD34 
expression (Table 1-1).  
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Cell type 
 
Phenotype 
 
 
 
HSC 
 
CD34
+ Lin
- 
CD38
- CD33
- 
HLA-DR
low 
c-Kit
+ 
CD133
+ 
CD90
+ 
 
 
MPP and lineage-
committed progenitors 
 
 
CD34
+ Lin
+/- 
CD38
+ CD33
+ 
HLA-DR
high 
 
 
Mature cell 
 
 
CD34
- Lin
+ 
 
Table 1-1 Lineage phenotypes of the human haemopoietic system 
 
 
Other than cell surface phenotype, primitive haemopoietic cells can be identified 
and  purified  based  on  their  ability  to  efflux  certain  fluorescent  dyes,  such  as 
Rhodamine-123 (Rho) and Hoechst 33342 (Hst). The majority of the HSCs in adult 
human and murine tissues are Rho-/lo (33) and this phenotype is attributed to the 
activity of the adenosine triphosphate-binding cassette (ABC) transporter, multi-
drug resistance-1 (MDR-1), expressed at the HSC surface (34).  
 
In 1996, Goodell et al. identified a new population of HSCs, by staining with Hst 
and visualising the dual wavelength by flow cytometry. These cells were able to 
efflux Hst and were designated as side population (SP) cells, because they form a 
cluster of events to the lower left side of a dual wavelength flow cytometric plot. 
The ability of SP cells to efflux Hst has been attributed to the high expression of 
the  ABC  transporter,  breast  cancer  resistance  protein  (ABCG2)  (35).  The  SP 
population was also thought to be enriched for stem or progenitor cells, as they   31 
were  subsequently  shown  to  have  a  primitive  phenotype  and  were  capable  of 
reconstituting lethally irradiated recipients (36).  
 
In order to isolate the most quiescent HSCs and distinguish between cells in G0 
and G1 phases of cell cycle, it is necessary to combine DNA- and RNA-labelling. 
Pyronin Y (PY) is an RNA-selective dye, which was first used in combination with 
Hst, by Shapiro in 1981, for two-parameter cell cycle assessment of intact cells 
(37). Using this technique, quiescent cells in G0 phase and out of cycle, can be 
detected as they have diploid DNA content and low RNA content, reflecting a low 
number of ribosomes. As the cells enter G1, they accumulate RNA and are able to 
uptake PY. As the cells progress through cell cycle to the S/G2 and M phase, they 
accumulate tetraploid DNA and appear double positive for both Hst and PY. 
 
Primitive haemopoietic cells are also relatively resistant to alkylating agents, such 
as the active derivatives of cyclophosphamide (38). This resistance is due to the 
expression of the enzyme aldehyde dehydrogenase (ALDH) on HSCs (39). The 
highest expression of ALDH has been found on the CD34
+38
- subset of human 
BM  cells  and  therefore,  fluorescent  ALDH-substrates  have  also  been  used  to 
identify and isolate HSCs by FACS (40).  
 
1.1.1 The leukaemic stem cell hypothesis 
The characterisation  of HSCs  has allowed parallels to be  drawn  between their 
identity and that of cancer cells, with human leukaemias frequently called stem cell 
diseases (41).  Early experiments by the group led by Philip Fialkow, where they 
used  patterns  of  inactivation  in  X-linked  genes,  demonstrated  that  leukaemias 
such  as  chronic  myeloid  leukaemia  (CML)  (42)  and  acute  myeloid  leukaemia 
(AML) (43) are clonal disorders with origins in a multipotent stem cell (44). The   32 
concept of a tumourigenic or leukaemic stem cell (LSC) was further explored in 
studies where only a small fraction of leukaemic cells was capable of extensive 
proliferation in vitro and in vivo. Park and colleagues demonstrated that only 1 in 
10000 to 1 in 100 murine myeloma cells were capable of forming colonies in vitro 
in clonal colony-forming assays (45). Furthermore, only 1-4% of the total number 
of leukaemic cells was able to form colonies within the spleen when transplanted 
in vivo (46).  
 
In  1997,  adaptation  of  the  existing  quantitative  assays  for  normal  HSC 
repopulation in vivo, allowed the first direct evidence for the LSC hypothesis to be 
demonstrated in AML (47, 48). Bonnet and Dick demonstrated that only a small 
proportion  of  leukaemic  blasts,  which  were  referred  to  as  ‘SCID  leukaemia-
initiating cells’ (SL-IC) and possessed the immature phenotype, CD34
+38
-, were 
capable  of  causing  human  AML  in  non-obese  diabetic/severe  combined 
immunodeficient (NOD/SCID) mice. Additionally, these primitive cells were found 
to  possess  a  high  self-renewal  capacity  in  serial  transplantation  experiments. 
Based  on  these  findings,  the  authors  proposed  that  AML  forms  a  stem  cell 
hierarchy that is similar to normal haemopoiesis. This concept suggests that many 
tumours may be maintained by a small population of LSCs which are capable of 
life-long self-renewal, differentiation and proliferation.  
 
Due to the phenotypic and functional similarities between the HSC and LSC, the 
authors also propose that the initial transforming events occur within a stem cell 
rather  than  a  committed  progenitor  cell.  HSCs  already  have  the  self-renewal 
pathways  activated,  therefore  may  require  fewer  mutations  to  maintain  self-
renewal  properties than  more differentiated  cells. Indeed, other  studies support 
this model, whereby the transduction of the potent oncogene BCR-ABL, did not   33 
confer  similar  self-renewal  properties  to  committed  progenitor  cell  populations 
(49). However, the idea that an LSC must arise from a normal stem cell is not 
universally accepted, with the alternative view suggesting that the LSC could be a 
more  restricted  or  differentiated  mature  cell,  which  has  transformed  and 
reacquired  the  stem  cell  capability  of  self-renewal.  Evidence  for  this  was  first 
demonstrated  in  murine  models  of  leukaemia  (50).  Populations  of  murine 
progenitor  cells,  which  lacked  the  capacity  for  self-renewal,  were  retrovirally 
transduced with either the MLL-ENL or MOZ-TIF2 human leukaemia oncogenes. 
This  led  to  the  reacquisition  of  self-renewal  properties  in  these  progenitor 
populations, as they were able to form colonies in serial methylcellulose-plating 
experiments in vitro. Similarly the transduced cells were also able to induce AML 
when  transplanted  into  irradiated  mice,  which  could  then  be  transferred  to 
secondary recipients. Furthermore, expression of the MLL-AF9 oncoprotein has 
also  since  been  shown  to  initiate  AML  in  isolated  granulocyte-macrophage 
progenitor  cells  (51).  More  recently,  Bonnet  has  herself  demonstrated 
transplantation capacity for CD34
+38
+ AML cells in at least a proportion of AML 
samples (52), thus expanding the LSC compartment and beginning to separate 
LSC from HSC phenotypes (Figure 1-2). 
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Figure 1-2 Schematic models of leukaemic initiation and progression 
 
 (A) The initial transforming mutation disrupts the normal development of an 
HSC and gives rise to a self-renewing LSC, which is present in the stem cell 
compartment. (B) Conversely, the transforming mutation may occur in the 
downstream  progeny.  These  cells  have  then  reacquired  the  stem  cell 
capability of self-renewal, to generate the LSCs. 
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1.2 CML 
Compelling evidence suggests that CML is one such malignancy which is driven 
by  LSCs.  CML  is  a  clonal  myeloproliferative  disorder  of  primitive  haemopoietic 
progenitor  cells,  which  accounts  for  15%  of  all  adult  leukaemias  and  has  an 
incidence  of  1-2  cases  per  100,000  population  (53).  It  is  defined  by  the 
Philadelphia  chromosome  (Ph),  which  results  from  the  reciprocal  translocation 
between the 3’ end of the c-ABL (Abelson) gene from chromosome 9 and the 3’ 
end  of  the  BCR  (Breakpoint  Cluster  Region)  gene  on  chromosome  22 
(t(9;22)(q34;q11)) (54). The novel fusion oncogene generated on chromosome 22 
as  a  result  of  this  translocation  is  called  BCR-ABL  (breakpoint  cluster  region-
abelson)  (55,  56)  (Figure  1-3).  In  the  majority  of  CML  patients,  this  oncogene 
transcribes  a  210-kDa  constitutively  active  non-receptor  tyrosine  kinase  (TK), 
often referred to as p210
BCR-ABL, which is necessary for the transformation of the 
disease (57). 
 
 
 
 
 
 
 
 
Figure 1-3  The Ph chromosome  
The reciprocal translocation between chromosomes 9 and 22 results in the 
formation of the Ph chromosome. This is the shortened chromosome 22 and 
results in the production of the fusion gene product BCR-ABL. 
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CML  is  a  clinically  triphasic  disorder,  where  the  majority  of  patients  present  in 
chronic phase (CP), a stage which is characterised by an abnormal blood count, 
increased megakaryocytes in BM and splenomegaly (58). Diagnosis is confirmed 
by the detection of the Ph chromosome by BM cytogenetics and by measurement 
of BCR-ABL transcripts, in peripheral blood or BM, by highly sensitive quantitative 
reverse transcriptase-polymerase chain reaction (qRT-PCR) (59). If left untreated, 
the initial CP lasts for approximately 3-6 years, before progressing to accelerated 
phase (AP). As the disease develops, additional cytogenetic abnormalities arise 
and eventually terminate in blast crisis (BC). This is a period of overproduction of 
immature leukaemic blast cells within the BM compartment, where prognosis is 
generally poor (58). The most widely used criteria for AP and BC CML diagnosis 
are defined by the World Health Organisation (WHO) and are outlined below (60): 
 
AP CML  Diagnosis if one or more of the following is present: 
·  Blasts 10 to 19% of peripheral blood white cells or BM cells 
·  Peripheral blood basophils at least 20% 
·  Persistent  thrombocytopenia  (100  x  10
9/L)  unrelated  to  therapy,  or 
persistent thrombocytosis (1000 x 10
9/L) unresponsive to therapy 
·  Increasing  spleen  size  and  increasing  WC  count  unresponsive  to 
therapy 
·  Cytogenetic evidence of clonal evolution 
 
BC CML  Diagnosis if one or more of the following is present: 
·  Blasts 20% or more of peripheral blood white cells or BM cells 
·  Extramedullary blast proliferation 
·  Large foci or clusters of blasts in BM biopsy 
 
 
Table 1-2 Criteria for diagnosis of AP and BC CML 
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1.2.1 BCR-ABL structure and function 
The  mammalian  c-ABL  gene  is  ubiquitously  expressed  and  encodes  a  non-
receptor TK, with two 145-kDa isoforms arising from alternative splicing of the first 
exon  (61).  The  amino-terminus  of  human  c-ABL  protein  contains  three  SRC 
homology domains (SH1-SH3) that mediate TK (SH1), phospho-tyrosine protein-
binding  (SH2)  and  kinase  inhibitory  (SH3)  functions.  The  centre  of  the  protein 
contains proline-rich sequences which can in turn interact with the SH3 domains of 
other adaptor-proteins, such as Crk. The carboxyl-terminus of c-ABL encodes a 
lysine-rich motif required for nuclear localisation, a DNA-binding domain and actin-
binding  domains.    In  c-ABL,  the  structural  motifs  which  are  thought  to  be 
necessary for cellular transformation are the SH1, SH2 and actin-binding domains 
(62-64). The c-ABL proto-oncoprotein is commonly distributed in both the nucleus 
where it is bound to chromatin and in the cytoplasm where it is bound to F-actin 
(65). Normal c-ABL protein is predominantly nuclear and appears to be involved in 
the  regulation  of  cell  cycle,  suppression  of  cell  growth,  regulation  of  gene 
transcription and integrin signalling. In contrast, transforming c-ABL proteins are 
often localised in the cytoplasm, implying that the cytoplasmic fraction of c-ABL 
may normally be involved in the signalling cascades that induce mitogenesis (65). 
 
Like  c-ABL,  the  160-kDa  BCR  protein  is  ubiquitously  expressed  and  localised 
within the cytoplasm, although its exact function is not clearly defined. The amino-
terminus  of  BCR  contains  a  serine/threonine  kinase  domain,  including  at  least 
three SH2 binding sites which can bind with substrates such as, BRCA1 (breast 
cancer 1)-associated protein (Bap)-1, a member of the 14-3-3 family of proteins 
(66).    A  coiled-coil  (C-C)  domain  (amino  acids  1-63)  at  the  amino-terminus  of 
BCR-ABL allows dimer formation in vivo. The C-C structural motif, along with the 
tyrosine  177 (Y177) phosphorylation site, which is necessary for the binding of   38 
growth-receptor-binding-2 (Grb-2) and subsequent activation of the Ras pathway, 
are thought to be necessary for the transforming function of BCR-ABL (67-69).  
The  most  important  structural  domains  of  BCR  and  c-ABL  proteins  are 
demonstrated in Figure 1-4. 
 
 
 
 
 
 
 
 
Figure 1-4 The important structural motifs of BCR and c-ABL proteins 
In  BCR,  the  coiled-coil  (C-C)  (also  known  as  the  oligomerisation  domain) 
resides at the amino (NH2) terminus. This is followed by a domain which is 
thought  to  facilitate  binding  to  SRC-homology  2  (SH2)-domain-containing 
proteins. BCR also contains a serine/threonine (Ser/Thr) kinase domain, a 
tyrosine at position 177 (Y177), a Rho guanine-nucleotide-exchange factor 
(Rho-GEF)  domain  and  a  Rac  GTPase  activating  protein  (Rac-GAP) 
homology domain. In ABL, there are SH3, SH2 and SH1 tyrosine kinase (TK) 
domains  at  the  amino  terminus,  several  proline-rich  domains  (P)  and  a 
nuclear localisation signal (NLS). At the carboxy terminus (COOH) there are 
DNA- and actin-binding domains. 
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Three predominant products are formed depending on which breakpoint located 
within the BCR gene is fused with exon a2 of ABL. These different forms of BCR-
ABL are associated with three distinct forms of leukaemia. In the majority of CML 
cases, the breakpoint occurs within the major BCR (M-BCR), which spans exons 
b1-4. This results in the formation of fusion transcripts with b2a2 or b3a2 junctions, 
which  encode  the  p210
BCR-ABL  oncoprotein.  A  second  breakpoint  is  located 
upstream  of  M-BCR  -  minor  BCR  (m-BCR)  -  and  encodes  a  190-kDa  protein, 
referred to as p190
BCR-ABL. This commonly occurs in Ph
+ acute B lymphoblastic 
leukaemia (ALL) (70), occasionally in AML (71) and in rare cases of CML (72). 
Lastly, a third downstream BCR (m-BCR) encodes a 230-kDa protein (p230
BCR-
ABL), which is found in chronic neutrophilic leukaemia and some cases of CML 
(73). 
 
The first evidence that BCR-ABL was responsible for the malignant transformation 
of  HSCs  in  CML  was  provided  by  Daley  et  al.,  who  demonstrated  that  mice 
transplanted  with BM transduced with p210
BCR-ABL, developed many features of 
CML (74). The importance of BCR-ABL was further demonstrated in transgenic 
mice  in  which  the  tetracycline-responsive  element  (tet-O)  was  used  to  induce 
BCR-ABL1  expression  in  HSCs.  The  BCR-ABL1-tet-O  mice  then  developed  a 
CML-like disease upon the withdrawal of tetracycline treatment (75). 
 
It is suggested that BCR-ABL gives rise to this malignant transformation through a 
number  of  mechanisms,  namely,  alteration  of  the  BM  microenvironment,  anti-
apoptotic defences, constitutive activation of proliferation and survival pathways 
and growth factor (GF) independence.  
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1.2.2 BCR-ABL and alteration of the BM microenvironment  
In normal haemopoiesis, progenitor cell proliferation is negatively regulated by the 
microenvironment through adhesion of integrin receptors, such as the b1-integrin 
receptors,  to  BM  stromal  cells  (76).  The  increased  proliferation  and  abnormal 
circulation of primitive CML cells may, in part, be explained by perturbed adhesion 
between  the  BM  microenvironment  and  the  CML  progenitors  (77,  78).  CML 
progenitors  express a  variant  of the b1-integrin  receptor that is  not  present  on 
normal  cells  and  evade  this  regulation  through  impaired  adhesion.  Following 
receptor-binding,  integrins  are  capable  of  initiating  normal  signal  transduction; 
therefore,  it  is  possible  that  in  CML  cells,  the  signalling  that  usually  inhibits 
proliferation  is  impaired.  BCR-ABL  may  have  a  further  impact  on  this  altered 
signalling,  as  proteins that  are  also involved in signal transduction through b1-
integrins,  such  as  paxillin,  and  phosphatidylinositol  3-kinase  (PI3K)  (79),  are 
constitutively activated by BCR-ABL in cell lines transduced with the oncogene. 
Bhatia  et  al., have demonstrated  that treatment  with  interferon  alpha (IFNa), a 
therapeutic  agent  in  CML,  can  restore  b1-integrin  mediated  adhesion  of  CML 
progenitors to BM stroma and restore this anti-proliferative mechanism (80).  
 
SDF-1a-CXCR4 signalling positively regulates the homing of HSC to the BM (81). 
In primary blast CML cells, BCR-ABL has been shown to down-regulate CXCR4 
expression resulting in attenuated adhesion and migratory responses to SDF-1a, 
increasing  the  ability  of  these  immature  cells  to  escape  from  the  marrow  (82). 
Inhibition of BCR-ABL kinase activity, has been demonstrated to restore CXCR4 
expression in CML cells co-cultured with mesenchymal stem cells. This resulted in 
the migration of CML cells to the BM niche and an acquisition of stroma-mediated 
resistance of CML progenitor cells (21). These results suggest that the SDF-1a-  41 
CXCR4 interaction contributes to the resistance of CML cells against agents which 
inhibit BCR-ABL activity in the BM microenvironment. 
 
1.2.3 BCR-ABL and anti-apoptosis  
CML stem cells demonstrate elevated and continuous growth and expansion as 
compared  to  their  normal  counterparts,  but  do  not  exhibit  greater  proliferation 
potential  (83).  This  indicates  that  the  increased  TK  activity  of  BCR-ABL  within 
CML progenitors may act to suppress the normal programmed cell death process, 
apoptosis.  The  “protection  from  apoptosis”  hypothesis  has  been  confirmed  in 
transformed  haemopoietic  cell  lines,  whereby  transfection  with  BCR-ABL 
upregulated  the  anti-apoptotic  survival  proteins,  B-cell  lymphoma  (Bcl)-2  (84), 
myeloid cell leukaemia (mcl)-1 (85) and Bcl-XL (86).  
 
1.2.4 BCR-ABL and constitutive activation of proliferation and survival 
pathways 
A  consequence  of  BCR-ABL  is  an  increase  in  cellular  proliferation.  At  first  the 
“discordant maturation hypothesis” was proposed, where it was assumed that the 
most  mature  proliferating  cells  in  CP  CML  caused  the  expansion  of  Ph
+  cells. 
However, this was refuted by other investigations demonstrating that the myeloid 
expansion is a result of increased numbers of primitive CML progenitor cells (87).  
 
BCR-ABL  is  localised exclusively to  the cytoplasm and  is  able to constitutively 
tyrosine  phosphorylate  a  host  of  substrates.  Importantly,  due  to 
autophosphorylation, there is increased phospho-tyrosine (p-Tyr) on the BCR-ABL 
oncoprotein itself. This then, generates many binding sites for the SH2 domains of 
other proteins. A number of target substrates of BCR-ABL have been reported as 
shown  in  Table  1-3.  Substrates  of  BCR-ABL  can  be  grouped  into  three  broad   42 
categories,  depending  on  function:  (1)  adaptor  molecules  such  as  CrkL  and 
p62
Dok;  (2)  cell  membrane  and  cytoskeleton  related  proteins  such  as  talin  and 
paxillin  and  (3)  proteins  with  catalytic  function  such  as  Ras-GAP  and 
phospholipase  Cg  (PLCg)  (88).  Tyrosine  phosphorylation  of  these  BCR-ABL 
substrates results in the constitutive activation of multiple cytoplasmic and nuclear 
signalling  cascades,  which  are  shared  with  cytokines  known  to  regulate  the 
proliferation, differentiation and survival of haemopoietic cells (Figure 1-5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5 BCR-ABL associated signalling cascades that contribute to 
cellular proliferation, differentiation and survival 
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Table 1-3 Examples of BCR-ABL PTK substrates 
 [Grb- growth-receptor-binding protein; Dok- docking protein; CrkL- Crk-like; 
GAP-  GTPase-activating  protein;  PI3K-  phosphatidylositol  3-kinase;  STAT- 
signal transducer and activator of transcription; Fak- focal adhesion kinase; 
PLC- phospholipase C; Bap- BRCA1 (breast cancer 1)-associated protein.] 
Table adapted from Smith et al. 2003 (88). 
 
 
Substrate  Function  References 
Grb-2  Adapter molecule  (69) 
P62
Dok  Adapter molecule  (89) 
CrkL  Adapter molecule  (90) 
Crk  Adapter molecule  (91) 
Ras-GAP  Ras-GTPase activation  (92) 
Ras  Signalling switch; 
cellular oncogene  (93) 
Raf-1  Serine/threonine kinase  (94) 
Cbl  E3 ligase for 
ubiquitination  (95) 
PI3 kinase 
(p85 subunit)  Serine kinase  (96) 
STAT1 and 5  Transcriptional 
activators  (97, 98) 
Paxillin  Cytoskeleton  (99) 
Fak  Cytoskeleton  (100) 
Talin  Cytoskeleton  (101) 
PLCg g g g  Phospholipase  (102) 
Bap-1  14-3-3 adaptor protein  (66) 
Vav  Guanine-nucleotide-
exchange factor  (103)   44 
1.2.4.1 BCR-ABL and the Ras-Raf-MEK-ERK pathway 
Ras is a small guanine-nucleotide-binding protein (G-protein) that is active when 
bound  to  GTP,  or  inactive  when  GDP-bound.  Ras  is  activated  when  GEFs 
catalyse the exchange of Ras-bound GDP for GTP. In contrast, GAPs inactivate 
Ras by catalysing its intrinsic GTPase activity.  
 
In normal cells, activation of Ras by haemopoietic GFs, such as IL-3, leads to the 
recruitment of the serine/threonine Raf-1 kinase to the cell membrane. Activated 
Raf-1  can  then  phosphorylate  mitogen-activated  protein  kinase  (MAPK)  kinase 
(MEK) on both serine and threonine residues. MEK is then able to phosphorylate 
and  activate  extracellular  signal-regulated  kinase;  ERK,  which  can,  in  turn, 
phosphorylate transcription factors, such as c-Jun and c-Fos and thereby direct 
gene regulation (93).  
 
It has also been demonstrated that elevated Ras activation occurs in CML cells 
(104). Autophosphorylation of Y177 on BCR-ABL provides a docking site for the 
adapter molecule Grb-2 (69). Activated Grb-2 can then bind the positive regulator, 
Son of sevenless (SOS; a GEF) and then stabilise Ras in the active form. Grb-2 
mutants  that  lack  SH3  domains  block  the  activation  of  Ras  and  suppress  the 
transforming  capability  of  BCR-ABL  (105).  Two  other  BCR-ABL  adaptor 
molecules, Shc and CrkL, can also activate Ras (90, 106). The importance of Ras 
in CML cell growth was demonstrated in cell line models in which the introduction 
of  a  dominant-negative  Ras  into  BCR-ABL-transfected  cells  inhibited  malignant 
transformation  (107).  Further  investigations  have  shown  that,  in  BCR-ABL-
transformed haemopoietic cells, the constitutive activation of Ras is likely to lead 
to the activation of an anti-apoptotic pathway (108, 109). These data highlight an   45 
important role for the Ras-Raf-MEK-ERK pathway in the pathogenesis of BCR-
ABL
+ leukaemias. 
 
1.2.4.2 BCR-ABL and the JAK-STAT pathway 
The  JAK-STAT  pathway  is  activated  by  cytokines,  such  as  IL-3,  IFNa  and 
granulocyte  macrophage-colony  stimulating  factor  (GM-CSF).  Janus  family  of 
activated kinases (JAK1, JAK2, JAK3, Tyk2) are cytoplasmic protein TKs (PTKs) 
that  mediate  signalling  downstream  of  cytokine  receptors.  Activated  JAKs 
phosphorylate a family of downstream transcription factors called the STAT family 
members.  STAT  proteins  then  translocate  to  the  nucleus  and  activate  the 
transcription  of  specific  genes  necessary  for  the  growth,  survival  and 
differentiation of haemopoietic cells. The JAK-STAT pathway is tightly regulated 
by  the  suppressors  of  cytokine  signalling  (SOCS)  and  cytokine-induced  SH2-
containing (CIS) family of proteins (110). 
 
The constitutive activation of STATs is observed in BCR-ABL expressing cell lines 
and  primary  CML  cells  (111,  112)  and  the  activation  of  STAT5  appears  to 
contribute  to  malignant  transformation  (113).  The  effect  of  STAT5  activation  in 
BCR-ABL
+ cells appears to be predominantly anti-apoptotic, as the activation of 
STAT5 in CML cells contributes to upregulated expression of the anti-apoptotic 
family members, mcl-1 and Bcl-XL  (114, 115).  Although BCR-ABL is known to 
activate JAKs, there may also be a distinct BCR-ABL-mediated pathway for the 
phosphorylation of STAT5, as the introduction of dominant-negative JAK mutants 
in BCR-ABL transformed cells did not abrogate STAT5 phosphorylation (112). 
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1.2.4.3 BCR-ABL and the PI3K pathway 
PI3K is a heterodimer consisting of an 85-kDa (p85) regulatory subunit containing 
one SH3 domain and two SH2 domains and a 110-kDa (p110) catalytic subunit 
(116). PI3K is found in cellular complexes with ligand-activated GF and oncogene 
PTKs (117).  These interactions are mediated by the SH2 and SH3 domains of 
p85 (118). The PI3K signalling pathway plays an important role in many biological 
processes, such as survival, proliferation, differentiation, mobility and metabolism 
in a number of cell types (119, 120).  
PI3K  can  bind  to  activated  haemopoietic  GF  receptors  via  its  SH2  and  SH3 
domains  and  is  recruited  to  the  cell  membrane  following  haemopoietic  GF 
stimulation. Activated PI3K can produce PI-(4,5)-bisphosphate (PIP2) which may 
be  converted  to  PI-(3,4,5)-triphosphate  (PIP3),  an  important  second  messenger 
(121). PIP3 and other PI3K lipid products on the inner cell membrane generate 
binding sites for other proteins that contain pleckstrin homology domains. PI3K 
signalling  is  negatively  regulated  by  phosphatases,  such  as,  phosphatase  and 
tensin  homologue  deleted  on  chromosome  10  (PTEN)  which  removes  the  3-
phosphate  from  PIP3  (122).  SH2-containing  inositol-5-phosphatase  (SHIP)  - 
removes the 5-phosphate from PIP3 to generate PIP2, a second messenger which 
may have different signalling functions (Figure 1-6). 
 
 
 
Figure 1-6 Diagram of PI3K inositol lipid second messenger synthesis and 
degradation 
 
 
PI3K signalling is deregulated in a large number of cancers and has also thought 
to contribute to cellular transformation by BCR-ABL. Skorski et al. demonstrated 
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that PI3K activity was regulated by BCR-ABL and required for the growth of CML 
cells, using antisense oligonucleotides against PI3K expression (84). Furthermore, 
a specific inhibitor of the p110 subunit of PI3K, wortmannin, was shown to inhibit 
the proliferation of BCR-ABL
+ cells, but not normal haemopoietic cells (96). These 
findings  are  corroborated  by  the  fact  that  BCR-ABL-transformed  cells  have 
increased PI3K class 1A activity and an accumulation of PIP3 (79). 
A YXXM motif is contained within the ABL sequence of BCR-ABL, which when 
phosphorylated corresponds to the optimal binding sequence for the SH2 domains 
of  the  p85  regulatory  subunit  of  PI3K  (123).  However,  the  BCR-ABL-PI3K 
interaction does not appear to be direct as mutation of the YXXM motif does not 
attenuate PI3K activity. This finding indicates that PI3K activation occurs through 
associations  with  other  tyrosine-phosphorylated  proteins  that  are  recruited  to 
BCR-ABL (123).  
 
1.2.4.3.1 The adapter protein Gab2 
The majority of evidence indicates that the main pathway for PI3K activation in 
BCR-ABL
+ cells occurs via the Y177 autophosphorylation site on the BCR portion 
of the fusion protein. The Y177 site is important for Grb2 binding via its SH2 and 
generates a docking site for Gab2 through its SH3 domain (124).  BCR-ABL can 
then phosphorylate Gab2 on tyrosines within its YXXM motif which, in turn, act as 
binding sites for the SH2 domains of PI3K regulatory subunits. Mutations within 
the Y177 site resulted in decreased transformation by BCR-ABL. Similarly, loss of 
Gab2 inhibited myeloid transformation both in vitro and in vivo (124).  
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1.2.4.3.2 The adapter protein CrkL 
A further possible Gab2-independent mechanism of PI3K activation involves the 
39-kDa protein CrkL. CrkL was originally identified by ten Hoeve et al. (125) and is 
one of the most prominent tyrosine-phosphorylated proteins detected in BCR-ABL-
transformed cells (90). CrkL belongs to the Crk family of adapter proteins which 
includes  v-Crk  and  c-Crk.  It  is  ubiquitously  expressed  and  contains  one  SH2 
domain, an SH2’ domain (has no known function) and two SH3 domains (126).  It 
is thought to be involved in the regulation of cellular motility and integrin-mediated 
cell adhesion by association with other focal adhesion proteins such as paxillin 
(99). In CML, CrkL interacts and is phosphorylated on tyrosine 207 (127) directly 
by the BCR-ABL oncoprotein (90, 125, 128). Tyrosine phosphorylated CrkL then 
binds to c-CBL with its SH2 domain and forms a multimeric complex with PI3K, c-
ABL and BCR-ABL through its SH3 domain (95, 129).  The exact function of CrkL 
tyrosine  phosphorylation in leukaemic cell  signalling  remains to  be determined, 
however,  it  seems  likely  that  CrkL  binding  to  other  tyrosine  phosphorylated 
proteins, such as PI3K, leads to the activation of pathways that could contribute to 
leukaemic  transformation. Due to the specificity  of BCR-ABL signalling  to CrkL 
activation and also the inherent instability of the BCR-ABL oncoprotein, detection 
of the activated form of CrkL (p-CrkL) has become a standard indirect method to 
assess  BCR-ABL  status,  as  illustrated  by  our  own  laboratory  (130,  131)  and 
others (132, 133).  
 
1.2.4.3.3 Akt - a major downstream signalling effector of PI3K 
Akt  is  a  serine/threonine  kinase  (also  known  as  protein  kinase  B)  which  is 
activated  by  PI3K  and  is  the  effector  most  closely  associated  with  cellular 
transformation. Activated Akt has a number of different substrates which regulate   49 
proliferation, metabolism and survival, as illustrated in Figure 1-7 and described 
below. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-7 Downstream substrates of PI3K/Akt phosphorylation 
Signalling via GF stimulation of cognate receptors or by BCR-ABL, results in 
the activation of PI3K and the subsequent recruitment of Akt. Activated Akt 
then phosphorylates many substrates to promote cell growth, proliferation 
and  survival.  See  text  for  details.  [TSC-  tuberous  sclerosis,  mTOR- 
mammalian  target  of  rapamycin,  GSK3b b b b-  Glycogen  synthase  kinase  3b b b b, 
FOXO-  forkhead  box,  subgroup  O,  Bad-  Bcl-2-associated  death  promoter, 
mdm2-  murine  double  minute  2,  4EBP1-eukaryotic  translation  initiation 
factor 4E, eIF4E-eukaryotic initiation factor 4E] 
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1.2.4.3.3.1 Forkhead Box, Subgroup O  
The forkhead box, subgroup O (FoxO) family of transcription factors are a sub-
class of the Fox forkhead transcription factors that have a variety of roles in the 
regulation of proliferation, cellular metabolism and survival (134). The mammalian 
members of the FoxO transcription factors include FoxO1, FoxO3a, FoxO4 and 
FoxO6 and contain three evolutionarily conserved Akt phosphorylation sites within 
each of the FoxO proteins. Following GF stimulation, Akt phosphorylates FoxO 
transcription factors within the nucleus. This allows for the binding of the 14-3-3 
chaperone protein (135, 136), resulting in the efficient export and re-localisation of 
FoxO transcription factors to the cytoplasm. Cytoplasmic sequestration prevents 
the FoxO-dependent transcription of genes that may antagonise cell survival, such 
as  Bim  and  Trail  (137,  138)  and  also  promote  cell  cycle  arrest,  such  as  the 
downregulation  of  cyclins  D1  and  D2  (139).    Recent  investigations  have 
demonstrated the importance of FoxO function in haematological malignancies. 
BCR-ABL  transformation  was  shown  to  inhibit  FoxO3a,  via  the  constitutive 
activation of PI3K/Akt signalling and the subsequent cytoplasmic sequestration of 
Foxo3a (140). The expression of a constitutively active FoxO3a triple mutant in 
BCR-ABL
+ cells resulted in the induction of apoptosis (140, 141). Furthermore, 
FoxO3a inhibition by BCR-ABL was also shown to affect the expression of the cell 
cycle regulatory gene, cyclin D2 (142). These data indicate that the inhibition of 
FoxO3a by BCR-ABL may represent a potentially important mechanism in CML 
tumourogenesis. 
 
1.2.4.3.3.2 Bcl-2-associated death promoter 
The Bcl-2-associated death promoter (Bad) protein is a pro-apoptotic member of 
the Bcl-2 gene family which is involved in initiating apoptosis. Non-phosphorylated   51 
Bad exerts pro-apoptotic effects through binding to, and preventing the function of 
anti-apoptotic  proteins  such  as  Bcl-2  and  Bcl-XL  (143).  Conversely,  Bad 
phosphorylation by Akt (triggered by PIP3) causes the formation of the Bad-(14-3-
3) protein homodimer. This results in the sequestration of Bad in the cytoplasm 
and leaves Bcl-2 free to inhibit Bax-triggered apoptosis (144). In vitro studies have 
demonstrated that BCR-ABL can promote the phosphorylation and inactivation of 
Bad. However, within the same study, it was also noted that BCR-ABL-mediated 
phosphorylation of Bad was not essential for BCR-ABL-induced cell survival, as 
the cells continued to survive in the absence of Bad phosphorylation (145). This 
thereby  suggests  that  the  transforming  ability  of  BCR-ABL  is  not  due  to  one 
pathway, it is rather the activation of complex network of signalling cascades. 
 
1.2.4.3.3.3 Murine double minute 2 
Murine  double  minute  2  (Mdm2)  is  an  E3  ubiquitin  ligase  which,  when 
phosphorylated  by  Akt,  acts  as  an  important  negative  regulator  of  the  tumour 
suppressor, p53 (146). Studies suggest that BCR-ABL may promote cell survival 
by p53 downregulation via increased expression of Mdm2 (147).  
 
1.2.4.3.3.4 Glycogen synthase kinase 3b b b b 
Glycogen  synthase  kinase  3b  (GSK3b)  is  a  serine/threonine  kinase  that  is  a 
downstream  target  of  Akt  and  becomes  inactivated  following  phosphorylation 
(148).  Two  downstream  targets  of  GSK3b,  include  cyclin  D1  and  b-catenin. 
Activated  GSK3b  phosphorylates  these  proteins  and  targets  them  from 
proteasome-mediated degradation (149). Recent studies have demonstrated that 
HSCs which were deficient in b-catenin, demonstrated a reduction in long-term   52 
self-renewal  as  measured  by  serial  transplantation  assays.  Furthermore,  BCR-
ABL-transduced cells deficient in b-catenin, failed to develop CML (150). These 
data highlight an important role for b-catenin in the maintenance of both normal 
and  CML  stem  cells.  However,  a  direct  functional  role  for  the  inactivation  of 
GSK3b  downstream  of  PI3K/Akt  in  BCR-ABL  transformed  cells  has  yet  to  be 
determined. 
 
1.2.4.3.3.5 Tuberous Sclerosis-2 and the Mammalian Target of Rapamycin 
pathway 
The serine/threonine kinase, mammalian target of rapamycin (mTOR) functions as 
both  a  nutrient  sensor  and  an  important  downstream  substrate  of  PI3K/Akt 
signalling, following GF or oncoprotein stimulation (151). The activation of mTOR 
results in the regulation of processes, such as cell growth, cell-cycle progression, 
protein synthesis and autophagy (152, 153).  
 
mTOR  can  form  at  least  two  multi-protein  complexes,  mTORC1  and  mTORC2 
(152).  mTORC1  is  a  heterotrimeric  protein  kinase  that  consists  of  the  mTOR 
catalytic  subunit  and  two  associated  proteins  -  regulatory-associated  protein  of 
mTOR (raptor) and mLST8. mTORC1 has been demonstrated to be involved in 
cellular proliferation, autophagy and translation in response to nutrients. mTORC2 
also  contains  mTOR  and  mLST8  but,  instead  of  raptor,  it  contains  two  other 
proteins  -  rapamycin-insensitive  companion  of  mTOR  (rictor)  and  mSin1. 
mTORC2  is  less  well  understood  than  the  first  mTOR-containing  complex, 
however studies suggest that it is involved in the PI3K/Akt pathway as it directly 
phosphorylates Akt (154).   53 
The mTOR pathway has proven to be an attractive target for the drug treatment of 
several malignancies which display excessive PI3K/Akt signalling, including breast 
and ovarian cancers (155). Furthermore, rapamycin was observed to enhance the 
anti-leukaemic effects of IM on both IM-sensitive and -resistant CML cells both in 
vitro and in vivo (156, 157).    
 
The exact mechanism by which BCR-ABL activates mTOR in CML cells has yet to 
be  defined  but  appears  to  be  PI3K/Akt-dependent  (156).  PI3K/Akt-signalling 
regulates  mTOR  indirectly  through  activation  of  tuberous  sclerosis  complex  2 
(TSC2). TSC2 forms a heterodimer with TSC1 which acts as a brake on mTOR-
dependent  signalling  in  the  absence  of  GF/oncogene  signals.  When  TSC2  is 
phosphorylated by activated Akt, the TSC1/TSC2 complex becomes inactive and 
its  ability  to  inhibit  the  small  G-protein  Rheb  is  blocked.  Rheb  is  then  able  to 
activate mTOR once released from this inhibition (158) (see Figure 1-7). 
 
The mTOR pathway controls cell growth through regulators of translation, such as, 
eukaryotic translation initiation factor 4E (4EBP1) and the p70 ribosomal protein 
S6 kinases 1 and 2 (S6K1 and S6K2) (159). Phosphorylation of 4EBP1 by mTOR 
blocks its ability to inhibit eukaryotic initiation factor 4E (eIF4E). The eIF4E protein 
is then released and is free to bind the 5’-cap structure of mRNAs to allow an 
increase in cap-dependent translation (159). The S6K activation of the S6 protein 
of  40S  ribosomes  promotes  cell  growth  and  proliferation  by  an  unknown 
mechanism (160). 
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1.2.4.3.3.5.1 mTOR and autophagy   
As described previously, mTOR mediates the control of cellular growth. mTOR is 
active under favorable growth conditions, and promotes the initiation of  translation 
and nutrient import. However, during conditions of nutrient starvation, rapamycin 
treatment  or  mTOR  depletion  there  is  a  dramatic  downregulation  of  general 
protein synthesis and an activation of a process known as autophagy.  
 
The term autophagy is derived from the Greek, “auto” - oneself and “phagy” - to 
eat; and refers to a cellular catabolic degradation process. During autophagy, a 
cell’s own long-lived proteins and organelles are degraded through a lysosome-
dependent pathway and recycled to sustain metabolism (161).  Autophagy occurs 
at low basal levels in virtually all cells and has an important homeostatic function, 
to  maintain  organelle  and  protein  turnover.  It  has  a  critical  role  during  early 
mammalian development as mice lacking essential autophagy genes die within 
hours  after birth. This is possibly due to their inability to adapt to the neonatal 
starvation  period  (162).  Autophagy  is  also  thought  to  have  a  critical  role  in 
response to conditions of cellular stress, such as nutrient deprivation, hypoxia and 
pathogen infection (163). 
 
Macroautophagy (herein referred to as autophagy) involves the delivery of cellular 
material  sequestered  inside  double  membrane  vesicles  to  the  lysosome  in 
eukaryotic  cells.  In  conditions  of  starvation  or  GF  deprivation,  a  drop  in 
intracellular nutients allows “protective” autophagy to occur. Initially, an isolation 
membrane  (also  called  a  phagophore)  is  formed  (vesicle  nucleation)  and 
expanded (vesicle elongation). This structure sequesters the cytoplasmic material 
to  be  degraded,  which  may  include  mitochondria,  endoplasmic  reticulum,  and 
ribosomes (Figure 1-8). The edges of the phagophore then fuse to form a double-  55 
membrane structure, known as the autophagosome. This is followed by a fusion of 
the  outer  membrane  of  the  autophagosome  with  the  lysosome,  where  the 
sequestered material, together with the inner membrane is degraded. Degradation 
of  the  sequestered  material  generates  nucleotides,  amino  acids,  and  free  fatty 
acids  that  may  be  recycled  by  the  cell  for  protein  synthesis  and  adenosine 
triphosphate (ATP) generation, thereby promoting cell survival (161).  
 
One  of the main  regulators of autophagy is mTOR,  which  is the key inhibitory 
signal  that  turns  off  autophagy  in  the  presence  of  GFs  or  an  abundance  of 
nutrients. The binding of GFs to cell surface receptors activates class I PI3K/Akt 
signalling, leading to activation of mTOR. This results in the negative regulation of 
autophagosome  formation  and  prevents  the  autophagy  process  from  occuring 
(164). Autophagy may also be pharmacologically inhibited by targeting the fusion 
of autophagosomes with lysosomes, using inhibitors of the lysosomal H
+ATPase 
proton pump, such as, bafilomycin A1 (BAF) or lysosomotropic alkalines, such as 
chloroquine (CQ) or 3-hydroxychloroquine (HCQ). Conversely, autophagy can be 
pharmacologically induced by targeting mTOR with rapamycin (163).  
 
 
 
 
 
 
 
 
 
   56 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-8 The autophagy pathway and its role in cellular adaptation in 
response to nutrient deprivation 
Autophagy is activated by a decrease in intracellular nutrients and involves 
the sequestration of cytoplasmic material by an isolation membrane to form 
the  autophagosome.  The  autophagosome  then  fuses  with  a  lysosome,  to 
form  an  autolysosome,  where  the  sequestered  material  is  degraded. 
Degradation of this material by the autolysosome generates free fatty acids 
and amino acids that can be used by the cell to maintain mitochondrial ATP 
energy production and protein synthesis, thus promoting cell survival.  
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In yeast, approximately 30 genes (known as the Atg genes), which are essential 
for autophagy or autophagy-related processes, are located downstream of TOR 
kinase. Most of these genes have homologues in higher eukaryotes and encode 
proteins that act in different stages of autophagosome formation. The Atg proteins 
can  be  divided  into 5 functional  groups depending  on function.  They  include  a 
protein serine/threonine kinase complex that responds to upstream signals such 
as mTOR (Atg1, Atg13, Atg17); a lipid kinase signalling complex that mediates the 
formation  of  the  isolation  membrane  (Atg6  (or  beclin  1),  Atg14,  Vps34,  and 
Vps15), ubiquitin-like conjugation pathways that allow vesicle expansion (the Atg8-
Atg-7  and  Atg12-Atg7  systems),  a  recycling  pathway  that  mediates  the 
disassembly of Atg proteins from matured autophagosomes (Atg2, Atg9, Atg18) 
and vacuolar permeases that alow the efflux of amino acids from the degradative 
compartment (Atg22) (165).  
 
The identification of the genes and signals which regulate the autophagy process 
has  also  allowed  the  cellular  manipulation  and  detection  of  autophagy.  
Classically,  electron  microscopy  (EM)  was  used  as  the  gold-standard  to 
demonstrate  autophagosomes  in  cells.  However,  more  recently  the 
autophagosome-associated protein microtubule-associated protein 1 light chain 3 
(LC3)  (mammalian  homologue  of  yeast  Atg8)  has  been  used  as  a  marker  of 
autophagy. When autophagy is not activated, LC3 is localised in the cytoplasm; 
however,  upon  the  execution  of  autophagy,  LC3  links  up  with  the  isolation 
membrane and remains associated with the autophagosome membrane. For this 
reason,  transfection  with  the  green  fluorescent  protein-linked  LC3  (GFP-LC3) 
chimeric plasmid is useful for the detection of autophagosomes by fluorescence 
microscopy (166). LC3 has two forms: type I is cytosolic and type II is membrane-
bound. During autophagy, LC3-II increases by conversion from LC3-I. Therefore,   58 
the increase of LC3-II can be detected by immunoblot analysis because LC3-I and 
LC3-II have different molecular weights (166). 
 
Increasing evidence suggests that autophagy is important in tumour development. 
In  all  eukaryotic  organisms,  autophagy  promotes  the  survival  of  normal  cells 
during  nutrient  starvation.  Similarly,  autophagy  might  promote  the  survival  of 
rapidly  growing  cancer  cells  that  have  outgrown  their  vascular  niche  and  face 
conditions of hypoxia or metabolic stress (167).  
 
It has also been shown that autophagy may also enhance the survival of cancer 
cells  by  targeting  damaged  mitochondria  and  other  organelles  for  lysosomal 
degradation  (168),  thus,  evading  the  oxidative  stress  response  that  can  be 
triggered by activated cancer-causing genes or by anti-cancer treatments. Recent 
data suggests that CML cells undergo autophagy in response to TK inhibitor (TKI) 
treament  (169,  170).  Moreover,  combination  therapy  with  autophagy  inhibitors, 
augmented  the  anti-leukaemic  effects  of  both  suberoylanilide  hydroxamic  acid 
(SAHA) (171) and dasatinib (to be discussed further later in this thesis) (172) on 
human primary CML cells in vitro. 
 
In the majority of circumstances, autophagy serves as an adaptation pathway to 
cellular stress that promotes cell survival. However, an apparent paradox is the 
fact that autophagy is also considered as a form of non-apoptotic cell death or 
“type II” cell death. Indeed, allelic loss of the essential autophagy gene beclin 1 is 
found with high frequency in human breast, prostate and ovarian cancers (173, 
174).  Furthermore,  inactivation  of  beclin1  leads  to  increased  tumourigenesis  in 
mice  (175,  176).  Therefore,  whether  autophagy  protects  against  or  causes 
disease is controversial and whether to turn autophagy on or off in a cancer cell   59 
also remains a subject of much debate. This further highlights the need to clarify 
the mechanisms of autophagy and its inhibition in more detail. 
 
1.2.5 GF independence of BCR-ABL
+ cells  
1.2.5.1 Interleukin-3 
Interleukin-3  (IL-3)  is  a  17-kDa  cytokine  which  functions  as  a  multipotent 
haemopoietic GF. Through activation of the IL-3 receptor, IL-3 induces activation 
of JAK-STAT, PI3K/Akt and Ras signalling pathways, to promote the proliferation, 
maturation, survival and probably self-renewal of pluripotent HSCs and cells of 
myeloid, erythroid and megakaryocytic lineages (177).  
 
1.2.5.2 Granulocyte-Colony Stimulating Factor 
Granulocyte-colony stimulating factor (G-CSF) is a 25-kDa secreted glycoprotein 
which also functions  as a cytokine  and was named for its specific induction of 
growth  of  haemopoietic  progenitor  cells  in  semi-solid  cultures  (178).  The  main 
biological  effect  of  G-CSF  is  to  cause  an  increase  in  proliferation  and 
differentiation of cells in the neutrophil lineage, from HSCs to mature neutrophils, 
through the activation of JAK-STAT, PI3K/AKt and Ras signalling (179).   
Neutropenia is a significant side effect of many cytotoxic chemotherapy regimes 
used to treat cancer. Therefore, the actions of G-CSF meant that it was initially 
tested in clinic for its ability to prevent or reduce severe neutropenia (180). Other 
functional roles for G-CSF include the mobilisation of HSCs from the BM into the 
peripheral blood (181) and the possible regulation of immune responses (182). 
 
1.2.5.3 The autocrine production of IL-3 and G-CSF in CML cells 
Several studies suggest that the aberrant production of haemopoietic cytokines, 
such as IL-3 and G-CSF, could play a role in CML pathogenesis. Investigations   60 
have  shown  that  similar  biochemical  changes,  which  occur  in  normal  cells 
following exposure to high concentrations of IL-3, can be demonstrated in both 
BCR-ABL-transformed cell lines and primary CML cells (183). Murine models have 
demonstrated  that  the  transplantation  of  BM  cells,  retrovirally  transduced  or 
transgenically-engineered  to  produce  IL-3,  may  induce  the  development  of  a 
myeloproliferative disorder (184-186). Further in vitro investigations have shown 
that retroviral introduction of p210
BCR-ABL into cytokine-dependent cell lines induced 
GF-independent proliferation, in association with autocrine production of IL-3 and 
G-CSF (187-189). However, one group did note that IL-3 and GM-CSF were not 
required for the induction of a BCR-ABL-mediated CML-like disorder in mice, but 
may be required for disease maintenance (189).  Jiang et al. furthered this work by 
showing that primitive CD34
+ cells, isolated from patients with CP CML, express 
aberrant  RNA  transcripts  for  IL-3  and  G-CSF.  This  was  associated  with  an 
autocrine  production  of  IL-3  and  G-CSF  which  resulted  in  increased  STAT5 
phosphorylation  and  autonomous  proliferation  in  cytokine-free  cultures  (190). 
Other groups have shown that normal progenitor cells die when cultured under the 
same conditions (83, 191). This evidence suggests that the autocrine GF loop is a 
further mechanism for selective CML cell proliferation and survival. 
 
1.2.6 Historical Treatment of CML 
The  management  of  CML  has  changed  significantly  since  the  first  treatment 
attempts with arsenic (Fowler’ solution) in 1856. Other early treatment strategies 
included benzene, radiotherapy and splenectomy which were used as palliative 
therapies and did not affect the overall survival of patients (192).   
 
In the 1950’s, the oral alkylating agent bulsulfan was introduced for the treatment 
of  patients  with  CP  CML.  Bulsulfan  was  convenient  to  administer  and  was   61 
relatively  specific  for  the  haemopoietic  tissue.  However,  bulsulfan  therapy  was 
associated  with  severe  side  effects  such  as  prolonged  myelosuppression, 
idiosyncratic pulmonary reactions (“bulsulfan lung”) and BM fibrosis (193). 
 
In the 1970’s, bulsulfan therapy was largely replaced by hydroxyurea, a cell cycle-
specific inhibitor of DNA synthesis. It produces rapid but transient haematological 
control  and  is  well  tolerated  with  fewer  adverse  effects.  Both  bulsulfan  and 
hydroxyurea produced complete haematologic responses in 50 to 80% of treated 
patients with CML and these responses could be maintained for several years. 
However, cytogenetic responses were rare and most patients progressed to the 
BC  stage  (194).  Although  these  agents  did  provide  some  clinical  benefit  for 
patients with CML they did not significantly alter the natural history of the disease. 
 
Allogeneic stem cell transplantation (alloSCT) was introduced in the 1980’s, which 
for the first time, offered a curative potential for younger CML patients (<50-55 
years of age) with HLA-matched donors (195). Indeed, the complete elimination of 
the malignant clone in CML, defined by inability to detect BCR-ABL transcripts by 
qRT-PCR,  is  only  possible  with  alloSCT  (196).  However,  this  procedure  has  a 
significant morbidity and mortality rate of between 20-40%, due to the associated 
graft-versus-host  disease  and  frequent  infections  (58).  Further,  the  majority  of 
patients are not eligible for this therapy, due to age, the lack of a suitable donor 
and the associated high risk of mortality (197). 
 
The early 1980’s also saw the introduction of IFNa and began a new era for the 
treatment  of  CML.  IFNa  is  given  by  subcutaneous  injection  and  provides  a 
significant  survival  advantage  when  compared  to  bulsulfan  or  hydroxyurea 
treatment (198). It is effective in reducing the leukocyte count and reversing the   62 
clinical and laboratory features of CML. Additionally, it was observed that 5-15% of 
IFNa-treated patients achieved a significant reduction in Ph
+ metaphases (199). 
Combination  with cytosine  arabinoside (AraC) further improved  response rates, 
with  the  induction  of  a  complete  haematological  response  (CHR)  of  66%  and 
major cytogenetic response (MCR) of 41% with a survival rate of 85.7% within 
three  years  (200).  Cytogenetic  response  is  an  important  prognostic  factor  for 
improved  survival.  Definitions  of  response  are  given  in  Table  1-4.  These  early 
studies  with  IFNa  demonstrated  that  cytogenetic  responses  could  be  achieved 
using  drug  treatment.  Therefore,  this  became  the  overall  therapeutic  target  for 
patients with CML 
 
 
Haematological 
response 
 
Cytogenetic 
response¥ 
Molecular 
response† 
Complete* 
Plt <450x10
9/L 
WC <10x10
9/L 
normal differential 
spleen not palpable 
Complete Ph
+ 0% 
Partial Ph
+ 1-35% 
Minor Ph
+ 36-65% 
Minimal Ph
+ 66-95% 
None Ph
+ >95% 
Complete 
Undetectable 
Major <0.10% 
 
Table 1-4 CML disease response definitions 
[  *Plt-  Peripheral  blood  platelet  count,  WC-  white  cell  count  with  normal 
differential  implying  a  lack  of  immature  granulocytes  and  <5%  basophils. 
¥Ph+ as % of total metaphases (at least 20) examined in the BM. †BCR-ABL 
to control gene ratio. Undetectable levels depend on the sensitivity of assay. 
A major response may also be defined as a 3 log reduction from baseline. 
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1.2.6.1 The development of an ABL TKI 
Studies investigating the structure of BCR-ABL and its importance in the malignant 
transformation  of  HSCs  in  CML  provided  the  rationale  for  targeting  BCR-ABL 
function therapeutically. This led to one of the most important advances in CML 
therapy to date - the development of imatinib mesylate (IM). 
 
In  the  early  1990’s,  Anafi  et  al.  first  reported  that  the  tyrphostins,  AG568  and 
AG112 inhibited the TK activity of BCR-ABL in a BC-derived CML cell line, K562 
(201).  Tyrphostins  have  competitive  activity  towards  ATP  and/or  substrate. 
However, despite showing effective activity in vitro, these compounds were not 
developed for clinical use. A further early compound which demonstrated activity 
towards BCR-ABL was the benzoquinonoid ansamycin antibiotic, herbimycin A. 
Herbimycin  A  was  shown  to  inhibit  the  growth  of  a  number  of  p210
BCR-ABL 
transformed cells, without affecting the growth of Ph
- haemopoietic cell lines (202) 
and  also  prolonged  the  survival  in  a  SCID  mouse  model  of  a  disease  akin  to 
human Ph
+ ALL (203). It  was originally thought that herbimycin  A inhibited the 
BCR-ABL kinase, however, it was later shown to promote the degradation of BCR-
ABL protein (204). Taken together, the data from investigations using these early 
compounds suggested that the development of a specific inhibitor towards BCR-
ABL would be an effective therapeutic agent in CML and other Ph
+ leukaemias. 
 
1.2.7 The development of IM  
Scientists  at  Ciba  Geigy  (now  Novartis)  led  the  early  development  of  IM  by 
initiating a screen of a large number of ATP-competitive 2-phenylaminopyrimidine 
compounds for protein TK inhibitory activity. STI 571 (formerly CGP 57148B, now 
IM;  GlivecTM  or  GleevecTM,  Novartis  Pharmaceuticals,  Basel,  Switzerland) 
emerged from the screen as the lead TKI for preclinical development (Figure 1-9).    64 
                         
 
Figure 1-9 Structure of IM 
 
IM was found to have potent inhibitory activity towards ABL, c-Kit and platelet-
derived  GF  receptor  (PDGF-R).  It  exerts  effect  on  BCR-ABL  by  competitive 
inhibition  of  ATP.  It  selectively  binds  to  the  NH2-terminal  anchor  region  of  the 
ATP-binding  pocket  or  “activation  loop”  thereby  preventing  BCR-ABL 
autophosphorylation, TK activity and subsequent phosphorylation of downstream 
target  substrates  (205)  (Figure  1-10).  The  activation  loop  controls  the  catalytic 
activity  of  the  kinase  by  switching  between  the  active  and  inactive  states. 
Crystallographic  studies  show  that  IM  binds  to  the  ATP  site  only  when  the 
activation loop is closed, thereby stabilizing the inactive state and thus, preventing 
the conformational change to the active form of the oncoprotein (206). 
IM was found to inhibit ABL-kinase activity with 50% inhibitory concentration (IC50) 
values ranging between 0.1 and 0.35mM using in vitro kinase assays, in a range of 
cell lines expressing constitutively active ABL, such as viral ABL (v-ABL) (207), 
p210
BCR-ABL (205), p185
BCR-ABL (208, 209) and translocated ets leukaemia (TEL)-
ABL (208). Activity against the PDGFR and Kit were found to be in a similar range. 
Conversely, the IC50 values were at least 100-fold higher for a large number of 
other  tyrosine  and  serine/threonine  kinases,  indicating  that  IM  functions  with  a 
high level of selectivity (210). 
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Figure 1-10 Mechanism of action of IM 
BCR-ABL  requires  ATP  binding  for  phosphorylation  of  substrates  and 
subsequent activation of downstream pathways that promote cell survival, 
proliferation  and  regulation.  IM  can  compete  with  ATP,  binding  to  the 
inactive  state  of  BCR-ABL,  preventing  the  phosphorylation  of  substrates 
that would activate intracellular signals. 
 
In initial cellular studies, IM was shown to specifically inhibit the proliferation of 
myeloid cell lines expressing BCR-ABL or CML BC cell lines in vitro (205, 211, 
212). The inhibition of proliferation with cell death through apoptotic mechanisms 
was demonstrated to occur between 0.5 and 1mM of IM, whereas concentrations 
of up to  10mM IM  did not  affect the  growth of BCR-ABL
- cell lines (205, 211). 
Additional  experiments  showed that IM  was equally  potent in p185- and p210-
expressing cells (208, 209). Colony-formation assays were also performed, using 
mononuclear cells (MNC)s from CML patients and normal individuals, to assess 
the  effects  of  IM  on  committed  haemopoietic  progenitors.  In  these  studies,  IM 
induced a 92-98% decrease in the number of BCR-ABL
+ colonies formed with no 
or minimal inhibition of normal colony formation at concentrations up to 1mM (205, 
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211). These findings were then confirmed in stroma-dependent long-term cultures 
(213, 214). 
 
Animal  studies  demonstrated  a  dose-dependent  inhibition  of  tumour  growth  in 
animals inoculated with BCR-ABL-transformed 32D cells and treated daily with IM, 
with inactivity against v-SRC-expressing tumours. However, using a once-per-day 
injection  schedule  of  up  to  50mg/kg,  tumour  growth  was  inhibited,  but  not 
eradicated (205). This modest in vivo activity could be explained by the murine 
pharmacokinetic profile of IM. It revealed a short drug half-life in mice, where a 
single dose of IM inhibited BCR-ABL kinase activity for only 2 to 5 hours. This was 
not seen in any other species - ie. rat, dog or human. In nude mice, a 3-times daily 
administration of IM resulted in continuous inhibition of BCR-ABL kinase activity. 
This led to an eradication of tumours in 87% of IM-treated mice (215). From this 
data, it  was suggested that  IM  was  able to  target some,  but  not all leukaemic 
clones  and  therefore,  it  was  likely  that  continuous  exposure  to  IM  would  be 
required for optimal therapeutic effects. 
 
1.2.7.1 IM and Phase I Clinical Trials 
Phase I studies with IM began in June 1998 and were designed to establish the 
maximum tolerated dose. The study consisted of patients with CP CML who were 
refractory or resistant to therapy with IFNa (216). IM was given as a once daily 
oral therapy and was well tolerated. Side effects were generally mild and included 
occasional  nausea,  periorbital  oedema,  and  muscle  cramps.  98%  of  CP  CML 
patients, who had failed IFNa therapy and were treated with IM at 300mg and 
above, achieved a CHR. Furthermore, only one of these patients had relapsed at 
one-year of follow-up. Pharmacokinetic studies showed that with a dose of 300mg, 
plasma levels of IM were equivalent to the effective in vitro concentration of 1mM.   67 
Using the current standard dose for CP CML of 400mg IM, a peak plasma level of 
approximately  4.6mM  and  trough  level  of  approximately  2.13mM  could  be 
achieved, with a half-life of 19.3 hours. These data indicated that the once-daily 
dosing schedule would be sufficient to cause continuous kinase inhibition.  
Following  these  promising  results,  the  initial  study  was  expanded  to  include 
patients with myeloid or lymphoid BC CML and relapsed or refractory Ph
+ ALL 
patients (217). With doses at or exceeding 300mg per day, 21 of 38 (55%) myeloid 
BC patients responded, with 11% achieveing a CHR. In patients with lymphoid BC 
or ALL, 70% responded, including 20% who had complete responses. However, 
all but one patient with lymphoid BC or ALL had relapsed within weeks to months. 
 
1.2.7.2 IM and Phase II Clinical Trials 
The successful data from the Phase I trial led to the commencement of Phase II 
studies, which began in late 1999 using IM as a single agent for all stages of CML. 
In CP patients who had failed IFNa therapy, 95% achieved a CHR and 60% a 
MCR, which was defined as a reduction to less than 35% Ph
+ metaphases. Only 
13% of these patients had relapsed at the median follow-up of 29 months (218). 
However, although the response rates in AP and BC CML patients were also quite 
high,  the  relapses  were  much  more  common,  with  the  majority  of  BC  patients 
relapsing during the first year of therapy (219, 220). Overall, these clinical trials 
confirmed the promising results of the phase I studies. This led to Food and Drug 
Administration (FDA) approval of IM for the treatment of CML in advanced phase 
and after failure of IFNa therapy. 
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1.2.7.3 IM and Phase III Clinical Trials - A Randomised Comparison of IM with 
IFNa a a a Plus Ara-C 
The next clinical trial was a phase III study of newly diagnosed CP CML patients 
which compared IM treatment with the standard therapy of IFNa plus Ara-C. This 
was named the International Randomized Study of Interferon and STI571 (IRIS) 
study  and  was  initiated  in  June  2000.  The  trial  managed  to  reach  its  goal  of 
recruiting  more  than  1000  patients  in  a  7-month  period  (221).  At  the  median 
follow-up  of  18  months,  patients  who  had  been  randomised  to  IM  therapy 
responded significantly better than the patients treated with IFNa plus Ara-C in all 
measured parameters, as shown in Table 1-5.  
 
  IM (% responding at 
400mg/day) (n=553) 
IFNa a a a plus Ara-C 
(n=553) 
CHR  97  69 
MCR  87  35 
CCR  76  14 
Intolerence  3  31 
Progressive disease  3  8.5 
 
Table 1-5 Phase III results of IM versus IFNa a a a plus Ara-C for newly diagnosed 
CP patients with CML - taken from (221). 
Results  are  with  a  median  follow-up  of  18  months.  [CHR-  complete 
hematologic response; MCR- major  cytogenetic response;  CCR-  complete 
cytogenetic  response;  intolerance  leading  to  discontinuation  of  first-line 
therapy;  progressive  disease,  progressing  to  AP  or  BC.  All  of  these 
differences are highly significant, with p < 0.001.] 
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The apparent superiority of IM treatment, led to the results being disclosed early 
and most of the patients were crossed over into the IM arm.   
 
Five  year  follow-up  studies  have  shown  more  impressive  results for  IM.  In  the 
most  recent  update  of  the  IRIS  study,  the  estimated  overall  survival  for  newly 
diagnosed CP CML patients, who received IM as an initial therapy was 89%. The 
best observed rate of CHR (normal white count and loss of symptoms) was 97% 
and the CCR (no Ph
+ metaphases) rate was 87%. Furthermore, an estimated 93% 
of IM-treated patients remained free from disease progression to AP or BC phase 
CML (222). 
 
1.2.8 Molecular persistence 
The  monitoring  of  residual  disease  in  CML  patients  is  generally  performed  by  
qRT-PCR for BCR-ABL. It was observed that in the Phase III trial, for complete 
cytogenetic responders, the risk of disease progression was inversely correlated 
with the reduction of BCR-ABL transcripts as compared with pre-treatment levels 
(223). However, despite the fact that the majority of patients randomised to the IM 
arm achieved a CCR, most of these patients still had detectable leukaemia. Only a 
small proportion (4%) of patients obtained a complete molecular response (CMR), 
where they became negative for BCR-ABL transcripts by qRT-PCR. Therefore, for 
the majority of IM-treated patients, there is persistence of the leukaemic clone and 
most  have  relapsed  if  treatment  was  discontinued.  It  is  hypothesised  that  this 
minimal residual disease (MRD) is a result of a primitive “quiescent” subpopulation 
of  leukaemic  cells  (224),  which  may  be  the  cause  for  relapse  at  a  later  date. 
Holyoake et al. were the first to isolate such primitive, quiescent cells - which were 
found to account for around 0.5% of the CD34
+ compartment - from CML cells 
using two different approaches (224, 225). The authors first obtained viable G0   70 
and G1/S/G2/M fractions by fluorescence-activated cell sorting (FACS), using Hst 
and PY staining, with quiescence being confirmed by the subsequent analysis of 
Ki67 and cyclin D expression. In GF-supplemented serum-free cultures, this non-
proliferating  population  could  also  be  isolated  by  first  labelling  CD34
+  CML 
progenitor  cells  with  carboxyfluorescein  diacetate  succinimidyl  ester  (CFSE),  in 
order to track cell division at high resolution by FACS. The group found that these 
quiescent  cells  were  Ph
+  and  expressed  high  levels  of  CD34,  but  lacked 
expression of lineage markers, CD38, CD45RA or CD71.  They also had in vitro 
progenitor activity as demonstrated by colony-forming cell (CFC) and long-term 
culture-initiating cell (LTC-IC) assays and were capable of engrafting NOD/SCID 
mice (224). Significantly, these studies also demonstrated that quiescence is a 
temporary phenomenon, whereby the G0 cells can re-enter the cell cycle, via a 
mechanism associated with the upregulation of IL-3 expression (225). Therefore, 
the existence of a transiently quiescent leukaemic clone may account for the fact 
that  IM  is  unable  to  completely  eradicate  CML  and  also  provides  a  feasible 
explanation for patients often relapsing at a later date.  
 
In  vitro  studies  have  also  demonstrated  that  these  BCR-ABL
+  quiescent  cells 
appear to be inherently resistant to IM therapy, at concentrations up to 10 times 
higher than those achievable in vivo, whereas the more mature, proliferating cells 
remain sensitive (226, 227). Bhatia and colleagues also found that CD34
+ cells 
taken  from  IM-treated  patients,  who  had  achieved  CCR,  were  able  to  form 
colonies  in  both  CFC  and  LTC-IC  assays  (228).  Jorgensen  et  al.  identified  a 
second subset of primitive cells within a total CML cell population. These cells 
were found to undergo cell cycle arrest and accumulate in the G0/G1 phase in the 
presence of anti-proliferative agents, including IM (229). It was also demonstrated 
that these cells could be encouraged into cell cycle with sequential pulsed therapy.   71 
Overall,  these  data  suggest  that  IM  is  able  to  control  the  disease,  through 
inhibition  of  stem  cell  proliferation,  but  is  unable  to  eliminate  the  quiescent 
malignant clone. This has also since been postulated by a mathematical model 
which  has  demonstrated  that  during  IM  treatment,  the  clearance  of  BCR-ABL 
transcripts follows a biphasic decline. The initial phase is characterised by a rapid 
clearance  of  transcripts,  whereas  the  second  phase  shows  a  slower  rate  of 
clearance.  This  model  predicts  that  this  biphasic  decline  is  likely  due  to  the 
differential  susceptibility  of  a  total  CML  population  to  IM  treatment.  The  more 
mature differentiated cells are readily cleared by the drug, whereas the G0 CML 
cells escape IM-induced apoptosis, simply by virtue of their quiescent state (230).  
 
1.2.9 Molecular resistance 
Another major clinical concern is the observation of molecular resistance in IM-
treated patients. This is generally observed in CML patients at the advanced stage 
of disease, with an estimated 4-year resistance rate of 20% in later CP and 70% to 
90% in AP/BC phases (220, 222), although, it has also been seen in CP CML 
patients.  IM  resistance  can  be  described  either  as  primary  (“refractoriness”), 
defined as a failure to achieve CHR at 3 months, a cytogenetic response at 6 
months  or  a  MCR  at  12  months; or secondary  (“acquired”),  defined as  loss of 
established  IM  response  or  progression  to  AP  or  BC  (231).  It  has  also  been 
speculated  that  there  are  2  broad  categories  of  IM  resistance:  BCR-ABL-
independent and BCR-ABL-dependent.  
 
1.2.9.1 BCR-ABL-independent mechanisms of resistance 
BCR-ABL-independence suggests that the leukaemia cells are no longer reliant on 
BCR-ABL to drive proliferation; but have acquired additional oncogenic mutations 
and mechanisms, which are responsible for their growth and survival. Donato et   72 
al. demonstrated that compensatory SRC activation within a CML cell may play a 
role  in CML  progression to  BP and BCR-ABL independent IM resistance (232, 
233). It was found that patients who have progressed whilst being treated with IM 
had an elevated SRC kinase activity, while the BCR-ABL transcripts and protein 
were reduced. Furthermore, it has also been shown that the SRC family kinase 
(SFK), LYN, is persistently activated in patients who have failed IM therapy and 
who  harbour  no  BCR-ABL  mutations  (234).  These  data  have  led  to  the 
development of new agents that target the SRC kinase and inhibit other non-ATP 
binding  sites  (to  be  discussed  further  later).  The  induction  of  autocrine  GF 
secretion  is  another  potential  mechanism  for  IM  resistance.  Adaptive  autocrine 
secretion  of  GM-CSF  was  shown  to  mediate  BCR-ABL-independent  TKI 
resistance  via  activation  of  the  anti-apoptotic  JAK2-STAT5  pathway.  This  GM-
CSF-induced resistance could then be overcome by the inhibition of JAK2 (235). A 
further possibility is that IM resistant cells are inherently refractory to TKI treatment 
and resistance reflects intrinsic properties of CML stem cells, to sustain survival in 
the presence of drug treatment. Thus, BCR-ABL is no longer a relevant target for 
IM in these cells and any specific BCR-ABL inhibitor would be ineffective in this 
situation.  
 
1.2.9.2 BCR-ABL-dependent mechanisms of resistance 
Conversely,  resistance  in  Ph
+  leukaemias  may  be  dependent  on  BCR-ABL. 
Proposed  mechanisms  of  resistance  include  BCR-ABL  amplification-  where 
multiple  copies  of  BCR-ABL  gene  can  be  detected  in  the  interphase  nuclei  in 
patients who relapse after initially responding to IM, resulting in overexpression of 
the  BCR-ABL  oncoprotein  (236-238).  However,  BCR-ABL  dependent  IM 
resistance is most often attributed to the development of point mutations within the 
ABL-kinase  domain,  which  are  found  in  more  than  50%  patients  with  acquired   73 
resistance  (132,  238-240).  In  2001,  Gorre  and  colleagues  described  the 
development of BCR-ABL mutations in 11 patients with BC phase CML or Ph
+ ALL 
who relapsed on IM therapy (238). BCR-ABL gene amplification was only detected 
in  three  patients.  Following  sequencing  of  the  ATP-binding  pocket  and  the 
activation loop of the kinase domain, an identical cytosine to thymidine mutation at 
ABL nucleotide 944 in 6 of 9 assessable patients was identified. This mutation 
resulted  in  a  single  amino-acid  change  at  position  315,  is  designated  T315I. 
Threonine 315 (also known as the “gatekeeper” residue) is located at the binding 
site  of  ABL  and  forms  a  crucial  hydrogen  bond  interaction  with  IM  (241).  The 
T315I  mutation  disrupts  this  bond  interaction  which,  along  with  the  bulkier 
isoleucine  side  chain,  sterically  inhibits  IM  binding.  This  results  in  complete 
insensitivity to IM therapy at clinically achievable doses (238). The T315I mutant 
remains  the  most  clinically  significant  as  it  linked  to  poor  prognosis  in  CML 
patients  (242).  To  date,  more  than  100  kinase  domain  mutations  have  been 
described in vivo and from in vitro screens (240, 241, 243, 244), each conferring a 
different transforming potential and level of resistance relative to wild-type BCR-
ABL. These include mutations within the ATP binding site (P-loop), activation loop 
(A-loop) or the caboxy terminus. Some mutations only confer a moderate degree 
of resistance; however, the mutations within the P-loop are often associated with a 
poorer outcome (239). This is probably due to the restriction of IM-binding due to 
mutations  altering  and  destabilising  the  conformation  of  the  ATP-binding  site 
(240). However, it is also worth noting that the presence of BCR-ABL mutations 
does not always explain resistance in IM-treated patients (245).  
 
It has been noted that the concentration of drug within a target cell is a further 
important treatment consideration; therefore, the active efflux of chemotherapeutic 
drugs  from  target  cells  could  be  a  mechanism  of  drug  resistance.  The  ABC   74 
transporter  (ABCB1  (or  MDR-1))  is  a  cell-surface  transmembrane  protein  that 
mediates multi-drug resistance in a variety of malignancies through the regulation 
of chemotherapeutic agent efflux. Cells from BC CML patients have demonstrated 
a higher expression of ABCB1 compared with those from CP patients and has 
been linked to the development of IM resistance (237). Several groups have also 
shown that IM is a substrate for ABCB1 (246, 247). However, the role of ABCB1 in 
CML  remains  unclear  as  in  vitro  studies  have  shown  that  overexpression  of 
ABCB1  in  K562  cells  does  not  confer  resistance  to  IM  (248).  Furthermore, 
inhibition of ABCB1 did not enhance the therapeutic effect of IM against BCR-ABL 
activity in primitive CML cells (249). Another related ABC transporter, ABCG2, is 
also  present  on  HSCs  and  has  been  suggested  as  another  candidate  for 
regulating  intracellular  IM  availability.  However,  Jordanides  and  colleagues 
demonstrated  that  IM  is  an  inhibitor  of,  but  not  a  substrate  for  ABCG2  and 
therefore does not modulate the intracellular IM concentrations within CML stem 
cells (250).  
 
1.2.10 Second generation TKIs   
In  an  attempt  to  overcome  IM-resistance,  a  second  generation  of  BCR-ABL 
inhibitors have been developed. These include the ATP-competitive compounds, 
nilotinib, bosutinib and dasatinib. 
 
1.2.10.1 Nilotinib (AMN107, Tasigna
TM) 
Nilotinib  (Tasigna™;  AMN107,  Novartis,  Basel,  Switzerland)  is  an  orally 
administered second-generation TKI which inhibits ABL-kinase, PDGFR, Kit and 
ephrin receptor kinase and is currently approved by the FDA for the treatment of 
CP CML or AP CML (Figure 1-11). Nilotinib is an analogue of IM, which disrupts 
the  ATP-phosphate-binding  pocket,  binding  exclusively  to  the  inactive   75 
conformation of the ABL-kinase domain. Nilotinib has additional alterations in its 
structure  that  allow  higher  binding  affinity  and  in  IM-sensitive  cell  lines, 
demonstrates  43-  to  60-fold  greater  potency  than  IM.  In  IM-resistant  cell  lines, 
nilotinib  demonstrates  at  least  20-fold  more  potency  than  IM.  Indeed,  nilotinib 
inhibited 32 of 33 IM-resistant mutant cell lines in vitro, except for cells containing 
the T315I mutation (251, 252), and also prolonged survival in mice injected with 
cells expressing both wild-type and IM-resistant BCR-ABL mutants (253). 
                      
                                 
Figure 1-11 Structure of nilotinib 
 
Phase I studies determined the appropriate dosing of nilotinib and established its 
clinical safety and efficacy in patients with CML or Ph
+ B-ALL who were resistant 
or intolerant to IM. Promising response rates were observed in patients with CP 
disease, with a CHR achieved in 92% (11 of 12). Responses in advanced stage 
disease were lower, with 72 (33 of 46) and 48% (22 of 46) of patients with AP 
disease  achieving  haematological  and  cytogenetic  responses,  respectively. 
Among  patients  with  BP  disease,  39%  (13  of  33)  achieved  a  haematological 
response and 27% (9 of 33) achieved a cytogenetic response (254). 
Subsequent  clinical  evaluation  has  since  confirmed  the  safety  and  efficacy  of 
nilotinib treatment. In Phase II studies, IM-resistant or -intolerant CP CML patients, 
who were treated with 400 mg nilotinib twice daily, demonstrated MCR and CCR 
rates of 48 and 31% at 6 months, respectively. The estimated overall survival rate 
at 12 months was 95% (255). Within the group of patients whose baseline BCR-
ABL  mutation  status  was  available,  IM-resistant  patients  with  no  BCR-ABL   76 
mutations  showed  similar  MCR  rates  as  patients  with  mutated  BCR-ABL  -  51 
versus 42%, respectively. Furthermore, consistent with the in vitro data, 4 out of 4 
patients with the T315I mutation showed no response to IM treatment (255). 
Further in vitro studies have shown that nilotinib has anti-proliferative effects on 
CD34
+ CML cells, but does not eradicate the most primitive cells within the stem 
cell  compartment  (256).  Therefore,  whether  nilotinib  like  IM,  contributes  to  the 
disease persistence phenomenon still remains to be seen. 
 
SFKs  comprise  of  nine  structurally  homologous  cytoplasmic  non-receptor  TKs 
(SRC, FYN, YES, BLK, YRK, FGR, HCK, LCK and LYN) which regulate signalling 
pathways  involved  in  cell  growth,  differentiation  and  survival  (257).  As  stated 
previously,  studies  have  shown  that  the  overexpression  of  SFK, such  as  LYN, 
plays a role in the proliferation and survival of CML cells, and in some cases, IM 
resistance  (233).  Further,  experiments  with  SRC-dominant-negative  mutants 
suggest  that  SFKs  are  involved  in  the  proliferation  of  BCR-ABL
+  cell  lines 
(258),(259). Therefore, the simultaneous inhibition of BCR-ABL and SRC kinase 
makes a further attractive option for CML therapy. 
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1.2.10.2 Bosutinib (SKI-606) 
Bosutinib  (SKI-606,  Wyeth,  Madison,  NJ)  is  an  orally  available  4-anilino-3-
quinolinecarbonitrile derivative (Figure 1-12) that is a potent dual inhibitor of the 
SF and ABL TK activity with an IC50 of 1.2 and 1nM, respectively.  
 
                      
 Figure 1-12 Structure of bosutinib 
 
Bosutinib showed in vitro activity against all IM-resistant mutants, except T315I, 
and caused regression of large K562 xenografts in nude mice (260). Unlike both 
IM and nilotinib, bosutinib does not significantly inhibit PDGFR  and Kit activity, 
which may result in a safer toxicity profile in vivo. Indeed, bosutinib demonstrated 
favourable  toleribility  in  Phase  I  and  II  trials  with  patients  who  are  resistant  or 
intolerant to IM. Responses up to CCR were achieved in patients who harboured 
various  BCR-ABL  mutants,  however,  no  patient  with  the  T315I  mutation 
responded  (261).  Recent  in  vitro  studies  suggest  that  bosutinib  does  not 
demonstrate increased ability to eliminate primitive CML progenitors by apoptosis, 
as compared to IM (262), however due to its toleribility; bosutinib may be a good 
option for patients who have failed therapy with IM or any other second generation 
TKI. 
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1.2.10.3 Dasatinib (BMS-354825; Sprycel®) 
Dasatinib  (BMS-354825;  Sprycel,  Bristol-Myers  Squibb,  Princeton,  NJ)  is  a 
second-generation TKI for the treatment of IM-resistant or -intolerant patients with 
Ph
+ leukaemias, that was approved by the FDA in 2006 (263) (Figure 1-13). 
                    
                  Figure 1-13 Structure of dasatinib 
 
Like bosutinib, dasatinib is also a potent oral inhibitor of SFKs and BCR-ABL, and 
has added activity against Kit, PDGFR and Ephrin receptor TKs (264). Dasatinib 
has a 325-fold greater potency than IM against cells expressing wild-type BCR-
ABL, with an IC50 of less than 1nM, and is effective against all IM-resistant BCR-
ABL  mutants  tested  in  vitro,  except  T315I  (252).  Dasatinib  binds  to  the  ATP-
binding site in a similar position to IM, but is also able to bind both the active and 
inactive  conformation  of  ABL-kinase  (265).  This  less  stringent  conformation 
requirement  for  ABL-kinase  inhibition  may  be  a  further  way  of  overcoming  IM 
resistance.  
 
The clinical efficacy of dasatinib was demonstrated in a series of Phase II studies 
called the SRC/ABL Tyrosine Kinase Inhibition Activity Research Trials (START). 
The  START-C  trial  was  a  Phase  II  multicentre  study  for  the  assessment  of 
dasatinib treatment of patients with CP CML who were resistant or intolerant to IM 
(266). At the median follow-up of 24 months, data was available from 387 patients 
(288  IM-resistant  and  99  IM-intolerant).  In  91%  of  the  patients,  a  CHR  was   79 
achieved, with 62% obtaining a MCR. Responses were observed across all BCR-
ABL  mutations,  irrespective  of  the  location  (with  the  exception  of  T315I),  thus 
demonstrating  that dasatinib has activity across the  subgroups, including those 
patients with P-loop mutations (266). At the 24-month follow-up, progression-free 
and  survival  rates  were  determined  as  80  and  94%,  respectively.  Impressive 
responses have even been noted in myeloid and lymphoid BC CML with a CCR 
rate  of  more  than  20%  (267,  268).  However,  despite  these  promising  in  vivo 
results,  recent  in  vitro  data  showed  that  although  dasatinib  demonstrated 
increased efficacy over IM against earlier progenitor populations, it did not target 
the quiescent stem cell population (131). Therefore, dasatinib treatment alone may 
not have the ability to completely eradicate the disease. 
 
1.2.11 Oncogene Addiction 
The  term  ‘oncogene  addiction’  was  first  coined  by  IB  Weinstein  (269-271)  to 
describe the phenomenon by which some cancers acquire dependency on one or 
a few genes for the maintenance of the malignant phenotype and cell survival. 
Evidence for this concept has now been obtained from a number of systems such 
as, transgenic mice, where switching off the overexpressed “dependent” oncogene 
leads to growth inhibition, apoptosis and/or tumour regression. The dependence 
on  a  single  oncogene  for  survival  has  been  observed  in  murine  models  for  a 
number  of  different  cancers  including,  lung  tumours  induced  by  the  K-ras 
oncogene (272), melanoma induced by the H-ras oncogene (273), T-cell and AML 
induced by c-myc (274) and acute B-cell leukaemia induced by BCR-ABL (275). 
Similarly, mechanistic studies using human cancer cell lines have also illustrated 
the  oncogene  addiction  phenomenon.  The  inhibition  of  HER2  (276),  cyclin  D1 
(277), K-ras (278) and b-catenin (279) expression using antisense DNA or RNA 
interference systems attenuated the growth various human cancer cell lines. The   80 
most convincing evidence for the apparent dependency on oncogenes for tumour 
cell survival comes from examples of patients treated with molecularly-targeted 
drugs.  The  targeting  of  BCR-ABL  by  TKI  has  shown  remarkable  therapeutic 
efficacy.  TKI treatment has been demonstrated to efficiently kill a subset of cells 
expressing the oncogene, particularly in early CP CML (223).  However, despite 
the  impressive  clearance  of  the  majority  of  Ph
+  cells  by  IM  and  dasatinib,  the 
primitive  CD34
+38
-  cell  population  does  not  appear  to  undergo  apoptosis  even 
after several days TKI exposure (131). Therefore, it is still not clear whether early 
CML progenitor cells depend on BCR-ABL for their survival. 
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2. MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1  Small molecule inhibitors 
IM was provided as a white powder under a Materials Transfer Agreement from 
Novartis Pharma (Basel, Switzerland). It was dissolved in sterile H2O and stored 
as a 100mM stock solution at 4° C. Dasatinib was  pro vided as  a  white powder 
under a Materials Transfer Agreement from Bristol-Myers Squibb (Princeton, NJ, 
USA). It was dissolved in dimethyl sulfoxide (DMSO) to give a stock concentration 
of 20mM and stored in multiple aliquots at -20° C pr ior to use. All small molecule 
inhibitors were made up fresh and diluted to the appropriate concentration with 
PBS prior to use.   
 
 
2.1.2  Tissue culture supplies (including CD34
+ selection) 
Abbot Diagnostics 
Maidenhead, UK  LS1 BCR-ABL Dual Colour FISH probe 
Baxter Healthcare 
Nottingham, UK  Sterile water 
Becton Dickinson 
Plymouth, UK  Luer lock syringes 
Bio-Rad 
Hercules, CA, USA  Triton-X-100 
Chugai Pharma 
London, UK  Recombinant human G-CSF 
Greiner bio one 
Gloucestershire, UK 
25 and 75cm
3 tissue culture flasks 
96-well plates 
FACS tubes 
Pipette tips 
Hendley 
Essex, UK  Multispot microscope slides 
Invitrogen 
Paisley, UK 
2-Mercaptoethanol 
Colcemid 
Foetal calf serum (FCS) 
L-glutamine 200mM (100x) 
Phosphate buffered saline (PBS) 
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Penicillin-streptomycin solution 
(5000U/mL) 
RPMI 1640 medium 
Miltenyi Biotec 
Bisley, UK 
CliniMACS CD34 reagent 
CliniMACS PBS/EDTA buffer 
CliniMACS tubing set 
Nalge Nunc International 
Roskilde, Denmark 
35mm non-adherent tissue culture 
dishes 
75cm
3 non-adherent tissue culture 
flasks 
Cryotubes 
Cryofreezer container 
Vacubottles 
Sartorius 
Hannover, Germany 
Minisart 0.2m m m mM sterile filters 
Minisart 0.45m m m mM sterile filters 
Scottish National Blood 
Transfusion Service 
Glasgow, UK 
20% human albumin solution (ALBA) 
4.5% ALBA 
Sigma-Aldrich 
Dorset, UK 
Bovine serum albumin (BSA) 
Carbonate-bicarbonate buffer 
DMSO 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
E-64d protease inhibitor (1mg/mL) 
Ficoll/histopaque solution (1.077g/mL) 
G418 disulphite salt solution 
Hank’s buffered salt solution – calcium 
and magnesium free (HBSS-CMF) 
Hydrochloric acid (HCl) 
Hygromycin B 
Isocove’s Modified Dulbecco’s Medium 
(IMDM) 
Magnesium chloride (MgCl2) 
Pepstatin A protease inhibitor (1mg/mL) 
Poly-L-lysine 
Potassium chloride (KCl) 
Sodium azide 
Trisodium citrate 
Trypan blue 
Trypsin-EDTA 
Stem Cell Technologies 
British Columbia, Canada 
Bovine pancreatic deoxyribonuclease 
(DNAse I) 1mg/mL 
Bovine serum albumin/insulin 
/transferrin (BIT) serum substitute 
Flt-3 ligand 
Hydrocortisone 21-hemisuccinate 
IL-3 
IL-6 
Methocult
TM 
Myelocult
TM 
Stem cell factor (SCF) 
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Sterlin Ltd 
Hounslow, UK 
Iwaki Type I Collagen-coated 6-well 
plates 
Pastettes 
5mL, 10mL and 25mL disposable 
pipettes 
15 and 50mL sterile plastic falcon tubes 
90mm Petri dishes 
Thermo Fisher Scientific 
Loughborough, UK 
Immulon II HB 96-well flat bottomed 
plates 
Acetic acid 
Methanol 
Weber Scientific International, 
West Sussex, UK  Hawksley Neubauer counting chamber 
 
 
2.1.3  Flow cytometry reagents 
BD Biosciences, 
Oxford, UK 
Anti-human IgG FITC isotype control 
Anti-human IgG PE isotype control 
Anti-human IgG APC isotype control 
FACS flow 
FACS clean 
Mouse anti-human-active caspase-3-PE 
antibody  
Mouse anti-human-Ki67-FITC antibody  
Mouse anti-human-annexin-V-FITC 
antibody 
Mouse anti-human-CD34-APC 
Mouse anti-human-CD38-FITC 
Viaprobe- 7 aminoactinomycin D  
(7-AAD) 
Caltag Laboratories 
Silverstone, UK  Fix and Perm
® A and B 
Cell Signaling 
(New England Biolabs),  
Hitchin, UK 
 
Rabbit anti-human-p-CrkL antibody  
Rabbit anti-human-p-STAT5 antibody 
 
Molecular probes 
Eugene, OR, USA  CFSE 
Sigma-Aldrich 
Dorset, UK 
Anti-rabbit IgG-FITC conjugate 
Anti-rabbit IgG-PE conjugate 
Formaldehyde solution 
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2.1.4   Molecular biology supplies 
Abcam, Cambridge, UK  Anti-rabbit IgG 
Amersham Pharmacia Biotech Ltd 
Buckinghamshire, UK 
 
Rainbow  marker (RPN756) 
 
Applied Biosystems, 
Foster City, CA, USA 
High capacity cDNA archive kit 
Taqman gene expression assays- cyclin 
D1 and glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) 
qPCR mastermix plus 
Bio-Rad 
Hercules, CA, USA 
 
4-15% Tris-HCl gradient gels 
Laemmli sample buffer 
Immun-star ECL reagents 
Nitrocellulose membrane 
Tris/Glycine/SDS running buffer 
Tris/Glycine transfer buffer 
Tween-20 
Triton-X-100 
Cell Signaling  
(New England Biolabs), 
Hitchin, UK  
Anti-rabbit IgG horseradish peroxidase 
(HRP)-linked secondary antibody 
Rabbit anti-human-p-CrkL antibody  
Rabbit anti-human-LC3b antibody  
Rabbit anti-human-GAPDH antibody 
Rabbit anti-human-p-S6K antibody  
Rabbit anti-human-FoxO3a antibody  
Chemicon International 
Temecula, CA, USA 
Re-blot™ Plus Strong Antibody 
Stripping Solution 
Eurogentec Ltd 
Southampton, UK 
BCR-ABL p210 detection: 
ENF501 (FORWARD PRIMER): 
TCCGCTGACCATCAAYAAGGA 
ENF561 (REVERSE PRIMER): 
CACTCAGACCCTGAGGCTCAA 
ENP541 (PROBE): 
FAM-
CCCTTCAGCGGCCAGTAGCATCTGA-
TAMRA 
Fisher Scientific 
Loughborough, UK  Methanol 
Invitrogen (Molecular Probes) 
Paisley, UK  Anti-rabbit-Alexa Fluor 488 
Perbio 
Northumberland, UK  BCA kit 
Qiagen, 
Crawley, UK  RNeasy mini kit  
Roche, 
Burgess Hill, UK  PCR grade water 
Sigma-Aldrich 
Dorset, UK 
Ethylenediaminetetraacetic acid (EDTA) 
Ficoll/histopaque solution  
36.5% Formaldehyde solution 
NP-40   85 
Protease inhibitor cocktail 
Sodium chloride 
Tris (hydroxymethyl)aminomethane 
hydrochloride (Tris-HCl) 
Tris base 
Osmium tetroxide 
Uranyl acetate 
25% gluteraldehyde solution 
Sodium cacodylate 
SPI Supplies 
Loughborough, UK  300-mesh formvar-coated grids 
Taab Laboratories Equipment Ltd, 
Aldermaston, UK  Taab epoxy resin 
Upstate (Millipore) 
Watford, UK  Anti-phosphotyrosine (4G10) antibody 
Vector Laboratories Inc 
Burlingame, CA, USA 
VECTASHIELD
® mounting medium with 
DAPI 
 
 
2.2  Preparation of media and solutions 
2.2.1  Tissue culture media 
2.2.1.1 RPMI
++  
RPMI 1640  500mL 
FCS  50mL  
L-glutamine  5mL 
Penicillin/Streptomycin solution  5mL 
 
 
 
2.2.1.2 Serum free medium (SFM)  
 
BIT  25mL 
2-Mercaptoethanol  250m m m mL  
L-glutamine  1.25mL 
Penicillin/Streptomycin solution  1.25mL 
IMDM  97.25mL 
 
·  Made up in a Vacubottle and filter sterilised 
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2.2.1.3 SFM supplemented with GF cocktail (SFM+5GF) 
 
SFM  50mL 
IL-3 (50m m m mg/mL)  20m m m mL  
IL-6 (50m m m mg/mL)  20m m m mL 
G-CSF (50m m m mg/mL)  20m m m mL 
Flt-3 ligand (50m m m mg/mL)  100m m m mL 
SCF (50m m m mg/mL)  100m m m mL 
 
·  Filter sterilised through 0.22m m m mM filter 
 
 
 
2.2.1.4 RPMI for maintenance of stromal cell line M2-10B4 for LTC-IC 
 
RPMI 1640  500mL 
FCS  50mL 
L-glutamine  10mL 
Penicillin/streptomycin solution  10mL 
 
 
 
2.2.1.5 DMEM for maintenance of stromal cell line Sl/Sl for LTC-IC 
DMEM  500mL 
FCS  75mL 
L-glutamine  10mL 
Penicillin/streptomycin solution  10mL 
 
 
2.2.1.6 Myelocult 
Myelocult™  100mL 
Hydrocortisone hemisuccinate 
(1x10
-4M)  1mL 
 
 
 
2.2.2   Tissue culture solutions 
2.2.2.1 PBS/2% FCS 
 
PBS  490mL 
FCS  10mL 
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2.2.2.2 PBS/20% FCS 
 
PBS  80mL 
FCS  20mL 
 
 
 
2.2.2.3 ‘DAMP’ solution for thawing cryopreserved CD34
+  
or unmanipulated cell (MNC) aliquots from -150° C 
 
DNAse II solution (1mg/mL)  1 vial 
Magnesium chloride (400x; 1M)  625m m m mL 
Trisodium citrate (0.155M)  26.5mL 
20% ALBA  12.5mL 
PBS (magnesium/calcium free)  To 250mL 
 
 
2.2.2.4 20% DMSO/4.5% ALBA 
DMSO  20mL 
4.5% ALBA  80mL 
 
 
 
2.2.2.5 IMDM/2% FCS 
 
IMDM  98mL 
FCS  2mL 
 
 
 
2.2.3   Flow cytometry solutions 
 
2.2.3.1 PBS/0.4% formaldehyde 
 
PBS  48mL 
10% formaldehyde solution  2mL 
 
 
 
2.2.3.2 PBS/0.2% Triton-X-100 
PBS  50mL 
Triton-X-100  100m m m mL 
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2.2.3.3 Annexin/viaprobe buffer 
 
Annexin/viaprobe buffer (10X)  1mL 
Distilled water  9mL 
 
 
 
2.2.3.4 Fix perm wash – PBS/1% BSA 
 
BSA  10g 
PBS  To 1L 
 
 
2.2.4   Molecular biology solutions 
2.2.4.1 Lysis buffer for protein lysates (RIPA)  
 
dH2O  7.75mL 
1.5M NaCl  1mL 
1M Tris-HCl  0.5mL 
150mM EDTA  333m m m mL 
NP-40  50m m m mL 
10% (w/v) Sodium deoxycholate   250m m m mL 
 
·  Immediately prior to use, 100mL of protease  
inhibitor cocktail was added  
 
 
 
2.2.4.2 Running buffer 
 
10x TGS buffer  100mL 
PBS  900mL 
 
 
 
2.2.4.3 Transfer buffer 
 
10x TG buffer  100mL 
PBS  700mL 
Methanol  200mL 
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2.2.4.4 Tris-buffered saline (TBS) (1x) 
 
Sodium chloride  8g 
Potassium chloride  0.2g 
Tris base  3g 
dH2O  To 1L 
 
·  Adjusted to pH 7.4 with 1M HCl 
 
 
 
2.2.4.5 Wash buffer (TBS-Tween; TBS-T) 
TBS  1000mL 
Tween  100m m m mL 
 
 
 
2.2.4.6 Blocking buffer  
TBS  100mL 
BSA  5g 
 
 
 
2.2.4.7 3.65% Formaldehyde (Immunofluorescence) 
PBS  10mL 
36.5% Formaldehyde solution  1mL 
 
 
2.2.4.8 0.5% Triton-X-100 (Immunofluorescence) 
PBS  50mL 
Triton-X-100  250m m m mL 
 
 
 
2.2.4.9 0.1M Sodium cacodylate (pH 7.4) 
dH20  100mL 
Sodium cacodylate  2.14mg 
 
·  Buffer to pH 7.4 with 0.2M HCl 
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2.2.4.10 Fixing solution for EM 
25% gluteraldehyde solution  1mL 
0.1M Sodium cacodylate (pH 7.4)  9mL 
 
 
2.2.4.11 Post-fixation solution for EM 
Osmium tetroxide  0.1g 
0.1M Sodium cacodylate (pH 7.4)  10mL 
 
 
 
2.2.4.12 5% uranyl acetate 
dH20  10mL 
Uranyl acetate  0.5g 
 
 
 
2.2.4.13 2% uranyl acetate 
dH20  10mL 
Uranyl acetate  0.2g 
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2.3 Methods 
2.3.1 Cell culture 
2.3.1.1 Culture of cell lines 
The BC CML cell lines K562, LAMA84 and BV173 (BCR-ABL
+) and the AML cell 
line  HL60  (BCR-ABL
-),  which  were  all  available  “in-house”,  were  grown  in 
suspension culture in RPMI
++ medium in tissue culture flasks. Ba/F3 cells (murine 
IL-3 dependent pro-B cells) which stably expressed either wild-type p210 or BCR-
ABL with kinase domain mutations (M351T and T315I) were donated as a kind gift 
from Professor Junia  Melo  and  also maintained  in  RPMI
++.  M2-10B4  and Sl/Sl 
murine fibroblast cell lines were cultured in RPMI (see Section 2.2.1.4) and DMEM 
(see Section 2.2.1.5), respectively. 
 
All cell lines were maintained at 10ml in 25cm
3 tissue culture flasks, counted and 
passaged every two days with warm fresh media, to maintain a density of between 
1x10
5-1x10
6. 
 
2.3.1.2 Cell counting and cell viability assessment 
Cell counts and assessment of viability were performed using a counting chamber. 
Cells were counted with trypan blue exclusion. Trypan blue dye was first diluted 
1:10 with PBS and 90mL was added to 10mL of cell suspension to give a 1:10 
dilution  of  cells.  Approximately  10mL  of  the  mixture  was  transferred  to  a 
haemocytometer and a minimum of 100 viable cells were counted. Cells that have 
damaged membranes are porous and absorb the trypan blue dye, appearing dark-
blue under the microscope, whereas the cells with an intact membrane do not 
absorb  the  dye.  Hence,  the  unstained  cells  were  counted  and  the  remaining 
stained dead cells were deemed non-viable. 
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2.3.1.3 Cryopreservation of cells 
Between 4x10
6-2x10
7 CD34
+ selected CP CML cells, 1x10
8 unselected (MNC) CP 
CML cells and 5x10
6-1x10
7 cell line cells were cryopreserved at -150° C until use. 
To  each  cell  suspension,  an  equal  volume  of  20%  DMSO  in  4.5%  ALBA  was 
added to give a final concentration of 10% DMSO. The cryotubes were transferred 
to  a  cryofreezer  container  and  first  cooled  at  -80°C  to  provide  a  controlled 
temperature  reduction  and  then  transferred  to  a  -150° C  freezer  for  long-term 
storage. 
 
2.3.1.4 Collection of human primary cell samples 
All samples were collected with the approval from the Local Research and Ethics 
Committee and with written informed patient consent from patients at diagnosis of 
CP CML. Cells were collected by leukapheresis prior to any drug treatment. Each 
sample was determined to be Ph
+ by D-FISH and BCR-ABL
+ by PCR. Further 
samples were also obtained from patients, with normal BM undergoing autologous 
stem cell collection for either non-Hodgkin’s lymphoma or multiple myeloma, who 
had been mobilised with G-CSF following chemotherapy and had excess CD34
+ 
cells remaining after those required for clinical use had been processed.  
 
2.3.1.5 Purification of the MNC fraction from whole blood cell samples 
Either 6mL of ficoll/histopaque solution was added to a 15mL falcon tube, or 20mL 
of ficoll/histopaque solution was added to a 50mL falcon tube (depending on the 
volume  of  blood  sample)  and  brought  to  room  temperature.  The  whole  blood 
sample  was  first  diluted  (1:2)  with  PBS,  carefully  layered  drop-wise  onto  the 
ficoll/histopaque  solution,  until  it  reached  the  top  of  the  centrifuge  tube  and 
centrifuged  at  1500rpm  for  20  minutes  at  room  temperature.  Following 
centrifugation, the opaque interface containing the MNCs was carefully aspirated   93 
with a pastette. The interface was then transferred into a sterile centrifuge tube 
with a pastette and washed twice with sterile PBS (centrifuge at 1000rpm for 5 
minutes). The resultant MNCs were either used fresh or cryopreserved according 
to Section 2.3.1.3 until required. 
 
2.3.1.6 Selection of CD34
+ cells from MNC samples 
Enrichment  for  CD34
+  cells  was  achieved  using  the  sterile  CliniMACS  system 
(Miltenyi Biotec, Bisley, UK), which positively selects for CD34
+ cells according to 
the manufacturers’ instructions. Briefly, total MNCs were incubated with a specific 
anti-CD34  monoclonal  antibody  (Miltenyi  Biotec)  to  which  super-paramagnetic 
MACS  beads  (~50nM  in  diameter)  had  been  conjugated.  The  cell  sample  was 
then  passed  through  a  high-gradient  magnetic  separation  column,  where  the 
target CD34
+ cells were retained in the column and the unlabelled CD34
- cells 
flushed  through  and  discarded.  The  bound  CD34
+  cells  were  then  eluted  after 
removal from the magnetic field, collected and an aliquot was removed for flow 
cytometry  assessment  of  CD34  purity,  which  confirmed  that  all  samples  were 
>95%  CD34
+  post-selection  (Figure  2-1).  All  samples  were  for  stored  at  the 
indicated  concentrations  (see  Section  2.3.1.3)  in  cryotubes  at  -150° C,  until 
required for use.  
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Figure 2-1 Example of cellular CD34 purity following CliniMACS selection 
The  left  panel  shows  the  percentage  of  CD34
+  cells,  within  a  total  MNC 
population, prior to the selection. The right panel shows the purified cells 
following CD34 selection.  
 
2.3.1.7 Recovering frozen cells 
CML cells were removed from -150° C and immediately  thawed at 37° C in a water 
bath until the ice crystals had melted. Using a pastette, the cells were added to a 
15ml sterile tube and recovered by slowly adding 10ml of thawing solution (DAMP) 
drop-wise over a 20 minute period. This step was performed at room temperature 
to enhance the activity of the DNAse II, with constant agitation to prevent clumping 
of the cells. The cells were centrifuged at 1000rpm for 10 minutes, the supernatant 
was poured away and the pellet loosened by flicking the tube. The pellet was then 
washed twice in DAMP and centrifuged, then resuspended in SFM for counting 
and cell viability. The CML cells were then plated in 25cm
3 tissue culture flasks at 
~2x10
6/mL. 
 
1% 99.8%
F
S
C
CD34-APC
1% 99.8%
F
S
C
CD34-APC  95 
Cell lines were thawed in a 37° C water bath and rec overed slowly as above but in 
RPMI
++. The cells were then washed twice more with RPMI
++ and resuspended in 
10ml of RPMI
++, then plated in 25cm
3 tissue culture flasks.  
NB. The exception to this was with M2-10B4 and Sl/Sl murine fibroblast cell lines, 
which were thawed and cultured in RPMI (see Section 2.2.1.4) and DMEM (see 
Section 2.2.1.5), respectively. 
 
2.3.1.8 Selection of CD34
+38
- cells from total CD34
+ samples 
Total  CD34
+  cells  (2x10
7)  were  centrifuged  (1000rpm,  5  minutes)  and 
resuspended in 100ml PBS/2% FCS. Aliquots of cells (2x10
4 cells per tube) were 
removed  for  appropriate  isotype  controls  which  were  used  to  correctly  set  the 
detectors,  so  that  the  negative  isotype  population  was  placed  in  the  first  log 
decade  for  each  flow  cytometry  channel.  CD34  APC  and  CD38  FITC  positive 
controls (5mL of antibody per tube) were also set up. The remaining test cells were 
stained with 15mL of both CD34 APC and CD38 FITC antibodies and all samples 
were  incubated  for  20  minutes  at  room  temperature  in  the  dark.  Following 
incubation, samples were washed twice with PBS/2% FCS (1000rpm, 5min). The 
controls  were  resuspended  in  100mL  PBS/2%  FCS  and  the  test  cells  were 
resuspended  in  2mL  PBS/2%  FCS.  All  samples  were  sterile  filtered  through  a 
0.22mM filter before sorting. The controls were then run first and the compensation 
adjusted.  The  CD34
+38
-  cells  were  then  sorted  using  a  Becton  Dickinson 
FACSAria.  
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2.4 Cellular techniques 
2.4.1 CFSE staining 
In 1994, Lyons and Parish introduced a technique for tracking the cell division of 
lymphocytes by flow cytometry, using the serial dilution of a fluorescein-based dye 
- CFSE (280). CFSE is a lipophilic molecule which passively enters cells, where it 
is converted to a reactive dye by non-specific intracellular esterases. Once inside 
a cell, it binds irreversibly to the free amines of cytoplasmic proteins, resulting in 
stable  long-term  retention.  The  dye  is  then  equally  partitioned  between  two 
daughter cells during mitosis, so fluorescence intensity is halved with every cell 
division.  This  property  allows  both  the  identification  of  cell  progeny  and  the 
division-tracking  of  individual  cells  that  have  undergone  up  to  ten  sequential 
division  cycles.  Li  et  al.  have  demonstrated,  using  a  mixture  of  CFSE-stained 
human and unstained rat cells in an in vitro co-culture, that no dye leaks from the 
stained cells  and  that  the fluorescence  intensity  of the undivided cells remains 
constant  (281).  This  therefore,  confirms  the  reliability  of  this  technique  for  the 
identification of undivided cells. Figure 2-2A shows the intensity of CFSE halving 
with  each  cell  division  and  Figure  2-2B  demonstrates  the  subsequent  FACS 
histogram identifying the ‘peaks’, which each represent a cell division.  
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Figure 2-2 Tracking a cell with CFSE stain 
(A) A schematic diagram of the brightness of the CFSE stain in a cell halving 
in  the  daughter  cells  with  each  division.  (B)  A  histogram  of  a  FACS  plot 
showing  the  classic  ‘peaks’  pattern  with  the  undivided  cells  showing  the 
highest fluorescence and the intensity halving with each division. A single 
peak  can  be  gated  to  determine  the  percentage  of  cells  in  the  total 
population  that  have  undergone  the  equivalent  number  of  divisions.  [UD: 
undivided] 
 
Following  successful  recovery  of  cells  and  resuspension  in  PBS/2%  FCS,  an 
aliquot (~10%) of the CD34
+ cells was removed and set up in culture in SFM+5GF 
as an unstained control. A stock solution of 5mM CFSE (in DMSO) was diluted at 
1 in 10 dilution with PBS/2% FCS and 10mL added to 5mL of the remaining cells to 
give a final concentration of 1µM. The cells were then incubated in a water bath at 
37° C for exactly 10 minutes, after which the cells  were removed and the CFSE 
was quenched by adding 10x volume of ice-cold PBS/20% FCS. The cells were 
UD 1 2 3 4 5
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then centrifuged for 10 minutes at 1000rpm, the supernatant was discarded and 
the cells washed in fresh PBS/2% FCS. The cells were cultured overnight in 10mL 
SFM+5GF  in  non-adherent  (75cm
3)  tissue  culture  flasks  (1-2x10
7  CD34
+ 
cells/flasks) at 37° C, 5% CO 2. 
 
After  CFSE  staining  and  overnight  incubation,  the  CFSE-stained  cells  were 
removed from the tissue culture flask and placed in a sterile tube. The flask was 
then washed out with PBS/2% FCS and this was also added to the tube. The cells 
were then centrifuged at 1000rpm for 10 minutes and washed again in PBS/2% 
FCS. Following this, the CFSE
+ cells were resuspended in PBS/2% FCS and the 
cell count and viability was determined. An aliquot of cells (~2x10
4) was removed 
for flow cytometry to assess the position of the undivided (CFSEmax; CD34
+) cell 
population prior to culture in different treatment conditions. For every experiment, 
a colcemid control was set up using CFSE
+ cells to determine the position of the 
CFSEmax  peak  after  culture.  One  mL  of  the  colcemid  stock  (100mg/mL)  was 
added  per  mL  of  the  tissue  culture  medium  to  give  a  final  concentration  of 
100ng/mL. The cells unstained for CFSE were used to alter the voltage settings 
and optimally compensate for spectral overlap. 
 
2.4.2 Culture of CD34
+ cells 
Following either recovery from -150° C or CFSE stain ing, cells  were cultured in 
SFM or SFM+5GF (as indicated in the text) in 35mm suspension dishes at an 
initial cell concentration of ~5x10
5/mL for 1 to 12 days at 37° C, 5% CO 2. Drugs 
were added to each experiment as appropriate to the described conditions. The 
cells  were  harvested  at  indicated  time-points,  washed  in  PBS/2%  FCS  and 
aliquots were removed for performing a cell count and FACS analysis. In Chapter 
4, the cells were harvested every 4 days and at the end of the final cycle of each   99 
experiment (day 12), as well as performing a cell count and FACS analysis, an 
aliquot of cells was prepared for FISH to determine if the cells remaining after 
culture were BCR-ABL
+. Furthermore aliquots of cells were also taken for protein 
lysate  and  RNA  preparation  (methods  described  in  Sections  2.6.1  and  2.8.1 
respectively). 
 
2.4.3 LTC-IC 
Primitive  haemopoietic  cells,  with  proliferative  potential,  can  be  maintained  in 
culture  for  extended  periods  of  time,  typically  several  months.  These  culture 
conditions  have  been  called  long-term  bone  marrow  culture  (LTBMC)  (282). 
Briefly, LTBMC requires the formation of a supportive stromal layer which supplies 
the  necessary  microenvironment  to  allow  the  primitive  haemopoietic  cells  to 
proliferate  over  time.  An  application  of  LTBMC  is  an  assay  that  measures  the 
number of LTC-IC (283, 284). In this assay, the cells of interest are overlayed on 
pre-established, irradiated stromal layers. After 5 weeks culture the contents of 
each plate are set up in a committed progenitor assay for a further two weeks. At 
the  end  of  this,  the  number  of  colonies  formed  is  counted  and  this  allows  the 
frequency of LTC-IC to be determined. Figure 2-3 shows a schematic diagram for 
the method used in the LTC-IC assay. 
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Figure 2-3 Schematic diagram for the assessment of LTC-IC 
Test cells are overlayed on a supportive stromal cell monolayer and cultured 
for 5 weeks before being added to a commited progenitor assay (CFC). The 
number  of  colonies  counted  at  the  end  of  the  assay  correlates  with  the 
number of LTC-IC within the test cell sample.  
 
Two genetically-modified murine fibroblast cell lines, M2-10B4 and Sl/Sl fibroblasts 
(both  kindly  provided  by  the  Terry  Fox  Laboratories,  Vancouver,  BC,  Canada) 
were used to provide the stromal support necessary for the LTC-IC. The M2-10B4 
cells  have  been  genetically  modified  to  express  G-CSF  and  IL-3,  and  Sl/Sl 
fibroblasts have been genetically modified to express SCF and IL-3. After thawing, 
these  cell  lines  were  maintained  in  culture  at  37° C ,  5%  CO2.  The  cells  were 
trypsinised  and  passaged  when  the  monolayer  was  semi-confluent  to  allow 
propagation  of  sufficient  cells  for  LTC-IC.  To  minimise  the  proliferation  of 
untransduced  wild-type  cells,  the  cultures  were  fed  on  alternate  weeks  with 
hygromycin B (final concentration 62.5mg/mL for M2-10B4 and 125mg/mL for Sl/Sl 
SI/SI SI/SI
Irradiated and mixed
M2-10B4 M2-10B4
Stromal
monolayer
Test cells 5wk 
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fibroblasts) and G418 (final concentration 400mg/mL for M2-10B4 and 800mg/mL 
for Sl/Sl fibroblasts). 
 
Before the stromal layers  were  seeded  with  the test cells,  it  was necessary to 
irradiate  the  stromal  cells  to  render  them  incapable  of  proliferation.  Prior  to 
irradiation, the stromal cells were trypsinised and counted. A total of 1.5x10
5 M2-
10B4 and 1.5x10
5 SI/SI fibroblasts were required for each test well. The stromal 
cell layers were then irradiated at 80Gy. Following this, the M2-10B4 and SI/SI 
fibroblasts  were  mixed  and  resuspended  in  Myelocult
TM  supplemented  with 
hydrocortisone, to give a final cell concentration of 3x10
5/mL. Two millilitres of this 
stromal cell suspension was then aliquoted into the required number of wells of a 
Type I Collagen coated 6-well plate (to facilitate stromal adherence). The plates 
were then incubated at
 37° C, 5% CO 2. After the stromal cells had been incubated 
for 24 hours, the test cells (CD34
+ cells treated under different drug conditions as 
described  in  Section  2.4.2)  were  inoculated  onto  the  stromal  monolayers. 
Following drug treatment, the remaining CML cells were washed in PBS/2% FCS 
and then resuspended in 300mL of SFM. Duplicate LTC-IC wells were set up with 
150mL of treated CD34
+ cell suspension. The cells were then incubated for a total 
of  5  weeks  at  37° C,  5%  CO 2.  Every  week,  1mL  of  Myelocult
TM  medium  was 
removed  from  each  well  and  1mL  of  fresh  Myelocult
TM  was  added  and  this 
constituted a half medium change.  
 
At the end of 5 weeks culture, the LTC-IC were harvested and set up in committed 
progenitor  CFC  assays.  For  each  LTC-IC  culture  well,  the  culture  supernatant 
(containing non-adherent cells) was pipetted into a sterile 15mL centrifuge tube 
(harvest tube). Two  millilitres  of HBSS-CMF was added to remove any  serum-
containing Myelocult
TM medium and the plate swirled gently before the HBSS-CMF   102 
was transferred to the harvest tube. One millilitre of trypsin-EDTA was then added 
to  each  well  and  swirled  gently  at  intervals  until  all  the  adherent  cells  had 
detached (up to 5 minutes). Detachment was facilitated by repeatedly pipetting the 
trypsin-EDTA  over  the  surface  of  each  well,  helping  to  generate  a  single  cell 
suspension.  The supernatant was transferred  to the  harvest tube. Immediately, 
2mL  of  IMDM/2%  FCS  was  added  to  the  LTC-IC  well,  swirled  gently  and 
transferred to the harvest tube. A further 2mL of HBSS-CMF was added to the well 
and swirled gently before being transferred to the harvest tube. The harvest tubes 
were then centrifuged at 1000rpm for 10 minutes. Following this, the supernatant 
was gently poured off and the cells resuspended in the remaining supernatant. 
The  volume  of  the  remaining  cell  suspension  was  noted  and  a  cell  count 
performed. 
 
2.4.3.1 CFC assay 
Duplicate committed progenitor cell assays were set up for each cell volume of 
each  treatment  condition  at  two  different  cell  concentrations  -  2.5x10
4/mL  and 
5x10
4/mL.  The  appropriate  volume  of  cell  suspension  for  duplicate  wells  was 
added  to  2mL  of  Methocult
TM methylcellulose  medium for  committed  progenitor 
cell assays. The cell suspension and Methocult
TM medium were thoroughly mixed 
and 1mL of this mixture was added to a 35mm tissue culture dish. The dish was 
then gently swirled, so that the bottom of the dish was completely coated, and 
then incubated for 14 days at 37° C, 5% CO 2. At the end of this time, the number of 
viable colonies was counted in each dish and this allowed a comparison of the 
LTC-IC present in the different treatment conditions.  
 
In  experiments  where  CFC  assays  were  performed  alone  (without  LTC-IC), 
exactly the same methodology (described directly above) was carried out.   103 
2.4.4 Dual-colour fluorescence in situ hybridisation    
CML  cells,  pre-  and  post-culture,  and  colonies  from  LTC-IC  experiments  were 
assessed  for  the  presence  of  BCR-ABL  by  dual-colour  fluorescence  in  situ 
hybridisation (D-FISH). Aliquots of at least 5000 cells were transferred to a 1.5mL 
eppendorf,  washed  in  PBS/2%  FCS  and  re-suspended  in  500mL  pre-warmed 
(37° C)  hypotonic  solution  (0.075M  potassium  chlorid e).  Samples  were  then 
incubated at room temperature for 20 minutes. One hundred microlitres of freshly 
made fixative (methanol:acetic acid [3:1]) was added to the cells and the samples 
were incubated for a further 5 minutes at room temperature. The cells were then 
centrifuged  at  5000rpm  for  5  minutes;  the  supernatant  removed  and  a  further 
500mL  fixative  added,  the  cells  incubated  for  a  further  5  minutes  and  then 
centrifuged for 5 minutes. This step was repeated a further twice. The cell pellet 
was finally resuspended in 50mL of fixative and then stored at -20° C prior to fur ther 
preparation for D-FISH. 
  
Aliquots of 20mL of cell solution were spotted onto multi-spot microscope slides 
previously coated with poly-L-lysine and air-dried overnight. The prepared slides 
were wrapped in parafilm and stored at -20° C until  D-FISH was performed with the 
LS1  BCR-ABL  Dual  Colour,  Dual  Fusion  translocation  probe  according  to  the 
manufacturer’s  instructions.  Interphase  nuclei  were  evaluated  using  a  Leica 
fluorescence microscope with a triple band pass filter for DAPI, Spectrum Orange 
and Spectrum Green. All D-FISH slides were prepared and scored by Mrs Elaine 
Allan. 
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2.5 Flow Cytometry 
Flow Cytometry also known as FACS is a quantitative technique that permits the 
visualisation  and  sorting  of  cells  by  multiple  parameters  according  to  their 
fluorescence. A flow cytometer can also measure the size of a cell using forward-
angle light scatter (FSC) and the granularity of a cell using side-angle light scatter 
(SSC). Therefore, in comparison to spectrophotometry, flow cytometry allows the 
measurement of fluorescence per cell, hence allowing accurate analysis of single 
cells.  All  the  flow  cytometric  analyses  were  carried  out  on  a  Becton  Dickinson 
FACSCanto.  
 
2.5.1 Intracellular antibody staining 
First, 5x10
4 -1x10
5 cells were resuspended in 100mL of fixing reagent (reagent A) 
from the Fix & Perm
® Cell Permeabilisation kit and incubated for 15 minutes. The 
cells were then washed with PBS, the supernatant completely removed using a 
graduated pipette and the cell pellet resuspended in 50mL permeabilising reagent 
(reagent B) from the Fix & Perm
® Cell Permeabilisation kit. To this the appropriate 
volume of intracellular antibody was added (anti-active-caspase-PE; 1:10 dilution) 
and the cells incubated for 45 minutes at room temperature in the dark. Finally the 
cells were washed twice in PBS (1200rpm for 5 minutes) prior to FACS analysis. 
 
2.5.2 Assessment of phospho-proteins by flow cytometry 
There is no specific antibody that is able to detect the activity of BCR-ABL. 
However,  it  is  known  that  one  of  the  prominent  downstream  substrates 
constitutively phosphorylated by the BCR-ABL oncoprotein is the 39-kDa adaptor 
protein CrkL. It has previously been shown that CrkL phosphorylation is inhibited 
in  a  concentration  dependent  manner  when  CML  cells  are  treated  with  IM, 
correlating with BCR-ABL phosphorylation (130).   105 
The  rabbit  anti-human  phospho-CrkL  (p-CrkL)  antibody  used  for  this  assay 
detected endogenous levels of CrkL only when it was phosphorylated at tyrosine 
207  -  the  BCR-ABL  phosphorylation  site.  Measuring  the  difference  in  the 
geometric  mean  fluorescence  intensity  (MFI)  of  p-CrkL  peaks  between  drug-
treated samples and untreated controls, determined the effect of the treatments on 
the inhibition of BCR-ABL. Samples for analysis of p-CrkL levels were prepared by 
permeabilisation and staining using the Fix & Perm
® Cell permeabilisation kit as 
above (Section 2.5.1), but with minor modifications. Following fixation with 100µl 
fixing reagent, the cells were resuspended in 25ml of permeabilising reagent with 
2.5ml of the  p-CrkL antibody for 40 minutes. The cells were washed twice and 
resuspended in 100ml fix perm wash with 2µl of the secondary anti-rabbit IgG FITC 
conjugate (1: 50 dilution), or 10µl of the secondary anti-rabbit IgG PE conjugate (1: 
10  dilution)  and  incubated  at  room  temperature  in  the  dark  for  30  minutes. 
Different  secondary  antibodies  were  added  depending  on  the  requirements  for 
multi-parametric FACS. For example, in non CFSE-stained cells, anti-rabbit IgG 
FITC  conjugated  secondary  antibody  was  used,  whereas  in  CFSE
+  cells,  anti-
rabbit IgG PE conjugated secondary antibody was used. Following incubation, the 
cells were then washed twice and then analysed immediately by flow cytometry. 
 
The  amount  of  p-CrkL  in  an  untreated  CML  sample  was  assessed  as  the 
geometric MFI of the cell sample minus the geometric MFI of the isotype control. 
The p-CrkL status of the drug-treated samples was expressed as a percentage of 
the untreated control (100%). 
 
Assessment of phospho-STAT5 (p-STAT5) was carried out in exactly the same 
way, except the p-CrkL primary antibody was replaced by the p-STAT5 antibody at 
the same concentration   106 
2.5.3 High resolution cell cycle analysis 
Differing culture and treatment conditions may alter progression of cells through 
the cell cycle. Therefore, it was important to determine the effects of the different 
treatment conditions on progression of CML cells through the cell cycle.  
Ki67 is an antigen present in the nuclei of cells which are in the active phases of 
cell cycle - G1, S/G2 and M - and is not expressed in G0 cells. The precise function 
of Ki67 still remains unclear, however, since it is only present in proliferating cells 
(normal and malignant) (285); it has become a widely accepted marker for cellular 
proliferation. 7AAD is a fluorescent compound with a strong affinity for DNA, which 
has been used in chromosome analysis, cell cycle studies and, most commonly, to 
quantify apoptosis. Using the Ki67 stain in conjunction with an intercalating DNA 
stain  such  as  7AAD,  allows  for  a  high  resolution  of  cell  cycle  analysis,  as  it 
distinguishes between the different phases of cycling cells (286). G0 cells can be 
identified as they have low DNA content and are negative for Ki67. Cells in G1 
phase have the same DNA content; however, begin to express low amounts of 
Ki67. Both DNA content and Ki67 expression increase within cells from S and G2 
phases and staining is maximal in mitosis. Since LSCs exist within G0 phase of 
cell cycle, this staining technique has also proven invaluable for the discovery and 
isolation of primitive, quiescent malignant cells in CML (224). 
 
Approximately    3x10
5  cells  were  washed  in  PBS  (1200rpm  for  5  minutes),  the 
supernatant discarded and then resuspended in 500µL of PBS/0.4% formaldehyde 
for fixing and incubated for 30 minutes on ice. Following this, 500µL of PBS/0.2% 
Triton-X-100  was  added  to  permeablise  the  cells,  which  were  then  incubated 
overnight at 4° C. The following morning, the cells  were washed once in PBS and 
then  resuspended  in  1mL  PBS.  The  cell  suspension  was  then  divided  equally 
between two  FACS tubes  (500µL  each) and either  20µL  of Ki67-FITC  labelled   107 
antibody or 20µL of FITC isotype control was added to the tubes. The cells were 
then vortexed and incubated for 40 minutes at room temperature in the dark. After 
one  further  wash,  the  cells  were  resuspended  in  1mL  PBS  and  5µL  of  7AAD 
(1µg/mL)  was  added  and  then  incubated  for  at  least  6  hours,  but  preferably 
overnight, at 4° C prior to FACS analysis. Before FA CS analysis, the cells were 
washed once in PBS. To separate the cells from debris, the cell population was 
gated on using FSC versus FL3. The gated population was then analysed in FL1 
versus FL3 and this allowed the relative percentages of cells at each stage of the 
cell cycle. 
 
2.5.4 FACS for CFSE experiments 
CFSE  stained  cells  were  surface  stained  as  described  in  Section  2.4.1.  Flow 
cytometry analysis of CFSE-stained cells was performed at baseline to determine 
the  position  of  the  undivided  peak  and  confirm  uniform  staining  of  the  cell 
population (which allowed resolution of the peaks at subsequent analyses), and 
again at the time-points stated for each set of experiments. Isotype controls were 
used to correctly set the detectors, so that the negative isotype population was 
placed in the first log decade for each flow cytometry channel. A CFSE positive 
control was then run and the compensation adjusted. Because CFSE is a very 
bright  fluorescent  stain  which  has  substantial  spectral  overlap  into  other  FACS 
channels, considerable levels of compensation were required. 
 
2.5.4.1 Calculation of the undivided (CFSEmax) cell population 
To  determine  the  anti-proliferative  effect  of  different  treatment  conditions  and 
assess  the  size  of  the  non-proliferating  primitive  progenitor  population,  the 
percentage  recovery  of viable CML cells in  the  undivided  population  remaining 
after culture was assessed. At each analysis time-point, the number of viable cells   108 
harvested from each culture condition was recorded, as was the percentage of 
CML  cells  found  in  the  undivided  fraction  (CFSEmax).  Percentage  recovery  of 
input cells in the undivided peak could then be calculated by dividing the absolute 
number  of  CFSEmax  CML  cells  by  the  total  number  of  input  CML  cells  and 
multiplying  by  100%.  This  allowed  direct  comparison  of  different  treatment 
conditions on the non-proliferating primitive progenitor population. 
 
2.5.5 Assessment of apoptosis and necrosis 
For analysis of cell death, cells were incubated with 5µL annexin-V-FITC and 10µL 
viaprobe in 100µL annexin buffer for 15 minutes in the dark. The cells were then 
topped with 300µL annexin buffer and read by flow cytometry within the hour to 
identify necrotic (viaprobe detected in FL-3) and apoptotic (annexin-V detected in 
FL1) cells. 
 
2.6 Western blotting 
The Western blot, alternatively known as the protein immunoblot, is an analytical 
technique used to detect specific proteins in a given cell sample. A specific protein 
can  be  identified  after  fractionation  on  either  one  or  two  dimensional  gels,  by 
exposing all proteins present to a specific antibody coupled to an easily detectable 
enzyme such as HRP, a radioactive isotope or fluorescent dye. This is done after 
the  proteins  separated  on  the  gel  have  been  transferred  or  ‘blotted’  onto  a 
membrane - typically nitrocellulose paper or polyvinylidene fluoride (PVDF) as this 
is more robust than the gel. 
 
2.6.1 Preparation of protein lysate 
The RIPA lysis buffer was prepared immediately prior to use. Equal cell numbers 
from different treatment conditions were washed twice with ice cold PBS (1200rpm   109 
for 5 minutes). The cells were then transferred to a 1.5mL eppendorf and washed 
again in ice cold PBS (3000rpm for 5 minutes in a bench-top micro-centrifuge). 
The lysis buffer was added to the cells (50µL per 1-3x10
5 cells), mixed by pipetting 
up and down and incubated for 15 minutes on ice. Following this incubation, the 
cells were gently vortexed and then spun at 14,000rpm for 10 minutes at 4° C to 
clarify the supernatant which was then saved as a protein lysate and stored at       
-20° C until use. 
 
2.6.2 Protein quantification 
Protein quantification was performed using the bicinchoninic acid (BCA) method 
for  colorimetric  detection  and  quantification  of  total  protein  according  to  the 
manufacturers’ instructions. This method utilises the reduction of Cu
2+ to Cu
1+ by 
protein in an alkaline medium (the biuret reaction with the colorimetric detection of 
the  cuprous  cation  (Cu
1+)  using  a  reagent  containing  BCA  (287).  The  purple 
reaction product of this assay is formed by chelation of one cuprous ion with two 
molecules  of  BCA. The  water-soluble complex  exhibits a strong absorbance at 
562nm  that  is  nearly  linear  over  a  broad  range  of  protein  concentrations  (20-
2000µg/mL) 
 
First the BSA standards were prepared. BSA was dissolved in 0.9% saline to give 
a  concentration  of  2mg/mL.  Serial  dilutions  of  this  stock  were  then  made  to 
produce a concentration gradient for the controls. The following concentrations of 
BSA control were prepared: 1500; 1000; 750; 500; 250; 125; 50; 25; 5mg/mL and a 
blank  (dH2O).  The  controls  were  then  stored  at  -20° C  for  use  on  multiple 
occasions. To prepare the assay, 25µL of each control was pipetted onto the well 
of a 96-well plate in duplicate. Protein lysate (5µl) was added to 20µL of PBS in 
duplicate test wells. BCA solutions A and B were mixed in a 50:1 ratio (A:B) and   110 
200µL of the BCA mixture was added to each well. The 96-well plate was then 
incubated at 37° C for 30 minutes and the plate was  read using an enzyme-linked 
immunosorbent  assay  (ELISA)  plate  reader  according  to  the  manufacturers’ 
instructions. This allowed accurate protein quantification so that equal amounts of 
protein could be compared in Western blotting. 
 
2.6.3 Sodium dodecyl sulphate-polyacrylamide-gel electrophoresis  
Sodium  dodecyl  suphate-polyacrylamide  gel  electrophoresis  (SDS-PAGE)  is  a 
denaturing separation method commonly used to analyse protein samples, which 
uses  a  highly  cross-linked  gel  as  the  inert  matrix  through  which  the  proteins 
migrate.  The  proteins  are  in  solution  that  includes  SDS,  a  negatively  charged 
detergent, which binds to hydrophobic regions of the protein molecules, causing 
them  to  unfold  into  long  polypeptide  chains  and  become  freely  soluble  in  the 
solution. A reducing agent such as b-mercaptoethanol is also added to break any 
disulphide bonds present in the proteins, so that all the constituent polypeptides 
can be analysed separately. Each protein molecule binds many of the negatively 
charged detergent molecules, which masks the protein’s inherent positive charge. 
An electric current is then applied, resulting in migration of the protein towards the 
positive electrode. The direction, distance, and speed of migration are dependent 
on the size and shape of the polypeptides and the pore-size of the gel matrix; with 
smaller  polypeptides  travelling  more  rapidly  through  the  gel.  Common  gel 
materials are agarose (a polysaccharide) and acrylamide (a 3-carbon amide which 
is polymerized to form long chains with cross-links between the chains). The pore 
size of the gel is influenced by the percentage of gel material used and, in the 
case of acrylamide, the amount of cross-linking.    111 
To perform SDS-PAGE, equal volumes of protein lysate and Laemmli 2x sample 
buffer were mixed together in a 1.5mL eppendorf and then heated to 95° C for 5 
minutes.  The  samples  were  then  loaded  onto  a  4-15%  gradient  gel.  Ten 
microlitres of rainbow ladder marker was loaded onto a lane of the gel to allow 
determination of protein size. The gel was electrophoresed in a 1xTGS running 
buffer for 90 minutes at 120V using the Bio-rad Mini-PROTEAN
TM electrophoresis 
system. 
 
2.6.4 Transfer to nitrocellulose membrane 
The  protein  bands  were  then  transferred  from  the  gel  to  the  nitrocellulose 
membrane.  Sponges,  blotting  paper  and  nitrocellulose  membrane  were  first 
soaked in transfer buffer and the transfer sandwich was  prepared as shown in 
Figure 2-4. 
 
 
 
 
 
 
 
Figure 2-4 Preparation of transfer sandwich for wet transfer of protein from 
gel to nitrocellulose membrane 
 
The sandwich then underwent electrophoresis for 1 hour at room temperature at 
80V. 
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2.6.5 Immunolabelling 
After  transfer,  the  nitrocellulose  membrane  was  briefly  washed  in  TBS-T  and 
blocked  in  blocking  buffer,  with  shaking  at  room  temperature  for  1-2  hours. 
Following this, the blocking  buffer was discarded and the membrane incubated 
with the primary antibody solution (p-CrkL, LC3B, GAPDH; p-S6K; 1:1000 dilution 
in blocking buffer) overnight at 4°C with gentle agitation. The following morning, 
the nitrocellulose membrane was washed twice (15 minutes per wash) in TBS-T 
and then incubated with anti-rabbit HRP-conjugated secondary antibody (1:3000 
dilution) in blocking solution for 1 hour at room temperature with gentle agitation. 
The membrane was then washed twice (15 minutes per wash) in TBS-T and then 
developed  with  the  Immun-star  ECL  reagents  A  and  B  (first  diluted  1:2)  and 
developed directly using a Biorad Molecular Imager ChemiDoc XRS
+ System. 
 
2.6.6 Stripping and reblotting 
The Re-Blot Plus Strong stripping solution was diluted 1:10 with distilled water. 
The nitrocellulose membrane was then incubated in the stripping solution for 10-
15 minutes and then washed twice (5 minutes per wash) in TBS-T. The membrane 
was then re-blocked for 1 hour, prior to being incubated with another antibody. 
This allowed the re-blotting of the membrane 3-4 times. 
 
2.7 ELISA for the measurement of p-Tyr 
Whole cell protein lysates were prepared from 10
5-10
6 cells according to Section 
2.6.1. Lysates were diluted in carbonate-bicarbonate coating buffer, added to each 
well of an Immulon II HB 96-well flat bottom ELISA plate in triplicate (5mg protein in 
100ml carbonate-bicarbonate buffer/well) and plates were then incubated at 4° C, 
with shaking,
 overnight. Following incubation, plates were washed with TBS-T four 
times,  surfaces  were  blocked  with  100µl  of  blocking  buffer  (except  those  wells   113 
reserved  for  chromagen  blanks)  and  plates  incubated  for  1  hour  at  room 
temperature with shaking. Plates were then washed as previously and incubated 
with 100µl per well of 1:1000 4G10 anti-p-Tyr antibody or 1:500 anti-GAPDH in 
blocking buffer for 2 hours at room temperature on a shaker.  Plates were washed 
with TBS-T four times and incubated with  100ml per  well of 1:1000  anti-mouse 
IgG-HRP secondary antibody (anti-P-Tyr samples) or 1:1000 anti-rabbit IgG-HRP 
secondary antibody (anti-GAPDH samples) for 1 hour at room temperature on a 
shaker.  Plates  were  then  washed  four  times  with  TBS-T,  100µl  of  chromagen 
substrate (tetramethylbenzidine) was added to each well and plates incubated for 
20 minutes in the dark. The reaction was stopped by adding 50µl of 2N HCl and 
plates were then read at 460nm absorbance on an ELISA plate reader. 
 
Negative control wells were included in the assay (lysate only and antibody only) 
and  these  values  were  subtracted  as  background,  where  indicated,  from  each 
relevant test well. 
 
2.8 mRNA transcript measurement and mutation analysis 
2.8.1 RNA synthesis 
Total RNA was isolated from pellets using the RNeasy Mini Kit according to the 
manufacturer’s instructions. The resulting RNA was quantitated using a nanodrop 
spectrophotometer  Nd-1000  (Labtech  International,  East  Sussex,  UK).  An 
absorbance at 260nm quantified nucleic acid and the ratio of 260/280 determined 
purity (pure RNA ratio is 2.0). 
 
2.8.2 cDNA synthesis 
RNA was synthesised to cDNA by the High Capacity cDNA Archive kit according 
to the manufacturer’s instructions.   114 
2.8.3 qRT-PCR using Taqman 
The  TaqMan  probe  principle  relies  on  the  5´-3´  nuclease  activity  of  Taq 
polymerase  to  cleave  a  dual-labelled  probe  during  hybridization  to  the 
complementary  target  sequence.  As  in  other  qRT-PCR  methods,  the  resulting 
fluorescence signal permits quantitative measurements of the accumulation of the 
product during the exponential stages of the PCR; however, the TaqMan probe 
significantly increases the specificity of the detection. TaqMan probes consist of a 
reporter fluorophore covalently attached to the 5’-end of the oligonucleotide probe 
and a quencher at the 3’-end (Figure 2-5). The quencher molecule quenches the 
fluorescence  emitted  by  the  reporter  fluorophore  via  Fluorescence  Resonance 
Energy Transfer  (FRET), when excited by the thermal cycler’s light source. As 
long  as the reporter  and the  quencher  are in proximity, quenching inhibits any 
fluorescence  signals.  The  probes  anneal  within  a  DNA  region  amplified  by  a 
specific set of primers. As the Taq polymerase extends the primer and synthesises 
the nascent strand, the 5' to 3' exonuclease activity of the polymerase degrades 
the probe that has annealed to the template. Degradation of the probe releases 
the  fluorophore  from  it  and  breaks  the  close  proximity  to  the  quencher,  thus 
relieving  the  quenching  effect  and  allowing  fluorescence  of  the  reporter 
fluorophore.  Hence,  fluorescence  detected  in  the  RT-PCR  thermal  cycler  is 
directly proportional to the fluorophore released and the amount of DNA template 
present in the PCR. 
 
The mRNA levels of cyclin D1 and the endogenous reference gene GAPDH were 
measured using the ABI PRISM 7900HT sequence detector (Applied Biosystems 
(ABI),  Warrington,  U.K.).  The  cyclin  D1  PCR  products  were  detected  using  a 
probe containing a 6-carboxyfluorescein (FAM) reporter and tetramethylrhodamine 
(TAMRA) quencher. For the GAPDH reaction VIC replaced FAM. The cyclin D1   115 
and GAPDH mRNA levels were measured using the pre-developed Taqman Gene 
Expression Assays (primer and probe mix). For each reaction, 2.5ml of cDNA was 
used as template and added to 6.25ml q-PCR Mastermix Plus, 0.62ml of relevant 
Taqman Gene Expression Assay and made to a total volume of 12.5ml with PCR-
grade water. Each reaction was carried out in triplicate. Samples were run on the 
ABI PRISM 7900 with the following reaction conditions: 50° C for 2 minutes, 95 °C 
for  10  minutes  followed  by  40  cycles  of  95° C  for  15   seconds  and  60° C  for  1 
minute. The levels of cyclin D1 were calculated using the validated 2
-DDCT method 
to calculate the relative expression. 
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Figure 2-5 Schematic diagram on the mechanism of Taqman qRT-PCR 
(A)  While  the  probe  is  attached  or  unattached  to  the  template  DNA  and 
before  the  polymerase  acts,  the  quencher  (Q-fluorophore)  reduces  the 
fluorescence from the reporter (R-fluorophore). (B) Following denaturation, 
both the TaqMan
® probe and the primers anneal to the specific target DNA, 
allowing  Taq  polymerase  to  create  a  complementary  strand.  (C)  Taq 
polymerase  then  adds nucleotides  and  removes  the Taqman
® probe from 
the template DNA. This separates the quencher from the reporter, and allows 
the reporter to emit its energy which is then quantified using a computer.  
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2.8.4 RT-PCR and BCR-ABL kinase domain mutation analyses  
Quantitative  RT-PCR  to  amplify  BCR-ABL  fusion  transcript  was  performed 
according to Standardised EAC (European Against Cancer) protocols previously 
described  (288).  The  final  results  are  expressed  as  BCR-ABL/ABL  ratios  in 
percent according to the international scale (244). The mutation was detected by 
direct  sequencing  (on  both  strands)  according  to  the  methods  described  by 
Branford  et  al.  (239)  with  some  modification  (289).  BCR-ABL  transcript 
measurement  and  mutation  analysis  was  performed  by  Dr  Sandrine  Hayette, 
Hôpital Lyon, Lyon, France. 
 
2.9 Immunofluorescence 
2.9.1 Fixing cell samples onto multi-spot slides 
Cells  were  washed  in  PBS/2%  FCS  and  pellet  resuspended  in  PBS.  Twenty 
thousand cells were added to each relevant well of a poly-L-lysine-coated multi-
spot slide and cell samples were added in duplicate. Samples were allowed to 
adhere  to  the  slides  for  90  minutes  at  room  temperature.    Following  this,  the 
excess PBS was gently removed and 30mL of the 3.65% formaldehyde solution 
was added per well, in order to fix the cells. The slides were then incubated for 20 
minutes at room temperature and then washed twice, 5 minutes each in PBS. The 
slides  were  then  either  antibody-stained  straight  away  or  stored  at  4° C  in  a 
humidified  chamber  (with  enough  PBS  to  cover  the  cells  on  the  slides)  until 
required for immunofluorescence (IF) analysis. 
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2.9.2 Intracellular antibody-staining for IF  
All slides were first air-dryed until no moisture remained and 30mL of the 0.5% 
Triton-X-100 solution was added per well, in order to permeablise the cells. The 
slides were then incubated for 10 minutes at room temperature and then washed 
twice, 5 minutes each in PBS. Following this the slides were dried and each spot 
was  blocked  with  30mL  blocking  buffer  for  1  hour  at  room  temperature.  The 
blocking buffer was then gently soaked away with a tissue and antibody (LC3B or 
FoxO3a)  at  a concentration  of 0.5mg/mL  in  blocking  buffer was  added to  each 
relevant well. Thirty microlitres of anti-rabbit IgG (Abcam) (0.5mg/mL in blocking 
buffer) was added to the two wells reserved for isotype control. The slides were 
then  incubated  for  90  minutes  at  room  temperature.  Following  incubation,  the 
slides were washed 4 times with PBS (5 minutes per wash). The slides were then 
incubated with anti-rabbit-Alexa Fluor 488 secondary antibody (1mg/mL in blocking 
buffer; 30 mL per spot) for 1 hour at room temperature. Following incubation, the 
slides were washed 4 times with PBS (5 minutes per wash) and then air-dryed 
until no moisture remained. Two drops of VECTASHIELD
® mounting medium with 
DAPI were added to the centre of each slide and a coverslip was placed on the 
top.  The  coverslip  was  carefully  pushed  down,  so  that  the  mounting  medium 
spread over each well of the slide and was then sealed with nail varnish. The 
slides were stored at 4° C until analysis.  
 
All  slides  were  analysed  using  a  Zeiss  Imager  M1  microscope  at  100x 
magnification using oil immersion and Axiovision software.  
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2.10 EM 
CML cells (2x10
5-1x10
6) were pelleted in a 1.5mL eppendorf (1000rpm; 5 mins) 
immediately  prior  to  fixation.  One  millilitre  of  fixing  solution  for  EM  (Section 
2.2.4.10) was added, without resuspending pellet  and the samples were left to 
incubate  for  1  hour.  The  fixing  solution  was  then  carefully  removed,  without 
disturbing the pellet, and replaced with 1mL 0.1M sodium cacodylate solution, as a 
rinse.  The  cells  were  then  post-fixed  with  1mL  post-fixation  solution  for  EM 
(Section 2.2.4.11) for 1 hour. After 3 changes in distilled water (10 minutes each), 
specimens  were  stained  with  1mL  5%  uranyl  acetate,  and  embedded  in  Taab 
epoxy resin. Sections (100nm) were stained with aqueous 2% uranyl acetate for 
10 minutes and viewed on 300-mesh formvar-coated grids by zero-loss imaging 
on a LEO 912 AB energy filtering transmission electron microscope (Olympus).  
 
All EM procedures  were performed  by Dr  David  Dinsdale from  the microscopy 
facility at the University of Leicester, Leicester, UK. 
  
2.11 Statistics 
The  results  are  shown  as  the  mean  ±  standard  error  values  unless  otherwise 
stated. All statistical analyses were performed using the Student’s T-test on the 
Graph Pad prism software package. A level of p<0.05 was deemed significant. 
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3. RESULTS (I) Optimisation of methods to assess BCR-
ABL activity in Ph
+ cell lines and primary CML cells 
 
There  is  now  an  expanding  set  of  scenarios  in  which  the  ability  to  accurately 
assess  degrees  of  BCR-ABL  inhibition  by  TKIs,  either  in  the  laboratory  or  in 
patient samples, would be extremely valuable. With the development of second 
generation  TKIs,  including  dasatinib  (264),  nilotinib  (251)
  and  bosutinib  (260), 
clinicians  would  like  to  be  able  to  predict  response  for  individual  patients  at 
diagnosis, or at the time of a proposed change in therapy, in order to select the 
agent  with the best chance of success. Great progress has been made in this 
application by the group of Tim Hughes (290). Here, the group have demonstrated 
that the IC50 of IM, determined by Western blotting for the level of inhibition of 
phosphorylation of CrkL, on peripheral blood from individual patients, was highly 
predictive of molecular response to IM therapy.  
 
Since its introduction, a minority of patients have developed resistance to IM. For 
the individual patient with IM-resistant disease, methods to select the TKI likely to 
produce maximal BCR-ABL inhibition would be beneficial. Schultheis et al. (291) 
have developed a FACS-based assay that demonstrated differences in total p-Tyr 
inhibition  by  IM  between  CD34
+  cells  from  cytogenetic  responders  and  non-
responders to IM treatment. Our own group have since developed another rapid 
method for the detection of p-CrkL in CML cell lines, cell lines with known BCR-
ABL  mutations  and  human  primary  CML  cells,  at  the  single  cell  level  by  flow 
cytometry (130). This method also appeared to be predictive of response to IM 
therapy. Figure 3-1 shows the p-CrkL profiles of two patients’ CML CD34
+ cells 
cultured  in  the  presence  and  absence  of  5mM  IM  for  16  hours.  Panel  A   121 
demonstrates the p-CrkL profile of a CML patient who did not respond optimally to 
IM  treatment  (i.e.  did  not  achieve  any  degree  of  cytogenetic  response  by  6 
months).  It  was  observed  that  the  IM-treated  CD34
+  CML  cells  showed  no 
reduction in p-CrkL, consistent with the presence of IM-resistant  cells. Panel B 
shows a representative p-CrkL profile of a CML patient who responded well to IM 
treatment (i.e. CHR by 4 weeks and CCR by 6 months). Following IM treatment, 
there  was  only  7%  phosphorylation  of  CrkL  in  IM-treated  CD34
+  CML  cells, 
relative to no drug control (100%), indicating that most of the cells were sensitive 
to IM. 
 
 
 
 
 
 
 
Figure 3-1 The effect of IM treatment on BCR-ABL activity within CD34
+ CML 
cells as measured by flow cytometry 
CD34
+ CML cells were cultured ± 5m m m mM IM for 16 hours, before p-CrkL levels 
were determined by FACS and compared to the levels obtained from normal 
CD34
+ cells at baseline. Panels A and B demonstrate the p-CrkL profile from 
a ‘non-responder’ and ‘responder’ to IM, respectively.   
 
To  fully  understand  the  mechanism(s)  of  resistance  in  CML  stem  cells  it  is 
essential to be able to measure inhibition of BCR-ABL activity at the stem cell level 
and  using  very  small  cell  samples.  The  phosphorylation  of  proteins  in  signal 
transduction is traditionally studied by means of techniques such as ELISA, which 
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reliably provide information regarding homogeneous or purified cell populations. 
Hence, to further investigate the potential methods for the measurement of BCR-
ABL activity, the following studies were designed for the: 
 
1.  Development  of  a  novel  ELISA  method  for  the  detection  of  BCR-ABL 
activity in CML cells 
2.  Comparison  of  the  ELISA  method  with  established  techniques  for  the 
measurement of BCR-ABL activity in CML cells 
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3.1 Development of a novel ELISA method for the measurement 
of BCR-ABL activity in CML cells 
 
3.1.1 Comparison of plastics for use in a novel ELISA assay for the 
determination of BCR-ABL activity in CML cells 
To  further  explore  alternative  methods  for  assessment  of  BCR-ABL,  a  novel 
ELISA  method  was  developed.  Initially,  96-well  plates  from  two  different 
companies (Greiner bio-one and Thermo Fisher Scientific) were tested for their 
suitability for the ELISA method. For Western blot, 10mg of protein is generally 
added per lane and the blot probed with a 1:1000 dilution of relevant antibody. 
Therefore, for this preliminary ELISA, each well of an ELISA plate was first coated 
with 10mg of K562 protein lysate and a 1:1000 dilution of p-Tyr antibody in 5% 
BSA/TBST was added to each relevant test well. Absorbance was then read at 
460nm using an ELISA plate reader. Figure 3-2 shows that the ELISA plate from 
Greiner bio-one gave the best discrimination in absorbance between the test wells 
(lysate + Ab) and background (no lysate + Ab and lysate - Ab), with a significant 
difference  between  the  two  different  plates  (p=  0.032).  Therefore,  the  96-well 
ELISA plates from Greiner bio-one were used for all subsequent experiments.  
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Figure 3-2 Comparison of plastics for use in a novel ELISA assay for the 
determination of BCR-ABL activity in CML cells 
ELISA plates  from  indicated companies were  coated with  10m m m mg of protein 
lysate from K562 cells and p-Tyr antibody was added to each relevant test 
well in triplicate (p=0.032). Negative controls were included- lysate without 
antibody and no lysate with antibody. Absorbance was read at 460nm. [Ab: 
antibody] 
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3.1.2 Optimisation of blocking solution for use in a novel ELISA method 
Next, different buffers were tested to determine the optimal blocking solution for 
the p-Tyr antibody for use in the novel ELISA method.  Each well of the ELISA 
plates were first coated with 10mg of protein lysate from K562 cells and blocked in 
either 5% BSA/TBST or 5% MILK/TBST, with a 1:1000 dilution of p-Tyr antibody in 
either  5%  BSA/TBST  or  5%  MILK/TBST  added  to  each  relevant  test  well  in 
triplicate. Figure 3-3 demonstrates that the 5% BSA/TBST blocking buffer gave the 
greatest discrimination in absorbance between the test wells and background, with 
a significant difference observed between the two buffers (p=0.037). Therefore, 
the  5%  BSA/TBST  blocking  buffer  was  used  in  the  ELISA  for  all  subsequent 
experiments. 
 
 
 
 
 
 
 
 
Figure 3-3 Optimisation of blocking solution for use in a novel ELISA 
method 
ELISA plates were coated with 10m m m mg of protein lysate from K562 cells and 
blocked in either 5% BSA/TBST or 5% MILK/TBST, with a 1:1000 dilution of 
p-Tyr  antibody  in  either  5%  BSA/TBST  or  5%  MILK/TBST  added  to  each 
relevant  test  well  in  triplicate  (p=0.037).  Negative  controls  were  included- 
lysate without antibody and no lysate with antibody.  
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3.1.3 Antibody and protein concentration titration for optimal use in a novel 
ELISA method 
Since cellular material is limited when working with primitive populations of primary 
CML cells, it is  important to be  as efficient with the protein lysate as possible. 
Furthermore, since antibodies are relatively expensive it is also essential that they 
are not wasted unnecessarily. Therefore an ELISA was performed using different 
concentrations of protein lysate and probed with different concentrations of the p-
Tyr antibody. ELISA plates were first coated with either 1mg (A), 5mg (B) or 10mg 
(C)  of  K562  protein  lysate,  before  the  indicated  concentrations  of  p-Tyr  were 
added to the plate in triplicate (Figure 3-4). Both 5 and 10mg of K562 protein lysate 
were found to give significantly increased absorbance levels as compared to 1mg 
of lysate  (p= 0.0007  and 0.0011 for 1:2000 dilution; p= 0.0005 and 0.0029 for 
1:1000 dilution; p= 0.0023 and 0.0053 for 1:500 dilution and p= 0.0009 and 0.0005 
for  1:250  dilution  for  1mg  versus  5mg  and  10mg  of  K562  protein  lysate, 
respectively). Each of the antibody concentrations consistently gave absorbance 
levels of over 2.0 units using both 5 (B) and 10mg (C) of protein lysate. Therefore, 
it  was  decided  that  5mg  of  protein  lysate  per  well,  using  the  lowest  antibody 
concentrations  would  be  sufficient  to  give  effective  p-Tyr  absorbance  readings. 
However, since K562 cells express multiple copies of BCR-ABL and hence, have 
much higher TK activity than human primary CML cells, it was thought best to err 
on the side of caution in terms of the amount of p-Tyr antibody used. 
Therefore, in order to give the best results, whilst also being as economical as 
possible with both the amount of protein and antibody used, it was decided that 
the  optimal  conditions  for  the  ELISA  were  a  1:1000  dilution  of  p-Tyr  antibody, 
using 5mg of protein lysate. 
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Figure 3-4 Antibody and protein concentration titration for optimal use in a 
novel ELISA method 
ELISA plates were first coated with either 1m m m mg (A), 5m m m mg (B) or 10m m m mg (C) of 
K562 protein lysate, before the indicated concentrations of p-Tyr were added 
to  the  plate  in  triplicate.  Negative  controls  were  included-  lysate  without 
antibody and no lysate with antibody. Absorbance was read at 460nm. 
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3.1.4 Comparison of antibodies for optimal use in a novel ELISA method 
As the measurement of total tyrosine phosphorylation is not entirely specific to 
BCR-ABL, other antibodies were also tested in the ELISA method. Anti-p-ABL and 
anti-p-CrkL  were  compared  to  the  anti-p-Tyr  antibody,  for  the  measurement  of 
BCR-ABL  activity  within the Ph
+  cell  line, K562, in 3  replicate  experiments. As 
shown  in  Figure  3-5,  the  anti-p-Tyr  antibody  gave  the  best  discrimination  in 
absorbance between Ph
+ cells against background (p= 0.015 and 0.016 for p-Tyr 
versus p-CrkL and p-Abl, respectively). Therefore, this antibody was used in the 
ELISA for all subsequent experiments. 
 
 
 
 
 
 
 
 
 
Figure 3-5 Comparison of antibodies for optimal use in a novel ELISA 
method 
Activity  was  measured  in  K562  cells  by  ELISA  using  the  indicated 
antibodies, in triplicate (p= 0.015 and 0.016 for p-Tyr versus p-CrkL and p-
Abl, respectively).  
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3.1.5 Confirmation of effective protein-coating in a novel ELISA method 
In order to confirm good reproducibility of protein coating, several ELISAs were 
initially performed using anti-GAPDH antibody. Figure 3-6 demonstrates that the 
results were very consistent, with an average reading of 1.59 absorbance units 
(460nm) (n=6) (range: 1.5253 - 1.6439; coefficient of variation: 5.24%) per 5mg of 
protein per well from K562 cells and an average reading of 1.57 absorbance units 
(460nm) (n=6) (range: 1.455 - 1.674; coefficient of variation: 5.54%) per 5mg of 
protein per well from HL60 cells. No significant difference was observed between 
the  two  cell  lines  (p=0.595).  This,  therefore,  confirmed  good  protein-coating 
efficacy and to save on cell samples, the following ELISAs were conducted using 
the anti-p-Tyr antibody only. 
 
 
 
 
 
 
 
 
 
Figure 3-6 Confirmation of effective protein-coating in a novel ELISA method 
GAPDH  levels  were  measured  in  K562  and  HL60  cells  by  ELISA  in  6 
replicates.  
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3.1.6 Assessment of p-Tyr in BCR-ABL positive and negative cell lines using 
a novel ELISA method 
The ELISA was further tested using other Ph
+ BC CML cell lines, LAMA84 and 
BV173, in comparison with K562 cells and also the Ph
- cell line, HL60 (Figure 3-7). 
The  results  were  very  consistent  between  the  Ph
+  cell  lines.  The  anti-p-Tyr 
antibody produced absorbance readings of >3 absorbance units (460nm) for all 
Ph
+ cell lines, whereas the reading was around 0.5 absorbance units (460nm) for 
the Ph
- cell line, HL60. Further negative controls which consisted of lysate without 
antibody  and  antibody  without  lysate,  consistently  gave  readings  of  <0.5 
absorbance units (460nm). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7 Assessment of p-Tyr in BCR-ABL positive and negative cell lines 
using a novel ELISA method 
Total  p-Tyr  status  was  measured  by  ELISA  for  each  of  the  cell  lines,  in 
triplicate.  
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3.1.7 The effect on total p-Tyr levels upon drug treatment of K562 and HL60 
cell lines measured by ELISA 
The ELISA’s ability to detect changes in p-Tyr levels in CML cells following TKI 
treatment was next investigated. K562 and HL60 cells were first treated for 16 
hours with either IM or dasatinib and p-Tyr was measured by ELISA. Figure 3-8 
shows  that  in  response  to  increasing  concentrations  of  TKI,  the  absorbance 
readings decreased in K562 cells, reaching the background level of HL60 cells 
with 5mM IM and 150nM dasatinib treatment (p=0.000794 for no drug versus 1mM 
IM; p=0.000646 for no drug versus 2.5mM IM; p=0.000218 for no drug versus 5mM 
IM; p=0.000381 for no drug versus 10nM dasatinib and p=0.000274 for no drug 
versus  150nM  dasatinib).  As  expected,  neither  IM  nor  dasatinib  reduced  the 
absorbance for HL60 cells (p=0.612664 for no drug versus 1mM IM; p=0.097389 
for no drug versus 2.5mM IM; p=0.658101 for no drug versus 5mM IM; p=0.255663 
for no drug versus 10nM dasatinib; and p=0.290042 for no drug versus 150nM 
dasatinib). 
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Figure 3-8 The effect on total p-Tyr levels upon drug treatment of K562 and 
HL60 cell lines measured by ELISA 
K562 and HL60 cells were treated ± increasing concentrations of IM (1, 2.5 
and 5m m m mM) and dasatinib (10 and 150nM) for 16 hours (n=3). No significant 
differences  were  observed  between  no  drug  and  each  condition  in  HL60 
cells, whereas significant differences were observed between no drug and 
each  condition  in  K562  cells,  (p=0.612664  and  0.000794  for  1m m m mM  IM; 
p=0.097389 and 0.000646 for 2.5m m m mM IM; p=0.658101 and 0.000218 for 5m m m mM IM; 
p=0.255663 and 0.000381 for 10nM dasatinib; p=0.290042 and p=0.000274 for 
150nM dasatinib) for HL60 and K562 cells, respectively. 
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3.1.8 Effect of increasing concentrations of IM and dasatinib on Ba/F3 cell 
lines containing BCR-ABL mutations 
The ELISA was further tested by assessing the response of cells with known BCR-
ABL mutations to TKI treatment (Figure 3-9). Ba/F3 cells transduced with either 
BCR-ABL-p210 wild-type, M351T or T315I were exposed to IM (A) or dasatinib (B) 
for 16 hours. Following this, p-Tyr levels were assessed by ELISA. As expected, 
dasatinib was found to be more potent than IM, inducing 100% inhibition of p-Tyr 
in cells transduced with wild-type p210 at 150nm, as compared to 80% maximal 
inhibition  with  IM  at  5mM.  Consistent  with  the  literature  (292),  dasatinib  also 
inhibited  the  M351T  mutation  as  effectively  as  the  wild-type  p210  at  each 
concentration of drug. The specific type of mutation is a key factor in the level of 
resistance  conferred  to  IM  (293).  The  M351T  mutation  confers  only  moderate 
resistance to IM, which implies that dose escalation may be able to recapture a 
cellular response. This is indeed reflected in Figure 3-9A, where the level of p-Tyr 
inhibition reaches that of wild-type p210 at the highest concentration of IM. The 
T315I mutation was fully resistant to both agents as expected.  
 
 
 
 
 
 
 
 
 
 
   134 
A 
 
 
 
 
 
 
 
 
B       
 
 
 
 
 
 
 
 
Figure 3-9 Effect of increasing concentrations of IM and dasatinib on Ba/F3 
cell lines containing BCR-ABL mutations 
Ba/F3-BCR-ABL  p210,  M351T,  and  T315I  were  cultured  ±  increasing 
concentrations  of  IM  and  dasatinib  for  16  hours  (n=3).  Total  p-Tyr  levels 
were then determined by ELISA, in triplicate. The above figures demonstrate 
that  the  level  of  p-Tyr  detected  correlated  with  each  Ba/F3-BCR-ABL 
mutant’s degree of IM (A) or dasatinib (B) resistance. 
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3.1.9 Assessment of p-Tyr in primary CML CD34
+ and mature cells by ELISA 
Finally, the ELISA’s suitability for measuring BCR-ABL activity in both mature and 
primitive  primary  human  CML  samples  was  investigated.  Primary  CML  CD34
+ 
(n=3) and MNC samples (n=6) were found to have increased levels of p-Tyr at 
baseline, as compared to Ph
- samples from both CD34
+ (n=3) (p=0.012) and MNC 
(n=3) (p=0.0007) cell fractions (Figure 3-10).  
 
 
 
 
 
 
 
 
 
 
Figure 3-10 Assessment of p-Tyr in primary CML CD34
+ and mature cells by 
ELISA 
Total p-Tyr status was measured by ELISA in CD34
+ (n=3) and MNC (n=6) 
CML cells and compared to non CML cell samples from both fractions (n=3). 
Levels  of  p-Tyr  were  found  to  be  significantly  increased  in  the  CML  cell 
samples as compared to the Ph
- cell samples (p=0.012 for CML versus non 
CML CD34
+ cells and p=0.0007 for CML versus non CML MNC cells).  
 
Overall, these data confirm the novel ELISA’s ability to assess total p-Tyr levels in 
Ph
+ cell lines, cells with known BCR-ABL mutations and both mature and primitive 
primary human CML cells. 
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3.2 Comparison of the novel ELISA method with established 
techniques for the measurement of BCR-ABL activity in CML 
cells 
 
Western blot is a well established and reliable method which has previously been 
shown  to  reproducibly  measure  p-CrkL.  However,  it  is  time-consuming  and 
laborious which makes the testing of large sample numbers difficult. Furthermore, 
it  requires  a  relatively  large  number  of  cells,  which  is  often  unrealistic  when 
working with a small pool of primitive CML cells. More recently, flow cytometric 
methods have been developed to detect p-Tyr (291) and p-CrkL (130) levels in 
small numbers of primary CML cells. Although this technique requires few cells 
and is rapid, even within our own group we have found it to be less reproducible 
between individuals than Western blot. In order to determine how the novel ELISA 
method  compared  with  the  more  established  techniques,  further  investigations 
were carried out.  
 
3.2.1 Equivalence between Western blot, flow cytometry and ELISA methods 
as a means of detecting BCR-ABL activity in K562 cells 
K562 cells were first treated with IM (0, 1, 5mM) for 48 hours, before p-CrkL was 
measured by Western blot and FACS and p-Tyr was detected by ELISA. When 
phosphorylation  levels  from  3  independent  experiments  were  compared,  the 
methods appeared equivalent, with no significant differences observed between 
the 3 techniques (p=0.87 and 0.15 for Western versus flow cytometry; p=0.19 and 
0.24  for  Western  versus  ELISA  and  p=0.2  and  0.13  for  ELISA  versus  flow 
cytometry) for 1 and 5mM IM treatment, respectively (Figure 3-11).  
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Figure 3-11 Equivalence between Western blot, flow cytometry and ELISA 
methods as a means of detecting BCR-ABL activity in K562 cells 
K562 cells were treated with IM (0, 1, 5m m m mM) for 48 hours. Reduction of p-CrkL 
was then detected by Western blot and flow cytometry and total p-Tyr was 
measured by ELISA. No significant differences were observed between the 3 
methods  (p=0.87 and 0.15 for  Western  versus  flow cytometry; p=0.19  and 
0.24 for Western versus ELISA and p=0.2 and 0.13 for ELISA versus flow 
cytometry) for 1 and 5m m m mM IM treatment, respectively. 
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3.2.2 Comparison of flow cytometry and ELISA methods used to measure 
the effect of IM treatment on Ba/F3 cell lines containing BCR-ABL mutations 
The  ELISA  was  further  investigated  by  assessing  the  response  of  Ba/F3  cells 
transduced  with  either  BCR-ABL-p210  wild-type,  M351T  or  T315I,  to  16  hours 
treatment with 5mM IM, and the results were compared with data obtained from the 
p-CrkL flow cytometry method (Figure 3-12).  Inhibition of p-Tyr was maximal in 
BCR-ABL-p210 wild-type (80% reduction as compared to no drug control (100%)) 
and  each  mutant  was  inhibited  according  to  their  degree  of  low  and  high  IM-
resistance. Furthermore, the techniques appeared equivalent with no significant 
differences  observed  between  the  2  methods  (p=0.55  for  BCR-ABL-p210  wild-
type; p=0.08 for M351T and p=0.06 for T315I). 
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Figure  3-12  Comparison  of  flow  cytometry  and  ELISA  methods  used  to 
measure the effect of IM treatment on Ba/F3 cell lines containing BCR-ABL 
mutations 
Ba/F3-BCR-ABL p210, M351T and T315I were cultured ± 5m m m mM IM for 16 hours. 
Total p-Tyr levels were then determined by ELISA, and compared to p-CrkL 
levels  measured  by  flow  cytometry.  Percentage  phosphorylation  was 
calculated based on the relevant no drug control (100%). The level of p-Tyr 
detected  correlated  with  each  Ba/F3-BCR-ABL  mutant’s  degree  of  IM 
resistance,  with  no  significant  differences  detected  between  the  methods 
(p=0.55 for wild-type p210; p=0.08 for M351T and p=0.06 for T315I). 
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3.2.3 Equivalence between ELISA and flow cytometry methods as a means 
of detecting BCR-ABL activity in CML CD34
+ cells 
It was noted that the comparison made between p-Tyr and p-CrkL levels is not 
strictly accurate and that the assessment of total tyrosine phosphorylation assayed 
by  ELISA  and  flow  cytometry,  would  allow  a  better  evaluation  of  the  ELISA 
method. Therefore, primary CML CD34
+ cells (n=4, >90% Ph
+), were treated ± 
5mM IM before p-Tyr levels were measured by both ELISA and flow cytometry. 
Incomplete inhibition of p-Tyr was achieved following IM treatment (around 70% 
inhibition as compared to no drug control (100%)), with no significant difference 
observed between the ELISA and flow cytometric methods (p=0.54) (Figure 3-13). 
This  level  of  BCR-ABL  inhibition  in  response  to  IM  is  consistent  with  data 
previously published (131). 
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Figure 3-13 Equivalence between ELISA and flow cytometry methods as a 
means of detecting BCR-ABL activity in CML CD34
+ cells 
CML CD34
+ cells (n=4) were treated ± 5m m m mM IM for 16 hours and samples were 
taken for p-Tyr measurement by ELISA and flow cytometry. The IM-treated 
CD34
+ cells showed a 70% reduction in BCR-ABL activity as compared to no 
drug control (100%). No significant differences were observed between the 
methods (p=0.54).  
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3.3 Summary 
The  advantages  and  disadvantages  of  the  techniques  to  assess  the  activity  of 
BCR-ABL that have been described in this chapter and in the literature (130, 131, 
290, 291, 294-297) are described in brief in Table 3-1. Although Western blot has 
been shown to be a reliable and reproducible technique for the assessment of p-
CrkL, it requires >100 times the number of cells needed for flow cytometry.  This is 
often not feasible when attempting to characterise a rare population of CML stem 
cells. The main advantages of the p-Tyr ELISA are that it is reproducible between 
individuals  and  also  allows  the  assay  of  many  samples  at  once,  so  could  be 
adapted for high throughput applications. However, large cell numbers are also 
required, as one sample performed in triplicate would require a total of 15mg of 
protein lysate. The experiments performed in this chapter were performed without 
verification  of  sample  protein-coating.  However,  to  be  more  exact,  a  loading 
control,  such  as  GAPDH  should  be  included  for  each  sample,  taking  the  total 
amount  of  protein  required  up  to  30mg.  This  is  more  than  is  necessary  for  a 
Western  blot  and  an  unrealistic  amount  when  it  comes  to  working  with  very 
primitive CML cells. When analysing small numbers of immature CML cells the 
only reasonable option is flow cytometry. It also provides an accurate assessment 
of a viable cell population, as any dead cells or debris can be gated out prior to 
analysis,  which  would  be  impossible  with  either  Western  blot  or  ELISA. 
Furthermore,  multi-parameter  flow  cytometry  offers  the  valuable  advantage  of 
characterising  certain  cell  surface  and  intracellular  markers,  to  identify  cellular 
subpopulations in response to a stimulus or drug treatment. This is a key factor 
when attempting to identify CML stem cells, track their survival and proliferation, 
and also assess BCR-ABL activity in response to TKI treatment. 
   143 
In  summary,  for  the  single  measurement  of  BCR-ABL  activity,  it  would  be 
advisable  to  use  anti-p-CrkL  antibody  in  Western  blot  in  all  situations  where 
sufficient cells are available and the number of samples to be tested is low. When 
a large quantity of samples requires to be tested, then ELISA for p-Tyr can be 
used. Where cell numbers are limited and a number of parameters require to be 
tested  simultaneously,  flow  cytometry  should  be  used.  However,  wherever 
possible key results should be confirmed using a limited number of Western blots 
to  reassure  the  investigator  that  their  interpretation  of  results  obtained  by  flow 
cytometry and ELISA are consistent with the gold standard.    
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Western 
blot 
(BCR-ABL) 
(295-297) 
 
 
Western 
blot 
(p-CrkL) 
(130, 131, 
290, 294) 
Flow 
cytometry 
(p-Tyr) (291) 
Flow 
cytometry 
(p-CrkL) 
(130, 131) 
ELISA   
(p-Tyr) 
 
Required 
number of 
cells 
 
10
5 – 10
6 
 (≥10m m m mg/ 
well) 
10
5 – 10
6 
 (≥10m m m mg/ 
well) 
10
3 – 10
5  10
3 – 10
5 
10
5 – 10
6 
(5m m m mg/well) 
 
Ease of 
throughput 
 
+  +  ++  ++  +++ 
 
Time 
required 
 
≥ 2 days  ≥ 2 days  2-4 hours  2-4 hours  1 day 
 
Reproducib 
-ility 
 
+++  +++  ++  ++  +++ 
 
Suitability 
for cell lines 
 
+++  +++  +++  +++  +++ 
 
Suitability 
for mature 
primary 
cells 
 
X  +++  +++  +++  +++ 
 
Suitability 
for CD34
+ 
primary 
cells 
 
+++  +++  +++  +++  +++ 
 
Suitability 
for multi-
parametric 
analysis 
 
X  X  +++  +++  X 
 
Table 3-1  Summary of methods to assess BCR-ABL activity in Ph
+ cell lines 
and primary CML cells    145 
4. RESULTS (II) Is BCR-ABL relevant for the survival of 
cancer stem cells in CML? 
 
 
The importance of BCR-ABL for the malignant transformation of CML has led to 
the development of TKIs, such as IM. Despite IM’s initial therapeutic success, only 
a  small  proportion  of  patients  obtain  a  CMR,  where  they  become  negative  for 
BCR-ABL transcripts by RT-PCR. It is hypothesised that this MRD is the result of 
a  primitive  subpopulation  of  LSCs,  which  may  cause  relapse  at  a  later  date. 
Another major clinical concern is the observation of molecular resistance in IM-
treated  patients.  There  are  2  broad  categories  of  IM  resistance:  BCR-ABL-
independent and BCR-ABL-dependent. In most cases of acquired resistance to 
IM,  BCR-ABL-dependence  is  found.  Postulated  mechanisms  include  BCR-ABL 
amplification with over-expression and decreased intracellular IM concentrations 
caused  by  reduced  drug-uptake  and  increased  drug-efflux  through  drug 
transporters (298).  However, BCR-ABL dependent IM resistance is most often 
attributed  to  the  development  of  point  mutations  within  the  ABL-kinase  domain 
(240)
,(299).    A  further  possibility  is  that  IM  resistant  stem  cells  are  simply 
refractory to TKI treatment due to poorly understood properties that allow them to 
survive  drug  exposure.  For  example,  we  and  others  (131,  298,  300)  have 
demonstrated  that  CML  stem  cells  over-express  BCR-ABL,  which  may  be 
sufficient to render them IM resistant.  
 
BCR-ABL-independence suggests that resistance is a result of stem cell-related or 
intrinsic mechanisms whereby the leukaemia cells either do not require BCR-ABL 
for survival and the maintenance of a quiescent state; or are no longer reliant on 
BCR-ABL to drive proliferation. These cells may employ additional mechanisms   146 
which are responsible for their growth and survival. Although examples of this type 
of resistance have been demonstrated in more advanced phase CML (301, 302), 
this has not yet been proven for the CP CML stem cell population.  
 
In an attempt to understand the mechanisms of IM resistance in CML, the primary 
aim of this chapter is to determine  whether  CML stem cells are dependent on 
BCR-ABL kinase activity for their survival. Hence, the following experiments were 
designed for the: 
 
1.  Optimisation of culture conditions to maximise targeting of BCR-ABL kinase 
activity within CP CML cells. 
2.  Characterisation of primitive CML cells following kinase inhibition of BCR-
ABL 
3.  Analysis  of  functionality  of  the  CML  cells  remaining  following  prolonged 
BCR-ABL kinase inhibition 
 
If the CML stem cells are proven to be dependent on BCR-ABL kinase activity for 
survival then efforts to enhance intracellular concentration and binding of potent 
TKIs selective for BCR-ABL should lead to improved responses/cures for patients. 
If CML stem cell survival is proven to be independent of BCR-ABL kinase activity 
then  alternative  approaches  to  develop  CML  stem  cell  therapies  would  be 
required. 
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4.1 Optimisation of culture conditions to maximise targeting of 
BCR-ABL kinase activity within CP CML cells 
 
4.1.1 Comparison of GF culture conditions in TKI-treated CML cells 
In  order  to  determine  the  optimal  culture  conditions  for  maximal  BCR-ABL 
inhibition,  preliminary  experiments  were  carried  out.  CML  stem  cells  produce 
autocrine cytokines at low levels and are able to survive in culture in the absence 
of  added  GFs  (190),  however,  these  cells  may  also  respond  to  supplemental 
cytokines. There has therefore been concern that the addition of cytokines at high 
concentration to these cultures may support the survival of CML stem cells during 
exposure to TKIs (303)
,(235). Thus, an experiment was performed to compare the 
effects of TKI treatment on CML CD34
+ cells, cultured in SFM with and without 
added GF support. Figure 4-1 shows total cell numbers, determined by trypan blue 
dye  exclusion,  following  treatment  ±  either  2mM  IM  or  150nM  dasatinib  and 
cultured ± 5GF for 3 days (n=3). As predicted, untreated CML CD34
+ cells were 
able  to  survive  and  proliferate  in  the  absence  of  GFs.  However,  this  condition 
resulted  in  significantly  reduced  cell  numbers  as  compared  to  untreated  cells 
cultured with GFs (p=0.05). Treatment with either IM or dasatinib in the presence 
of  GFs  resulted  in  a  significantly  decreased  cell  number  as  compared  to  the 
corresponding  untreated  control  (p=0.05  for  no  drug  +GF  versus  IM  +GF  and 
p=0.04 for no drug +GF versus dasatinib +GF). Interestingly, TKI treatment in the 
presence of GFs also gave the same effect as removing the GF support from 
untreated  control  cells,  with  no  significant  difference  observed  between  the 
conditions (p=0.70 for no drug versus IM and p=0.94 for no drug versus dasatinib). 
This  demonstrates  the  protective  effect  that  cytokines  may  have  over  TKI 
treatment of CML cells. Due to the compelling evidence that autocrine stimulation   148 
via cytokines such as, G-CSF, IL-3 and GM-CSF could be of importance for the 
regulation of the growth and survival of CML cells (187, 190); it is perhaps not 
surprising that the exogenous GF support mediated such resistance against the 
TKI  treatment  of  these  CML  cells.  The  greatest  effect  was  observed  with  TKI 
treatment minus GFs, with a significantly decreased cell number as compared to 
TKI treatment plus GFs (p=0.03 for IM -GF versus IM +GF; p=0.04 for IM -GF 
versus dasatinib +GF; p=0.02 for dasatinib -GF versus IM +GF and p=0.03 for 
dasatinib -GF versus dasatinib +GF). There was no significant difference in cell 
number observed between IM- and dasatinib-treated cells cultured without GFs 
(p=0.774). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 Comparison of GF culture conditions in TKI-treated CML cells 
CML CD34
+ cells (n=3) were treated ± either 2m m m mM IM or 150nM dasatinib and 
cultured  in  SFM  ±  a  5GF  cocktail  for  3  days.  Viable  cell  counts  were 
determined by trypan blue dye exclusion. 
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4.1.2 Comparison of TKI treatments and exposure times in primary CML 
cells 
In order to compare the effects of different TKI treatments, studies were performed 
whereby CD34
+ CML cells were cultured in SFM without exogenous GF support 
and treated for 1, 2, 3, 4, 24 and 72 hours with increasing concentrations of either 
IM,  nilotinib  or  dasatinib.  At  each  treatment  time-point,  the  cells  were  washed 
twice with PBS to remove any trace of drug and put back into culture with fresh 
medium. A viable cell count was then performed by trypan blue dye exclusion at 
the 72 hour time-point. Figure 4-2 demonstrates the percentage of viable CML 
cells  remaining  following  the  treatment  timecourse  with  IM  (A),  nilotinib  (B)  or 
dasatinib (C). The percentage of viable cells was significantly increased, following 
exposure  for  the  shortest  treatment  time  (1  hour),  as  compared  to  the  longest 
treatment time (72 hours), using the lowest concentration of IM (1mM) (p=0.009). 
However,  no  significant  difference  in  cell  number  was  observed  as  the 
concentration was increased (p=0.11 for 5mM IM; p=0.18 for 10mM IM and p=0.5 
for  20mM  IM).  Furthermore,  no  significant  difference  in  viable  cell  number  was 
observed between the 1 and 20mM concentrations of IM at both the shortest and 
longest treatment time-point (p=0.07 and 0.14) for 1 and 72 hours, respectively 
(Figure 4-2A).  
No  significant  differences  in  viable  cell  number  were  observed  between  the 
shortest (1 hour) and longest (72 hours) treatment times using both the lowest and 
highest  concentration  of  nilotinib  (p=0.47  and  p=0.436)  (Figure  4-2B)  and 
dasatinib  (p=0.06  and  0.1475)  (Figure  4-2C)  for  the  lowest  and  highest 
concentrations of drug, respectively. Similarly, no significant difference in viable 
cell number was detected between 10 and 1000nM dasatinib treatment (p=0.1255   150 
and 0.081) and 1 and 20mM nilotinib treatment (p=0.27 and p=0.23) at both the 
shortest and longest treatment time-point, respectively.  
Figure  4-2D  demonstrates  a  comparison  of  each  TKI  treatment  at  clinically 
achievable concentrations. Although no significant differences in cell number were 
observed between each condition by the 72 hour time-point (p=0.31 for IM versus 
nilotinib; p=0.074 for IM versus dasatinib and p=0.19 for nilotinib versus dasatinib), 
there  was  a  trend  towards  a  greater  reduction  in  viable  cells  following  150nM 
dasatinib treatment. 
 
In  general,  these  data  show  that  transient  exposure  with  relatively  low 
concentrations  of  TKI  is  as  effective  as  continuous  treatment  with  increased 
concentrations of TKI, which are clinically unachievable. 
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Figure 4-2 Comparison of TKI treatments and exposure times in primary 
CML cells 
CD34
+ CML cells (n=3) were treated with increasing concentrations of IM (A), 
nilotinib (B) and dasatinib (C) for the indicated treatment times. Following 
each time-point, the cells were washed with PBS and put back into culture 
with  fresh  media.  Viable  cell  counts  were  performed  by  trypan  blue  dye 
exclusion at the 72 hour time-point and compared to no drug control cells 
(100%). A comparison of each TKI treatment at a clinically achievable dose 
is shown in Panel D.  
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4.1.3 Effect of TKI treatment on apoptosis induction within CD34
+ CML cells  
In  order  to  determine  which  TKI  had  the  greatest  effect  on  CML  cells,  further 
characterisation  was  carried  out.  First,  CML  CD34
+  cells  were  cultured  without 
GFs and treated ± either 5mM IM or 150nM dasatinib for 48 hours. Apoptosis was 
then  determined  by  annexin-V  and  viaprobe  staining  as  measured  by  flow 
cytometry  (n=3).  Figure  4-3  demonstrates  the  relative  fold  change  in  the 
percentage of early and late apoptotic cells (i.e. the cells which stained positive for 
both annexin-V and viaprobe) for each condition, as compared to no drug control. 
IM treatment significantly increased the number of apoptotic cells as compared to 
no drug control (p=0.05). Dasatinib treatment significantly increased the number of 
apoptotic cells as compared to both no drug control and IM treatment (p=0.02 and 
p=0.05, respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3 Effect of TKI treatment on apoptosis induction within CD34
+ CML 
cells 
CML CD34
+ cells were cultured for 48 hours in SFM without GFs and treated 
± either 5m m m mM IM or 150nM dasatinib (n=3). Apoptosis was determined at this 
time-point by annexin-V and viaprobe staining measured by flow cytometry. 
Each condition was then compared relative to a no drug control. 
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4.1.4 Effect of TKI treatment on p-CrkL levels within CML cells 
To compare the effects of TKI treatment on BCR-ABL activity within CML cells,    
p-CrkL was measured. CD34
+ CML cells were cultured in SFM and treated ± an 
IC90 concentration of TKI (5mM IM and 150nM dasatinib) for a total of 72 hours. 
The levels of p-CrkL were then measured by Western blot of whole cell protein 
lysates, prepared at 16 hours in order to measure the immediate effects of TKI 
inhibition of BCR-ABL and then at 72 hours to measure the effects of TKI on cells 
which  survive  the  initial  drug  treatment.  Pan-actin  was  included  as  a  protein 
loading control. Figure 4-4 demonstrates that IM treatment resulted in a reduction 
of p-CrkL, as compared to no drug control after 16 hours of treatment, suggesting 
that the majority of cells were IM-sensitive. However, despite re-exposure to IM 12 
hours before the 72 hour time-point, those cells that survived treatment showed no 
reduction  in  p-CrkL,  consistent  with  enrichment,  following  cell  death,  of  an  IM-
resistant population. Dasatinib treatment inhibited p-CrkL both at the early time-
point and also, unlike IM, at the later time-point. 
 
 
Overall, these data show that the greatest effect of TKI on CML cells is seen in 
culture conditions without added GF support. Further, that dasatinib is superior to 
IM, in terms of inducing apoptosis (which should lead to a reduction in CML cell 
numbers) and provides the greatest inhibition of BCR-ABL. Therefore, dasatinib 
treatment without added GFs was the culture condition used for all subsequent 
experiments. 
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Figure 4-4 Effect of TKI treatment on p-CrkL levels within CML cells 
Whole  cell protein lysates were prepared from CD34
+ CML cells treated ± 
either 5m m m mM IM or 150nM dasatinib for a total of 72 hours. The levels of p-CrkL 
were assessed in each sample at the 16 and 72 hour time-point by Western 
blot. Pan-actin levels were also measured as a protein loading control. 
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4.2 Characterisation of primitive CML cells following kinase 
inhibition of BCR-ABL  
 
4.2.1 Assessment of CML cell viability following treatment with dasatinib 
The  studies  described  in  Figure  4-1  demonstrate  that  up  to  6  days  dasatinib 
treatment does not completely eradicate CML CD34
+ cells, cultured without GFs. 
Timecourse studies also demonstrated that any CML cells which were sensitive to 
TKI, were likely to be targeted within the first few hours of treatment. In an attempt 
to completely isolate and then characterise the CML cells which are not initially 
targeted by TKI treatment, the exposure time to dasatinib was increased. Figure 4-
5A  demonstrates  the  cell  counts  as  determined  by  trypan  blue  dye  exclusion, 
following  treatment  ±  150nM  dasatinib  for  12  days.  Every  3  days,  cells  were 
washed  twice  with  PBS,  cultured  with  fresh  medium  and  re-drugged  with 
dasatinib, to ensure no degradation of drug over the timecourse. As with previous 
data,  untreated  cells  were  able  to  expand  despite  being  cultured  without  GFs, 
whereas, dasatinib-treated cells were significantly reduced in viable cell number to 
3.4x10
5   total cells by day 12 (<2% cells remaining relative to no drug control, 
p=0.01). Figure  4-5B shows the percentage viability, as compared  to input cell 
number, for dasatinib-treated cells. At the end of the timecourse, residual viable 
cells represented <10% of the starting cell number.  
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Figure 4-5 Assessment of CML cell viability following treatment with 
dasatinib 
Panel A demonstrates the viable cell counts from CD34
+ CML cells treated ± 
150nM dasatinib and cultured without exogenous GF support, as measured 
by  trypan  blue  dye  exclusion  at  each  time-point.  Panel  B  shows  the 
percentage  of  surviving  cells  at  each  time-point,  calculated  based  on 
starting cell number (100%). 
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4.2.2 D-FISH profiles of CML cells treated with dasatinib 
Previous  studies  have  reported  BCR-ABL  amplification  in  primary  cells  from 
patients with advanced phase CML and that this may be a mechanism of acquired 
drug  resistance  (238).  In  order  to  determine  whether  the  cells  which  survived 
dasatinib  exposure  showed  evidence  of  oncogene  amplification,  D-FISH  was 
performed. Only a single copy of the BCR-ABL gene was detected in each of the 
samples.  Figure  4-6  demonstrates  the  D-FISH  profile  of  one  representative 
patient’s CML cells following 12 days treatment ± 150nM dasatinib. In each of the 
three patients samples kindly tested by Mrs Elaine Allan, >95% of the cells were 
shown  to  be  BCR-ABL  positive  by  D-FISH,  both  before  and  after  dasatinib 
treatment. Although normal cells would not survive 12 days culture in SFM without 
GF support; these data definitively rule out both the presence of normal cells and 
oncogene amplification as explanations for resistance.  
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Figure 4-6 D-FISH profiles of CML cells treated with dasatinib 
Representative  FISH  profile  from  non  CML  CD34
+  cells  at  baseline  (A), 
untreated CD34
+ CML cells following the 12 day timecourse (B) and 150nM 
dasatinib-treated  CD34
+  CML  cells  following  the  12  day  timecourse  (C). 
Green signals represent BCR; red signals represent ABL and yellow signals 
represent the BCR-ABL fusion gene (denoted by the white arrows). 
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4.2.3 Analysis of ABL-kinase domain mutations in CML cells treated with 
dasatinib 
IM resistance is most often attributed to the development of point mutations within 
the ABL-kinase domain. To investigate whether this was a potential mechanism 
for the cells to remain resistant to dasatinib, a mutation screen of the ABL-kinase 
domain of BCR-ABL was kindly performed by Dr Sandrine Hayette (Hôpital Lyon, 
Lyon, France) on RNA purified from CML cells, both before and after ± 12 days 
dasatinib  exposure.  No  mutation  was  detected  in  any  of  the  patients’  samples 
(n=3). Direct sequencing of the ABL-kinase domain has a sensitivity of about 10-
20% (244), therefore if a mutation was present, it would be in less than 20% of the 
surviving  cells  following  dasatinib  treatment.  This  then  rules  out  mutation  as  a 
means of dasatinib resistance, in the majority of the cells which remained following 
prolonged dasatinib treatment. 
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4.2.4 Expression of BCR-ABL in CML cells following dasatinib treatment 
Previously,  it  has  been  demonstrated  that  patients  treated  with  allogeneic 
transplantation  had  Ph
+  cells  detected  by  D-FISH,  but  remained  BCR-ABL 
negative  by  RT-PCR.  To  determine  whether  the  primitive  CML  cells  from  this 
study were transcriptionally silent, the expression of BCR-ABL was measured in 
the untreated and 150nM dasatinib-treated cells at day 12 of the timecourse by 
qRT-PCR and these levels were compared to the same patients’ cells at baseline. 
Figure 4-7 demonstrates that CML cells at baseline expressed 82.7% BCR-ABL 
as compared to total ABL. For 12 day untreated and 150nM dasatinib-treated cells 
BCR-ABL  as  compared  to  total  ABL  was  71  and  59%,  respectively,  with  no 
significant  differences  observed  between  the  conditions  (p=0.427  for  baseline 
versus no drug; p=0.109 for baseline versus 150nM dasatinib and p=0.215 for no 
drug versus 150nM dasatinib). These data suggest that although BCR-ABL kinase 
activity  has  been  inhibited  within  these  surviving  CML  cells,  BCR-ABL  is  still 
expressed at the transcript level. 
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Figure 4-7 Expression of BCR-ABL in CML cells following dasatinib 
treatment 
BCR-ABL mRNA transcripts were measured by qRT-PCR in CD34
+ CML cell 
samples (n=3) either at baseline or following treatment ± 150nM dasatinib for 
12 days. 
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4.2.5 Analysis of p-CrkL within normal cells and compared to CML cells 
Since the previous experiments ruled out the most common means of resistance 
in TKI-treated CML cells, the level of inhibition of BCR-ABL kinase activity was 
next investigated. As stated in the introduction, p-CrkL has been found to be an 
excellent marker for the measurement of BCR-ABL kinase activity in CML cells. 
However,  in  addition  to  its  role  in  CML,  CrkL  is  also  implicated  in  signal 
transduction  by  integrins,  B-  and  T-cell  receptors,  and  cytokines  such  as 
erythropoietin, IL-3, SCF, and thrombopoietin (304-309). This, therefore, implies 
that some level of CrkL phosphorylation is evident in normal cells. In order to test 
this,  non  CML  CD34
+  cells  (n=3)  and  CML  CD34
+  cells  (n=3)  were  treated  ± 
150nM  dasatinib  for  24  hours  and  p-CrkL  levels  were  compared.  The  24  hour 
time-point was chosen in order to reflect the early effects of TKI treatment. The 
percentage of p-CrkL present in each sample was then calculated based on the 
levels of p-CrkL detected in untreated CML CD34
+ cells (n=3) (100%). Figure 4-8 
demonstrates that a level of 34 and 32.3% p-CrkL was observed in the non CML 
cells untreated and treated with dasatinib, respectively, as compared to 37% p-
CrkL  in  dasatinib-treated  CML  cells.  No  significant  differences  in  p-CrkL  levels 
were  observed  between  the  conditions  (p=0.35  for  dasatinib-treated  CML  cells 
versus untreated non CML cells; p=0.14 for dasatinib-treated CML cells versus 
dasatinib-treated non CML cells and p=0.28 for untreated non CML cells versus 
dasatinib-treated non CML cells).  
 
In  all subsequent experiments, the  level  of  p-CrkL present in  normal cells  was 
subtracted from the level present in CML cells treated ± dasatinib, in order to give 
a true measure of BCR-ABL inhibition.  
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Figure 4-8 Analysis of p-CrkL within normal cells and compared to CML cells 
Levels of p-CrkL were measured by flow cytometry in non CML (n=3) versus 
CML CD34
+ cells (n=3) treated ± 150nM dasatinib for 24 hours.  
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4.2.6 Flow cytometric analysis of p-CrkL expression within a total population 
of CML cells treated with dasatinib 
In  order  to  determine  whether  prolonged  dasatinib  exposure  could  completely 
inhibit BCR-ABL activity within the total CML cell population, flow cytometry was 
used to measure p-CrkL levels within the 12 day dasatinib-treated CML samples. 
Figure 4-9 demonstrates that within the bulk population of CML cells, dasatinib 
induced a maximal inhibition of p-CrkL by day 12 of treatment, with no significant 
difference  observed  between  the  time-points  (p=0.54  for  day  4  versus  day  8; 
p=0.84 for day 4 versus day 12 and p=0.3 for day 8 versus day 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9 Flow cytometric analysis of p-CrkL expression within a total 
population of CML cells treated with dasatinib 
CD34
+ CML cells (n=3) were cultured in SFM minus GFs and treated ± 150nM 
dasatinib  for  12  days.  The  levels  of  p-CrkL  were  then  measured  by  flow 
cytometry at each indicated time-point. 
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4.2.7 Western blot analysis of p-CrkL expression within a total population of 
CML cells treated with dasatinib 
In order to confirm the results from the flow cytometric anaysis of p-CrkL within the 
bulk population of dasatinib-treated cells (as described in Figure 4-9), a Western 
blot  for  p-CrkL  was  performed  on  the  cells  remaining  after  12  days  treatment. 
Figure 4-10A shows that near complete inhibition of p-CrkL was achieved in 2 of 
the patients’ dasatinib-treated CML cells (CML 232 and 219) and that complete 
inhibition  was  reached  in  1  patient’s  CML  cells  (CML  235).    To  determine  the 
percentage of p-CrkL in each sample, densitometry was performed on the blots 
shown in Figure 4-10A, with correction on each arm for its corresponding pan-
actin loading control. Figure 4-10B demonstrates that 94.5% inhibition of p-CrkL 
was achieved in the total population of dasatinib-treated CML cells, as determined 
by  Western  blot  (p=0.00014  for  dasatinib-treated  cells  versus  no  drug  control 
(100%)).  
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Figure 4-10 Western blot analysis of p-CrkL expression within a total 
population of CML cells treated with dasatinib 
Panel A shows p-CrkL profiles from 3 patients’ CD34
+ CML cells treated ± 
150nM dasatinib for 12 days. Pan-actin was included in each experiment as a 
protein  loading  control.  Panel  B  shows  the  mean  percentage  of  p-CrkL 
expressed in the samples shown in panel A, as measured by densitometry. 
Each  sample  was  corrected  for  its  corresponding  pan-actin  control 
(p=0.00014 for dasatinib treatment versus no drug control (100%)). 
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4.2.8 Levels of p-CrkL within each cell division of CML cells treated with 
dasatinib 
It  has  previously  been  demonstrated  by  our  own  group  (131)  and  others 
(300)
,(298), that BCR-ABL is over-expressed within very primitive populations of 
CML  cells.  Therefore,  it  is  unclear  whether  the  level  of  inhibition  of  p-CrkL 
following dasatinib treatment, as seen in the total population of CML cells (Figure 
4-10), is representative of all cells, or potentially 100% inhibition in the majority of 
cells  and  0%  inhibition  in  a  smaller  subpopulation.  To  determine  whether 
prolonged  dasatinib  exposure  could  completely  inhibit  BCR-ABL  activity, 
specifically  within the undivided primitive CML cell  population and also in each 
subsequent cell division, multi-colour flow cytometry was used. In the CML CD34
+ 
cells described in Figure 4-10, intracellular p-CrkL measurement was combined 
with  CFSE  analysis  by  flow  cytometry.  Cells  that  retain  maximal  CFSE 
fluorescence  (CFSEmax),  as  compared  to  a  colcemid  control,  represent  the 
primitive CD34
+
 cells that remain undivided. Figure 4-11A shows the levels of p-
CrkL within each cell division following 150nM dasatinib treatment, as calculated 
based on the levels of p-CrkL in each corresponding untreated control (100%).  
Statistical analysis revealed no difference in p-CrkL levels between the total CML 
cell population and each cell division at every time-point (Table 4-1). 
 
  Day 4  Day 8  Day 12 
Undivided population  0.152  0.578  0.377 
Division 1  0.312  0.457  0.645 
Division 2  0.748  0.391  0.805 
Division 3  0.061  0.743  0.776 
 
Table 4-1 p values for the total CML cell population versus each division of 
CML cells treated with 150nM dasatinib for 12 days   169 
In order to determine whether this was the maximal amount of BCR-ABL inhibition 
achievable by dasatinib, CML CD34
+ cells (n=3) were also treated with a much 
increased dose of dasatinib (1000nM; not achievable in patients). Figure 4-11B 
demonstrates  that,  using  a  higher  concentration  of  dasatinib,  no  significant 
difference was observed between the total  population and each  cell division at 
every time-point (Table 4-2). Furthermore, no significant difference was observed 
between 150nM and 1000nM dasatinib treatment (Table 4-3). 
 
  Day 4  Day 8  Day 12 
Undivided population  0.787  0.382  0.455 
Division 1  0.529  0.441  0.940 
Division 2  0.319  0.984  0.273 
Division 3  0.616  0.185  0.191 
 
Table 4-2 p values for the total CML cell population versus each division of 
CML cells treated with 1000nM dasatinib for 12 days 
 
  Day 4  Day 8  Day 12 
Total population  0.827  0.718  0.768 
Undivided population  0.748  0.947  0.494 
Division 1  0.954  0.567  0.715 
Division 2  0.694  0.143  0.877 
Division 3  0.945  0.422  0.425 
 
Table 4-3 p values for the 12 day 150nM dasatinib-treated CML cells versus 
the 12 day 1000nM dasatinib-treated CML cells 
 
Although there looks to be a trend towards increased p-CrkL inhibition in later cell 
divisions  as  compared  to  earlier  ones  (specifically,  division  3  versus  undivided 
cells)  in  both  150  and  1000nM  dasatinib-treated  cells,  the  difference  was  not 
significant (Table 4-4).  
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  Day 4  Day 8  Day 12 
150nM dasatinib  0.174  0.409  0.357 
1000nM dasatinib  0.803  0.332  0.329 
 
Table 4-4 p values for the undivided population of cells versus cell division 3 
of  both  12  day  150nM  dasatinib-treated  CML  cells  and  1000nM  dasatinib-
treated CML cells 
 
These  data  indicate  that  maximal  pharmacological  inhibition  of  BCR-ABL  is 
achieved  with  150nM  dasatinib  and  that  every  subpopulation  of  CML  cells  is 
inhibited equally. 
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Figure 4-11 Levels of p-CrkL within each cell division of CML cells treated 
with dasatinib 
CFSE-stained  CML  CD34
+  cells  (n=3)  were  treated  with  either  150nM 
dasatinib (A) or 1000nM dasatinib (B) for 12 days. Measurement of p-CrkL 
was performed by flow cytometry at the indicated time-points, within each 
cell  division.  The  level  of  p-CrkL  was  calculated  based  on  the  relevant 
untreated control (100%). 
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4.2.9 Comparison of the phosphorylation levels of CrkL and STAT5 within 
dasatinib-treated CML cells 
Shah  and  colleagues  have  recently  suggested  that,  since  CrkL  is  physically 
associated to- and highly phosphorylated by- BCR-ABL, the detection of p-CrkL 
may not be sensitive enough to detect modest changes in BCR-ABL activity. The 
authors suggest that other endpoints should also be measured in order to make 
an accurate assessment of BCR-ABL inhibition (310). Therefore, in order to verify 
whether the measurement of p-CrkL gave an exact representation of the amount 
of  BCR-ABL  inhibition  achieved,  the  phosphorylation  of  another  downstream 
substrate, STAT5, was also measured. Figure 4-12 demonstrates the levels of p-
STAT5 within each cell division of CFSE-stained CML CD34
+ cells, treated for 12 
days with 150nM dasatinib, as measured by flow cytometry. These data were then 
compared to the p-CrkL results at day 12 which were demonstrated in Figure 4-
11A.  No  significant  differences  were  observed  between  the  two  methods  for 
determining  the  inhibition  of  BCR-ABL  kinase  activity  (p=0.4  for  the  total 
population; p=0.95 for the undivided population; p=0.83 for division 1; p=0.8 for 
division 2 and p=0.52 for division 3).  
 
It should be noted that, since  non CML samples are relatively rare,  it was not 
feasible to use one sample solely for the purpose of measuring the baseline levels 
of p-STAT5. Therefore, the levels of p-STAT5 and p-CrkL were compared within 
CD34
+ CML cells only, without any non CML background correction. 
 
These data further confirmed the reliability of the p-CrkL flow cytometric method 
for the measurement of BCR-ABL activity. 
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Figure 4-12 Comparison of the phosphorylation levels of CrkL and STAT5 
levels in dasatinib-treated CML cells 
CFSE-stained CML CD34
+ cells (n=3) were treated ± 150nM dasatinib for 12 
days. Measurement of p-STAT5 was performed by flow cytometry at day 12, 
within each cell division. The level of p-STAT5 was calculated based on the 
relevant  untreated  control  (100%)  and  compared  to  the  p-CrkL  data 
described in Figure 4-11A. 
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4.2.10 Undivided CML cell recoveries as measured by CFSE-staining 
Previous studies by our lab have demonstrated the anti-proliferative effect of both 
IM  (226)  and  dasatinib  (131).  Since  the  quiescent  CML  stem  cell  population 
resides within the CFSEmax population, it is important to measure the percentage 
of  cells  within  this  gate,  in  order  to  determine  whether  these  cells  have  been 
targeted following TKI treatment. Therefore, CFSE staining was used to assess 
the most primitive CML cell recovery during the 12 day treatment timecourse of 
CML  CD34
+  cells  (n=3)  with  150nM  dasatinib.  Figure  4-13  demonstrates  the 
percentage  of  CML  cells  which  remain  undivided  at  day  12  of  treatment,  as 
compared  to  the  input  cell  number  from  the  start  of  the  timecourse.  The 
percentage  of  dasatinib-treated  CML  cells  which  remained  undivided  was 
significantly  increased  as  compared to untreated control (0.21%  versus 0.07%; 
p=0.03).  This  corroborates  previous  data  which  showed  an  enrichment  for  the 
CFSEmax undivided population following TKI treatment (131, 226).  
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Figure 4-13 Undivided CML cell recoveries as measured by CFSE-staining 
CFSE-stained CML CD34
+ cells (n=3) were treated ± 150nM dasatinib for 12 
days  and  measurement  of  CFSE  was  performed  by  flow  cytometry.  The 
percentage of undivided cells recovered at day 12 was calculated based on 
the input cell number at day 0.  
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4.2.11 CML cell recoveries within each division as measured by CFSE-
staining 
Next,  a  further  analysis  of  the  cell  division  status  of  the  cells  which  remained 
following  the  12  day  timecourse  was  performed.  Figure  4-14  demonstrates  the 
percentage of cells within each cell division, recovered following 12 days treatment 
± 150nM dasatinib. Consistent with previous data, an anti-proliferative effect was 
observed  with  dasatinib  treatment  as  compared  to  no  drug  control.  The  data 
described in Figure 4-13 showed enrichment for the undivided population of CML 
cells following TKI treatment. However, Figure 4-14 shows that it is not only the 
quiescent population of CML cells which is able to survive the prolonged dasatinib 
exposure. It would appear that a further resistant CML cell population, which is 
able to  reach  the  earlier cell  divisions,  exists. CFSE analysis of  the  CML cells 
which  survived  the  12  days  treatment  with  150nM  dasatinib  revealed  that  the 
majority of recovered cells resided within cell division 2 (Table 4-5). 
 
  No drug (%)  150nM dasatinib (%) 
undivided population  0.55  3.01 
Division 1  0.483  40.05 
Division 2  14.81  48.71 
Division 3  43.52  7.99 
Division 4  26.53  0.23 
Division 5  9.26  0 
Division 6  4.84  0 
 
Table 4-5 Percentages of CML cells residing within each division, following 
12 days treatment ± 150nM dasatinib 
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Figure 4-14 CML cell recoveries within each cell division as measured by 
CFSE-staining 
CD34
+ CML cells were first stained with CFSE, cultured in SFM minus GFs 
and treated ± 150nM dasatinib for 12 days. The percentages of cells residing 
within  each  cell  division  were  then  determined  by  CFSE-staining,  as 
measured by flow cytometry. 
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4.2.12 CML cell cycle status as measured by Ki67 and 7AAD staining 
Although CFSE staining has proven to be a reliable technique for the identification 
of  undivided  cells,  it  should  be  noted  that  cell  quiescence  cannot  be  directly 
confirmed by this method, as it does not give any information on cell cycle status 
i.e. cells within the undivided gate may either be quiescent or in G1 arrest. In order 
to determine the cell cycle status of the CML cells which have been treated ± 
150nM  dasatinib,  Ki67/7AAD  staining  was  carried  out.  Figure  4-15  shows 
representative  patient’s  CML  cells  left  untreated  (A)  and  treated  with  150nM 
dasatinib (B); cultured with (right hand panel) and without (left hand panel) GFs at 
day  12  of  treatment.  Panel  A  shows  that  the  majority  of  untreated  CML  cells, 
which have been cultured with exogenous GF support, are in division (G0: 26.5%; 
G1: 48.56%; S/G2/M: 24.47%). As expected, fewer cells had gone into division in 
the CML cells which were untreated and cultured without GFs (G0: 55.34%; G1: 
36.48%;  S/G2/M:  7.24%).  Panel  B  demonstrates  the  anti-proliferative  effect  of 
dasatinib, with the majority of cells residing within the G0 stage of cell cycle. Again, 
far fewer cells had gone into division in the CML cells which had been cultured 
without  GFs  versus  the  cells  which  had  been  cultured  with  GFs  by  day  12  of 
dasatinib  treatment  (G0:  86.49%  and  51.23%;  G1:  6.99%  and  40.31%;  S/G2/M: 
2.17%  and  7.57%,  respectively).  This  finding  is  consistent  with  previous  data, 
whereby a detailed analysis of CML cells revealed very little/no detectable levels 
of  Ki67  expression  within  the  quiescent  stem  cell  population  (224).  This  would 
suggest that the dasatinib-treatment without GFs in the culture media has selected 
for a quiescent population of CML cells. However, since the CFSE data (described 
in Figure 4-14) shows that the majority of the cells have been able to divide to 
division  2,  it  may  mean  that  the  cells  divided  early  in  the  timecourse  and  had 
stopped almost all cell division by the day 12 time-point.  
   179 
It is also interesting to note that the percentage of cells in G0 was approximately 
equal in the untreated cells cultured without GFs and the dasatinib-treated cells 
cultured  with  GFs  (G0:  55.34%  versus  51.23%,  respectively).  This  finding 
corroborates  the  data  presented  in  Figure  4-1,  where  TKI  treatment  in  the 
presence of GFs gave the same effect as removing the GF support from untreated 
control cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-15 CML cell cycle status as measured by Ki67 and 7AAD staining 
Representative Ki67/7AAD FACS profile from one patient’s CD34
+ CML cells 
left either untreated (A) or treated with 150nM dasatinib (B) and cultured ± 
GFs for 12 days. 
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4.2.13 The effect of dasatinib treatment on the localisation of FoxO3a within 
CML cells 
The previous data demonstrated that dasatinib treatment exerted a potent anti-
proliferative  effect  on  CML  cells,  consistent  with  other  studies  (131,  226). 
However, the mechanism by which dasatinib causes these anti-proliferative effects 
is  still  not  fully  understood.  Since  the  nuclear  localisation  of  FoxO3a  and  its 
subsequent  transcriptional  activity,  has  been  shown  to  be  important  for  the 
induction of cell cycle arrest (311); this was next investigated.  CML CD34
+ cells 
were first cultured in SFM ± GF and treated with 150nM dasatinib for 12 days, 
before being fixed onto slides and stained with anti-FoxO3a antibody. Nuclei were 
counterstained with then DAPI and levels of FoxO3a were then visualised within 
these cells by IF. Figures 4-16A and B demonstrate a representative FoxO3a IF 
profile and corresponding surface plot profile (using ImageJ software) from one 
patient’s  cells,  respectively.  In  the  untreated  CML  cells  cultured  with  (top  left 
panel) and without (top right panel) GFs, FoxO3a was found to be predominantly 
localised  to  the  cytoplasm  where  it  is  transcriptionally  inactive.  The  greatest 
amount  of  cytoplasmic  FoxO3a-positive  puncta  was  observed  in  the  untreated 
cells cultured with GFs. Treatment of the CML cells with dasatinib in the presence 
of GFs (bottom left panel), resulted in a localisation of FoxO3a to both the nucleus 
and  cytoplasm.  However,  treatment  of  the  CML  cells  with  dasatinib  without 
exogenous  GF  support  (botton  right  panel),  resulted  in  FoxO3a  to  be 
predominantly localised to the nucleus and therefore, in a transcriptionally active 
state. Since FoxOs transcription factors are direct targets of activated Akt, it could 
be said that the activation of the PI3K/Akt pathway within CML cells, by BCR-ABL 
and/or GF stimulation, induces the cytoplasmic localisation and hence inhibition of 
FoxO3a, which is consistent with previous studies (312-314). Treatment of CML 
cells  with  dasatinib  induces  the  nuclear  localisation  and  hence  activation  of   181 
FoxO3a transcriptional activity. However, this can  be partially  overcome  by the 
addition of exogenous GF support. 
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Figure 4-16 The effect of dasatinib treatment on the localisation of FoxO3a 
within CML cells 
CD34
+ CML cells were cultured in SFM ± 5GF and treated ± 150nM dasatinib 
for 12 days. Remaining CML cells were then fixed onto multi-spot slides and 
stained with anti-FoxO3a antibody. Nuclei were counterstained with DAPI. 
Representative IF profiles (A) and surface plots using ImageJ software (B) 
from one patient are shown. 
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4.2.14 Analysis of cyclin D1 expression in dasatinib-treated CML cells 
The cyclin D1 proto-oncogene is an important regulator of G1 to S phase transition 
in  many  different  cell  types  and  its  expression  is  often  disrupted  in  various 
cancers. It has been recently reported that BCR-ABL silencing by small interfering 
RNAs  (siRNA)  resulted  in  significantly  reduced  cyclin  D1  mRNA  and  protein 
expression in K562 cells (315). Furthermore, the nuclear localisation of FoxOs (as 
demonstrated in Figure 4-16) results in the activation of their transcriptional activity 
which  promotes  cell  cycle  arrest  through  down-regulation  of  cyclin  D  (139). 
Therefore, the effect of BCR-ABL activity inhibition on cyclin D1 expression was 
next assessed in the primary CML cells remaining after dasatinib treatment. The 
relative mRNA expression of cyclin D1 was measured by qRT-PCR, following 12 
days treatment ± 150nM dasatinib and cultured in the absence of GFs. Figure 4-
17 demonstrates that inhibition of BCR-ABL by dasatinib caused approximately a 
3-fold  reduction  in  cyclin  D1  mRNA,  relative  to  no  drug  control  (p=0.016), 
consistent with previous studies (314). This also is in keeping with the Ki67/7AAD 
data presented in Figure 4-15, where the majority of cells resided within the G0 
phase of cell cycle.  
 
These data taken together indicate that the treatment of CD34
+ CML cells with 
dasatinib leads to the nuclear localisation and subsequent activation of FoxO3a. 
This  then  contributes  to  the  reduced  transcription  of  the  FoxO3a  downstream 
target, cyclin D1, and maintenance of quiescence within these resistant CML cells.  
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Figure 4-17 Analysis of cyclin D1 expression in dasatinib-treated CML cells 
Expression  of  cyclin  D1  mRNA  transcripts  as  measured  by  qRT-PCR  in 
CD34
+ CML cell samples (n=3) following treatment ± 150nM dasatinib for 12 
days. 
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4.3 Analysis of functionality of the CML cells remaining following 
prolonged BCR-ABL kinase inhibtion 
 
4.3.1 Characterisation of 12 day dasatinib-treated CML cells following 
additional culture with GF support 
To investigate whether the dasatinib-resistant cells were still fully functional and 
able to proliferate when stimulated with cytokines, further analyses were carried 
out. First, the cells remaining following 12 days dasatinib treatment were washed 
with PBS to remove the drug and cultured in the presence of a potent 5GF cocktail 
for 7 days. A viable cell count using trypan blue dye exclusion was then performed 
at  this  time-point.  Figure  4-18A  demonstrates  that  the  ±  dasatinib-treated  cells 
were  found  to  expand  17-  and  5-fold,  respectively  (p=0.086).  The  lower  cell 
number within the dasatinib-treated arm may reflect the fact that this cell fraction 
contained more primitive CML cells, which were slow to proliferate as compared to 
the actively cycling untreated cells. The levels of p-CrkL, as a measure of BCR-
ABL activity, were also determined in the cytokine-cultured cells at this time-point. 
Figure 4-18B shows that the dasatinib-treated cells had a level of 98% p-CrkL as 
compared to untreated control (100%) (p=0.95). This therefore suggests that BCR-
ABL activity had been re-activated in these dasatinib-treated cells and that BCR-
ABL inhibition is survivable.  
Due  to  the  fact  that  there  was  a  trend  towards  lower  viable  cell  counts  in  the 
dasatinib-treated CML cells as compared to the untreated cells at the day 7 time-
point  (Figure  4-18A),  it  was  hypothesised  that  at  least  a  proportion  of  the 
dasatinib-treated cells may have undergone an irreversible growth arrest following 
drug treatment. In order to address this, Ki67/7AAD staining was also carried out 
on the cells following the 7 days culture with 5GF. Figure 4-18C demonstrates that   186 
the majority of both the untreated and the dasatinib-treated cells were in cycle, 
following drug wash out and 7 days culture with cytokines (G0: 2.73 and 6.43%; 
G1: 66.15 and 70.91% and S/G2/M: 31 and 22.55%, for untreated and dasatinib-
treated cells, respectively). These data indicate that the dasatinib treatment did not 
cause  irreversible  growth  arrest  in  the  vast  majority  of  these  cells.  As  this 
Ki67/7AAD profile is only a reflection of what is happening at a particular time-
point, it is also possible that the remaining 6.43% of cells in G0 would also go into 
cycle in time, particularly since the dasatinib treated cells contained more primitive 
cells and as suggested above would likely take longer to enter cell division upon 
GF  stimulation.  A  further  possibility  is  that  these  cells  represent  a  quiescent 
population which, consistent with previous studies (224), remain undivided even in 
the presence of high GFs. In order to verify the cell cycle data, CFSE staining was 
also carried out. Following 12 days dasatinib treatment, the cells were washed 
with PBS and stained with CFSE, before being cultured for 7 days in SFM+5GF. 
Figure 4-18D confirms the data from the cell cycle analysis (Figure 4-18C) as the 
majority of both the untreated and the dasatinib-treated cells were in a state of cell 
division,  following  drug  wash  out  and  7  days  culture  with  cytokines  (undivided 
population: 1.95 and 4.51% for untreated and dasatinib-treated cells, respectively). 
Since  the  proportion  of  undivided  cells  remaining  following  12  days  of  150nM 
dasatinib  treatment,  was  an  average  of  3.01%  (range:  2.05,  2.4  and  4.58%) 
(Figure 4-14), it is possible that the undivided cell fraction remaining at day 7 of 
culture in SFM+5GF, represents a quiescent population of CML cells which was 
both  unaffected  by  prolonged  treatment  with  dasatinib  and  also  remained 
undivided after exposure to high concentrations of cytokines. 
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Figure 4-18 Characterisation of 12 day dasatinib-treated CML cells following 
additional culture with GF support 
The 12 day ± 150nM dasatinib-treated cells were washed with PBS, stained 
with CFSE and cultured in 5GF for 7 days. At the 7-day time-point, viable cell 
counts  were  performed  by  trypan  blue  dye  exclusion  (A)  and  p-CrkL  (B), 
Ki67/7AAD (C) and CFSE (D) were all measured by flow cytometry. 
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4.3.1.1 The effect of dasatinib removal and GF culture on the localisation of 
FoxO3a within CML cells 
As stated in Section 4.2.13, the nuclear localisation of FoxO3a and its subsequent 
transcriptional activity, has been shown to be important for the induction of cell 
cycle arrest (311). Since we demonstrated that the treatment of CML cells with 
dasatinib  induces  the  nuclear  localisation  of  FoxO3a,  it  was  next  investigated 
whether this could be reverted following the removal of dasatinib and the culture 
with GFs. First, the CML cells remaining following 12 days dasatinib treatment 
were washed with PBS and cultured in SFM+5GF for 7 days. An aliquot of the 
CML  cells  was  then  fixed  onto  slides  and  stained  with  anti-FoxO3a  antibody. 
Nuclei  were  counterstained  with  then  DAPI  and  levels  of  FoxO3a  were  then 
visualised  within  these  cells  by  IF.  Figure  4-19  demonstrates  a  representative 
FoxO3a IF profile from one patient’s cells. In both the untreated and dasatinib-
treated  CML  cells,  FoxO3a  was  found  to  be  predominantly  localised  to  the 
cytoplasm  and  was  therefore  transcriptionally  inactive.  This  suggests  that  the 
reactivation of the PI3K/Akt pathway, by BCR-ABL and GF stimulation, following 
the dasatinib wash-out within the CML cells, induced the cytoplasmic localisation 
and inhibition of FoxO3a, which would thereby allow the cells to continue to divide.  
 
 
 
 
   
 
 
 
   190 
 
 
 
 
 
 
 
 
 
 
Figure 4-19 Detection of FoxO3a in dasatinib-treated CML cells following 
drug wash-out and additional culture with GFs 
The  12  day  ±  150nM  dasatinib-treated  cells  were  washed  with  PBS  and 
cultured in 5GF for 7 days. Aliquots of CML cells were then fixed onto multi-
spot  slides  and  stained  with  anti-FoxO3a  antibody.  Nuclei  were 
counterstained with DAPI.  
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4.3.2 Analysis of committed and primitive progenitor capacity in surviving 12 
day dasatinib-treated CML cells  
To  determine  whether  the  surviving  CML  cells  had  functional  committed  and 
primitive  progenitor  capacity,  the  ±  dasatinib-treated  cells  were  plated  in  CFC 
(committed progenitor) and LTC-IC (primitive progenitor) assays and compared to 
a  baseline  (CD34
+  CML  cells  which  had  no  prior  culture  or  treatment.)  The 
resulting colonies were picked and analysed for Ph
+ cells by D-FISH. In each of 
the three patients’ samples kindly tested by Mrs Elaine Allan, >98% of the cells in 
each of the conditions were shown to be BCR-ABL positive by D-FISH. Figure 4-
20A demonstrates that the untreated arm was able to form 3 times the number of 
CFC as compared to the cells at baseline (100%), suggesting differentiation and 
expansion from stem cells, even in the absence of GFs. Dasatinib-treated cells 
were only able to form ~2% CFC as compared to baseline and were significantly 
reduced as compared to no drug control (p=0.0125). Next, the number of CML 
cells which were able to form a CFC colony, per 1000 surviving cells at day 12 
was calculated. The no drug control was then normalised to 1 and the dasatinib-
treated arm was calculated based on this. Figure 4-20B shows that there was a 
trend towards a reduction in the CFC colonies produced per 1000 cells at day 12 
in the dasatinib treatment arm, as compared to untreated control. However, there 
was  no  significant  difference  observed  between  the  two  conditions  (p=0.25). 
These data indicate that dasatinib treatment effectively targeted the more mature 
committed  progenitor  CML  cell  population,  based  on  the  starting  cell  number. 
However,  the  ability  to  form  a  CFC  colony  within  the  cells  which  survived  the 
dasatinib treatment did  not  significantly alter, as compared to untreated control 
cells. 
   192 
Figure 4-20C shows that compared to baseline cells, the untreated cells formed 
50%  less  LTC-IC  colonies,  suggesting  that  half  of  these  cells  had  proceeded 
towards  terminal  differentiation.  Dasatinib-treated  cells  recovered  a  significantly 
reduced number of LTC-IC (~14%) as compared to both baseline and no drug 
control (p=0.01 and p=0.02, respectively). Next, the number of CML cells which 
were  able  to  form  a  LTC-IC  colony,  per  1000  surviving  cells  at  day  12  was 
calculated. Again, the no drug control was then normalised to 1 and the dasatinib-
treated arm was calculated based on this. Figure 4-20D shows that there was a 
21-fold increase in the LTC-IC colonies produced per 1000 cells at day 12 in the 
dasatinib treatment arm, as compared to untreated control (p=0.025). This mirrors 
the data described in Section 4.2.10, where the percentage of primitive undivided 
cells recovered at day 12 of dasatinib treatment was increased as compared to 
untreated control cells. 
 
Overall, these data suggest that following BCR-ABL inhibition by dasatinib, within 
a total CML cell population, the committed CML progenitor population is targeted, 
whereas, the primitive quiescent CML cells with LTC-IC potential remain relatively 
unaffected. However, in the population which survives drug treatment, the CML 
cells with CFC potential remain relatively unaffected, whereas the cells with    
LTC-IC potential are enriched. 
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Figure 4-20 Analysis of committed and primitive progenitor capacity in 
surviving 12 day dasatinib-treated CML cells 
Following  the  150nM  dasatinib  treatment  timecourse,  the  remaining  CML 
cells (n=3) were washed with PBS to remove any drug and added to CFC (A 
and B) and LTC-IC (C and D) assays. 
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4.3.3 Analysis of murine engraftment of surviving CML cells following 
treatment ± 150nM dasatinib for 12 days 
To further investigate the functionality of the cells that survived the 12 day 150nM 
dasatinib  treatment  timecourse,  the  remaining  CML  cells  (n=3)  were  also 
transplanted into NOD/SCID mice, to determine any reconstitution potential. The 
surviving cells were first washed twice with PBS and sent to the animal facility at 
the  University  of  Bristol,  where  Dr  Allison  Blair  kindly  performed  all  murine 
engraftment  experiments.  Engraftment  was  determined  by  the  flow  cytometric 
measurement of human CD45 in the murine BM cells. Figure 4-21 demonstrates 
that insufficient engraftment was achieved in both the untreated control and the 
dasatinib-treatment arm; therefore no definitive conclusion could be drawn from 
this experiment. 
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Figure 4-21 Analysis of murine engraftment of surviving CML cells following 
treatment ± 150nM dasatinib for 12 days 
Following the treatment timecourse, the CML cells (n=3) were washed with 
PBS to remove any drug and transplanted into NOD/SCID mice. Three mice 
were transplanted per patient sample. Mice were sacrificed at 16 weeks post-
transplant. Engraftment levels were determined by flow cytometric analysis 
of human CD45 in the murine BM cells. 
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4.4 Summary 
The  term  “oncogene  addiction”  is  used  to  describe  the  phenomenon  by  which 
some cancers acquire dependency on one or a few genes for the maintenance of 
the malignant phenotype and cell survival. The purpose of the work in this chapter 
was  to  determine  whether  CML  stem  cells  are  “addicted”  to  BCR-ABL  kinase 
activity, by exposing CD34
+ CML cells to TKI treatment and investigating whether 
the inhibition of BCR-ABL kinase correlated with cell death.  
In  experiments  designed  to  determine  optimal  treatment  conditions,  it  was 
confirmed that CD34
+ CML cells are able to survive and proliferate in the absence 
of cytokine support. Furthermore, the TKI treatment of CML cells in the presence 
of  high  GFs  gave  the  same  effect  as  leaving  the  CML  cells  untreated  in  the 
absence of GFs. This confirms work first published by Dorsey et al. whereby IL-3 
was  found  to  protect  IL-3  responsive,  BCR-ABL-transformed  haemopoietic 
progenitor cells from apoptosis caused by TKIs, including IM (303). This finding 
also has potential implications for the treatment of patients, in whom cytokines 
would  be  present  at  physiological  concentrations.  Studies  which  examined  the 
effect of TKI exposure time and concentration also showed that each TKI exerted 
its effects very early in the timecourse (after 1 hour and possibly even earlier) and 
transient exposure was as effective as prolonged treatment, confirming the results 
from  other  investigators  (310,  316).  Furthermore,  escalation  up  to  clinically 
unachievable doses, did not give any increased cell kill over lower concentrations 
of the drug. 
 
During a 12 day timecourse, dasatinib treatment in the absence of GF support 
resulted in a reduction in CML cell number to <2% of no drug control and <10% of 
the starting cell number. Investigation of possible resistance mechanisms revealed 
no  evidence  of  oncogene  amplification  by  D-FISH  and  no  ABL-kinase  domain   197 
mutation was detected in any of the patient samples. Both D-FISH and qRT-PCR 
confirmed  the  presence  of  BCR-ABL  within  the  surviving  cells,  ruling  out  the 
presence of normal cells as an explanation of dasatinib resistance. 
 
Since the most primitive CML cell fraction has previously been shown to express 
increased levels of BCR-ABL transcripts and protein, there was some concern that 
any resistance may be caused by the fact that dasatinib was not able to effectively 
inhibit  the  increased  levels  of  BCR-ABL  activity  within  these  primitive  cell 
subpopulations. The experiments which measured p-CrkL levels within each CML 
cell division demonstrated that 150nM dasatinib treatment inhibited p-CrkL within 
each cell subpopulation to the same degree as the bulk population of CML CD34
+ 
cells. This level of inhibition could not be increased on dose escalation to 1000nM 
dasatinib and was not significantly different to the level of inhibition achieved of 
another  downstream  target,  p-STAT5.  Furthermore,  since  dasatinib  treatment 
inhibited the phosphorylation of CrkL to the same level as that seen in non CML 
CD34
+  cells,  it  was  concluded  that  the  12  day  dasatinib  treatment  maximally 
inhibited BCR-ABL activity within each CML subpopulation.  
 
Analysis of the percentage recoveries within each cell division revealed that the 
most primitive undivided cell fraction was higher in the dasatinib-treated cells as 
compared to the untreated control. A further subpopulation of CML cells, which 
were able to reach the earlier cell divisions, also remained. Not surprisingly, cell 
cycle analysis revealed that the majority of surviving CML cells following dasatinib 
exposure had stopped all cell division and resided within the G0 stage of cell cycle 
by 12 days treatment. This was further confirmed by the observation of FoxO3a 
which was predominantly localised to the nucleus, with significantly reduced cyclin 
D1 expression in dasatinib-treated cells as compared to untreated control.  This   198 
data  corroborates  the  findings  from  previous  studies,  whereby  nuclear  FoxO3a 
and its subsequent transcriptional activity, was important for the maintenance of 
both CML  LICs in a  CML-like disease mouse model (317) and quiescent CML 
stem cells in vitro (314). Although it is highly likely that other cell cycle regulators 
are involved in the anti-proliferative effect induced by dasatinib or any other TKI 
treatment,  the  FoxO  axis  may  represent  an  important  stem  cell  quiescence 
mechanism for future investigation.  
 
The  cells  which  survived  the  12  day  dasatinib  treatment  course  were  able  to 
reactivate BCR-ABL activity (as measured by p-CrkL) to approximately the same 
level as that of untreated cells, had predominantly cytoplasmic, transcriptionally 
inactive  FoxO3a  and  were  also  able  to  expand  5-fold  when  cultured  in  the 
presence  of  cytokines.  Data  from  the  CFC  assay  confirmed  that  dasatinib 
treatment was able to effectively target mature committed progenitor cells which 
were able to form colonies. However, LTC-IC data suggested that the effect of 
dasatinib does not target the very primitive quiescent cell population to the same 
extent. 
 
Overall,  these  data  imply  that  since  only  10%  of  CML  cells  remain  following 
dasatinib treatment, 90% of CD34
+ CML cells are “oncogene addicted” to BCR-
ABL  kinase  activity.  Due  to  the  fact  that  dasatinib  is  a  dual  SRC/ABL-kinase 
inhibitor, it is difficult to  say  whether cell  death  is  exclusively  due to BCR-ABL 
inhibition.  However,  the  similarity  in  response  for  IM,  nilotinib  and  dasatinib 
(Section 4.1.2) suggests that sensitivity is mainly based on the potency of BCR-
ABL inhibition. Since BCR-ABL kinase is fully inhibited within the surviving CML 
cells, it could be said that this population is BCR-ABL-kinase-independent. It was 
also  observed  that  two  sub-populations  exist  within  the  BCR-ABL-kinase-  199 
independent CML cell fraction: the very primitive quiescent CML population and a 
further population of cells which is able to divide to the early cell divisions. It is 
likely that the quiescent CML cell population evades dasatinib treatment simply by 
virtue of their quiescent state. However, since the second BCR-ABL independent 
population  is  still  able  to  divide  even  without  both  exogenous  GF  support  and 
BCR-ABL kinase activation, which would normally allow these cells to proliferate, it 
is  probable  that  these  cells  use  other  survival  pathways  as  a  mechanism  of 
resistance against dasatinib treatment.  
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5. RESULTS (III) Analysis of the effects of autophagy on 
CML stem cell survival 
   
Clinical IM resistance has consistently  been  associated  with  gene  amplification 
and the detection of BCR-ABL kinase mutations. However, previous experiments 
performed by  our  own laboratory and demonstrated in the last results chapter, 
have shown that CML cells which survive IM or dasatinib exposure in vitro, do not 
show any evidence of amplification and do not contain any ABL-kinase domain 
mutations at levels that would explain their IM resistance (131). Furthermore, the 
previous chapter also demonstrated that BCR-ABL kinase activity was completely 
inhibited  in  the  CML  cells  which  survived  prolonged  dasatinib  treatment.  This 
suggests  that  resistance  may  be  partly  influenced  by  BCR-ABL  independent 
factors  or  pathways,  which  co-operate  with  BCR-ABL  transformation  and 
compensate for BCR-ABL inactivation. 
 
Autophagy is a conserved catabolic membrane-trafficking process which degrades 
long-lived cellular components, providing the cell with essential stores of energy. 
In  addition  to  important  housekeeping  functions,  autophagy  plays  an  important 
role in cell survival under conditions of nutrient and/or oxygen deprivation (164) 
and hence could be predicted to play a protective role in maintaining cancer cell 
survival (318). Therefore, the nutrient depletion and cellular stress caused by anti-
cancer agents may induce autophagy and compromise the efficacy of therapy. 
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To  examine  the  role  of  autophagy  as  a  BCR-ABL  independent  survival 
mechanism, experiments were designed to determine whether: 
 
1.  autophagy is induced following the TKI treatment of CML cells 
2.  targeting of autophagy potentiates the TKI-induced death of CML cells 
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5.1 Autophagy is induced following the TKI treatment of CML 
cells 
 
5.1.1 Analysis of key properties of cells undergoing autophagy 
In  order  to  determine  whether  CML  cells  undergo  autophagy  following  TKI 
treatment experiments were designed to study the cellular changes in CML cells 
induced by dasatinib treatment in more detail. CD34
+ CML cells, which remained 
viable  following  culture  with  either  SFM  only  (Figure  5-1A-C)  or  SFM  ±  5GF 
(Figure 5-1D) and treatment ± 150nM dasatinib for 12 days, were analysed by flow 
cytometry (Figure 5-1A+B), light microscopy (Figure 5-1C) or EM (Figure 5-1D). 
Flow cytometry measuring the FSC-height (FSC-H) parameter, revealed that the 
dasatinib-treated  CML  cells  were  significantly  smaller  in  size  as  compared  to 
untreated cells, as shown by a representative histogram from one patient’s cells 
(Figure 5-1A) and mean FSC-H from 3 patients’ cells (p=0.02) (Figure 5-1B). This 
was  also  demonstrated  by  morphology  analysis  using  conventional  light 
microscopy  (Figure  5-1C).  Figure  5-1D  (upper  panel)  demonstrates  that  GF 
deprivation  of  untreated  CML  cells  (upper  right)  resulted  in  a  reduction  of 
cytoplasm and an increase of vacuoles, as compared to untreated cells cultured in 
the presence of GFs (upper left). This is consistent with previous studies, whereby 
the cytoplasm of haemopoietic cells became progressively replaced by vesicular 
structures, following GF withdrawal. These investigators found that the cells had 
induced autophagy in order to combat the GF starvation (164). Figure 5-1D (lower 
panel) also shows that treatment with dasatinib caused an increase in both the 
size and number of these cytoplasmic vacuoles within CML cells, cultured both in 
the presence (lower left) and absence (lower right) of GFs. Many electron-dense   203 
inclusions within the vacuoles were also observed within the CML cells cultured 
without the presence of GFs (as denoted by the black arrows).  
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Figure 5-1 Analysis of key properties of cells undergoing autophagy 
CD34
+ CML cells were either cultured in SFM only (A-C) or SFM ± 5GF (D) 
and treated ± 150nM dasatinib for 12 days. Cell size was measured using the 
FSC-H parameter by flow cytometry, with a representative histogram from 
one patient (A) and the mean from 3 patients (B) shown. Cell size was also 
analysed by light microscopy, with a representative morphology profile from 
one  patient’s  cells  demonstrated  (C).  The  remaining  CML  cells were  then 
fixed, sectioned and examined unstained by EM (D). 
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5.1.2 Evaluation of autophagic structure formation by EM 
The  autophagosome  and  autolysosome  both  contain  cytoplasmic  material  at 
various stages of degradation. However, in this experiment, it was observed that 
many of the vesicles appeared to be empty (Figure 5-1D). Therefore, it was not 
possible  to  determine  whether  the  electron  lucent  or  empty  vesicles  were 
autophagic compartments or some other kind of vacuole. Since autophagy is a 
dynamic process, whereby an autophagosome is formed, the autophagic material 
is  delivered  to  the  lysosome  and  the  material  is  then  degraded  within  the 
lysosome,  it  is  probable  that  by  this  time-point  the  majority  of  the  autophagic 
material had already been degraded. Therefore in order to block this “autophagic 
flux”, the experiment was repeated using CD34
+ CML cells cultured in SFM ± 5GF 
and treated ± 150nM dasatinib, both in the absence and presence of lysosomal 
protease inhibitors (pepstatin A and E-64d both at a 1:100 dilution) for 24 hours. 
The lysosomal protease inhibitors act by preventing the degradation of material 
within the autolysosome. Figures 5-2A-D confirm the previous EM data, whereby, 
in the absence of lysosomal protease inhibition, GF deprivation of untreated CML 
cells (Figure 5-2B) increased the number of cytoplasmic vacuoles as compared to 
untreated  cells  cultured  with  GF  support  (Figure  5-2A).  Treatment  with  150nM 
dasatinib increased the number of vacuoles both in the presence (Figure 5-2C) 
and absence (Figure 5-2D) of GFs. Addition of lysosomal protease inhibitors to the 
cells, had little or no effect on the untreated CML cells cultured in the presence of 
GFs (Figure 5-2E), however, protease inhibition increased the amount of vacuolar 
material  (denoted  by  the  black  rings)  in  untreated  cells  cultured  without  GFs 
(Figure  5-2F)  and  in  the  dasatinib-treated  cells  cultured  both  in  the  presence 
(Figure  5-2G)  and  absence  (Figure  5-2H)  of  GFs.  Interestingly,  the  greatest 
accumulation  of  vacuolar  material  was  observed  in  the  dasatinib-treated  cells 
cultured without GFs (Figure 5-2H).    206 
Autophagosomes  and  autolysosomes  can  be  defined  as  membrane-bound 
structures which contain cytoplasmic material and/or organelles. Furthermore, in 
conventional  EM,  the  material  within  the  autophagosome  has  the  same 
morphology and electron density as the cytoplasm outside. Another feature of an 
autophagosome analysed by EM is a double limiting membrane, however this is 
not  always  the  case,  due  to  limitations  in  lipid  preservation  during  sample 
preparation (319). Therefore, although it is difficult to determine the characteristic 
double membranes surrounding each vacuole within these EM images (Figures 5-
2F-H), it is highly likely that these vacuoles are autophagic structures. Hence, it 
could be said that autophagy was likely induced following both GF deprivation and 
dasatinib treatment of CML cells. 
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Figure 5-2 Evaluation of autophagic structure formation by EM 
CD34
+ CML cells were cultured in SFM ± 5GF and treated ± 150nM dasatinib 
for 24 hours. The remaining CML cells were fixed, sectioned and examined 
unstained by EM (panels A-H). 
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5.1.3 Monitoring autophagy using LC3 
The protein LC3, a mammalian homologue  of Atg8, was  originally identified as 
microtubule-associated protein 1  light chain 3. To date, LC3 is the only known 
mammalian  protein  identified  that  stably  associates  with  the  autophagosome 
membranes (166) and therefore serves as a widely used marker for autophagy. 
There are three human isoforms of LC3 (LC3A, LC3B, and LC3C), where LC3B is 
the most widely studied (320). LC3 is first cleaved at the carboxy terminus by Atg4 
immediately following synthesis, to yield a cytosolic form LC3-I. During autophagy, 
LC3-I is conjugated with phosphatidylethanolamine (PE) to become LC3-II through 
lipidation  by  a  ubiquitin-like  system  involving  Atg7  and  Atg3.  Unlike  the 
cytoplasmic LC3-I, LC3-II associates with the inner and outer membranes of the 
autophagosome. LC3-I can be detected on an immunoblot at a molecular mass of 
around  16-kDa  and  LC3-II  at  approximately  14-kDa.  Following  fusion  with  a 
lysosome, LC3 on the outer membrane is cleaved off by Atg4 and LC3 on the 
inner  membrane  is  degraded  by  lysosomal  enzymes  resulting  in  low 
concentrations of LC3 within autolysosomes (166, 321). Therefore, the presence 
of endogenous LC3 as well as the conversion of LC3-I to the lower migrating form 
LC3-II  serve  as  good  indicators  of  autophagosome  formation  and  hence, 
autophagy induction. 
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5.1.4 Formation of LC3-positive puncta in dasatinib-treated CML cells 
In  order  to  verify  the  EM  data  described  in  Figure  5-2,  LC3  was  measured  in 
dasatinib-treated CML cells as a more specific indicator of autophagy. CD34
+ CML 
cells were cultured in SFM ± 5GF and treated ± 150nM dasatinib for 24 hours, 
before  being fixed  onto slides and stained  with  anti-LC3  antibody.  Nuclei  were 
counterstained with DAPI. Endogenous levels of LC3 were then visualised within 
these  cells  by  fluorescence  microscopy.  Figures  5-3A  and  B  demonstrate  a 
representative LC3 IF profile from one patient’s cells and the average LC3-positive 
puncta per cell from 3 patients, respectively. A significant increase in LC3-positive 
puncta was observed in the GF deprived untreated cells as compared to untreated 
cells cultured with GF support (p=0.015) (Figure 5-3A upper panel and Figure 5-
3B).  An  even  greater  increase  in  LC3-positive  puncta  was  observed  following 
dasatinib treatment of cells cultured, both with and without exogenous GF support, 
as compared the relevant untreated control (p=0.0004 and p=0.0044 for untreated 
+GF versus dasatinib +GF and untreated  -GF versus dasatinib -GF, respectively) 
(Figure 5-3A lower panel and Figure 5-3B). As with previous data, the greatest 
increase  in  autophagy  induction,  as  measured  by  LC3  puncta  formation,  was 
observed  in  CML  cells  cultured  without  GF  support  and  treated  with  dasatinib 
(p=0.009 for dasatinib treatment +GF versus -GF).      
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Figure 5-3 Formation of LC3-positive puncta in dasatinib-treated CML cells 
CD34
+ CML cells were cultured in SFM ± 5GF and treated ± 150nM dasatinib 
for 24 hours. Remaining CML cells were then fixed onto multi-spot slides 
and stained with anti-LC3 antibody. Nuclei were counterstained with DAPI 
and LC3-positive puncta were manually counted. 
A representative IF profile from one patient (A) and the average LC3-positive 
puncta per cell from 3 patients (B) are shown. 
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5.1.5 Accumulation of autophagosome-associated LC3-II in GF-starved cells 
In order to completely verify the previous results, the levels of autophagosome-
associated LC3-II were also measured. CD34
+ CML cells were left untreated and 
cultured in SFM ± 5GF for 24 hours, before whole cell protein lysates were made 
from  each  sample.  The  levels  of  LC3-I  and  LC3-II  were  then  determined  by 
Western blot using an anti-LC3B antibody. Beta-tubulin levels were also measured 
as a protein loading control. Figure 5-4 demonstrates a clear increase in the levels 
of  autophagosome-associated  LC3-II  within  the  GF-starved  CML  cells  as 
compared  to  cells  cultured  with  exogenous  GF  support.  These  data,  thereby, 
confirm the finding that autophagy is induced upon GF deprivation of CML cells.  
 
 
 
 
 
 
 
 
Figure 5-4 Accumulation of autophagosome-associated LC3-II in GF-starved 
CML cells 
CD34
+ CML cells were cultured in SFM ± 5GF for 24 hours and whole cell 
protein lysates were made at this time-point. Western blot determined the 
levels of LC3-I and LC3-II in each sample by LC3-antibody staining. Beta-
tubulin was also measured as a protein loading control. 
 
 
 
LC3-I
LC3-II
beta-tubulin
+ GF - GF
LC3-I
LC3-II
beta-tubulin
+ GF - GF  214 
5.1.6 Accumulation of autophagosome-associated LC3-II in dasatinib-treated 
CML cells 
Since  previous  data  showed  that  autophagy  appeared  to  be  induced  upon 
dasatinib treatment, LC3-II levels were also measured in dasatinib-treated CML 
cells.  CD34
+  CML  cells  were  cultured  in  SFM  only  and  treated  with  150nM 
dasatinib for 24 hours, before whole cell protein lysates were made from each 
sample. As previously, the levels of LC3-I and LC3-II were then determined by 
Western blot using an anti-LC3B antibody. Levels of p-CrkL were determined as a 
measure of BCR-ABL activity and beta-tubulin levels were also measured as a 
protein loading control. Figure 5-5 demonstrates that upon dasatinib treatment of 
CML  cells,  p-CrkL  and  hence,  BCR-ABL  kinase  activity  is  inhibited.  This  then 
results  in  an  accumulation  of  autophagosome-associated  LC3-II  within  the 
dasatinib-treated  CML  cells,  as  compared  to  untreated  control.  These  data, 
thereby, confirm the finding that autophagy is induced upon dasatinib treatment of 
CML cells. 
 
Overall, these data suggest that autophagy is induced following GF deprivation of 
CML cells. Autophagy induction is then further increased within these cells, upon 
BCR-ABL inhibition following dasatinib treatment.  
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Figure 5-5 Accumulation of autophagosome-associated LC3-II in dasatinib-
treated CML cells 
CD34
+ CML cells were cultured in SFM only, treated ± 150nM dasatinib for 24 
hours and whole cell protein lysates were made at this time-point. Western 
blot  determined  the  levels  of  LC3-I  and  LC3-II  in  each  sample  by  LC3-
antibody  staining.  BCR-ABL  activity  was  determined  by  p-CrkL-antibody 
staining. Beta-tubulin was also measured as a protein loading control. 
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5.1.7 The PI3K-Akt-mTOR signalling pathway in CML cell survival 
The PI3K-Akt-mTOR axis is a cell survival pathway that is important for normal cell 
growth and proliferation (322). However, this pathway has also been implicated in 
the transformed phenotype of most cancer cells (323). Once activated by BCR-
ABL, GF-signalling or cross-talk from the Ras pathway (324), it plays an important 
role in cell growth, protein translation and hence, survival of CML cells. It has also 
been  demonstrated  that  when  PI3K-Akt  signalling  is  activated,  autophagic 
degradation  is  decreased  (325).    The  downstream  effector  of  Akt,  mTOR,  has 
been shown to be  a  key negative regulator of autophagy,  where it inhibits the 
autophagic process in the presence of abundant GFs and nutrients (326, 327). 
The  mTOR  kinase  is  present  in  two  distinct  protein  complexes,  mTORC1  and 
mTORC2, which have distinct mechanisms of action (328). As a central GF and 
nutrient  sensor,  mTORC1  plays  a  key  role  in  the  regulation  of  cell  growth  by 
activating  protein  synthesis  and  suppressing  autophagy,  through  its  two  well 
characterised  downstream  substrates,  S6K  and  4EBP1.  The  phosphorylation 
levels of S6K and 4EBP1 are widely used as indicators of mTORC1 activity and 
decreased phosphorylation levels of these substrates are also used as markers for 
autophagy induction (329). It has previously been demonstrated that autophagy 
can  be  pharmacologically  induced  by  inhibiting  mTOR  activity  with  rapamycin 
(163) which suppresses mTORC1-mediated S6K activation (Figure 5-6). 
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Figure 5-6 The PI3K-Akt-mTOR signaling pathway in CML cell survival 
The PI3K-Akt-mTOR signaling axis is central to the transformed phenotype 
of CML cells. Inhibtion of the autophagy inhibitor, mTORC1, by agents such 
as rapamycin results in the induction of autophagy. 
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5.1.8 Analysis of mTOR activity in dasatinib treated K562 cells 
In order to investigate the status of mTOR activity following TKI treatment of CML 
cells, further experiments were carried out. K562 (BCR-ABL
+) cells were cultured 
in RPMI ± serum and treated ± either 150nM dasatinib or 20nM rapamycin for 8 
hours, before whole cell protein lysates were made. Western blot was then used to 
determined the levels of p-S6K within each sample. GAPDH was also measured 
as a protein loading control. Figure 5-7 shows that levels of p-S6K are reduced in 
serum-starved untreated K562 cells as compared to cells grown in the presence of 
serum-support (lane 1 versus lane 3). This is in keeping with the fact that mTOR 
acts as a nutrient sensor and promotes protein translation and cell growth, through 
phosphorylation of substrates such as S6K, in the abundance of GFs. Treatment 
with dasatinib caused an inhibition of p-S6K in both the absence and presence of 
serum (lanes 2 and 4). Treatment with the mTOR inhibitor, rapamycin, gave the 
same effect and also resulted in complete inhibition of p-S6K (lanes 5 and 6).  
 
These data may suggest that autophagy induction caused by dasatinib treatment 
is a result of the inhibition of mTOR activity. Furthermore, this suggests that within 
CML cells, autophagy may also be induced by agents which act downstream of 
BCR-ABL, such as Ras- or PI3K-Akt-pathway inhibitors. However, to completely 
verify that these hypotheses are the case, further investigations would be required. 
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Figure 5-7 Analysis of mTOR activity in dasatinib treated K562 cells 
K562  cells  were  cultured  in  RPMI  ±  serum  and  treated  ±  either  150nM 
dasatinib or 20nM rapamycin for 8 hours, before whole cell protein lysates 
were made. Western blot determined the levels of p-S6K. GAPDH was also 
measured as a protein loading control [UT: untreated; DAS: 150nM dasatinib 
and RAPA: rapamycin]. 
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5.2 Targeting of autophagy potentiates the TKI-induced cell death 
of CML cells 
 
5.2.1 Analysis of committed progenitor cell potential following TKI/FTI 
treatment in combination with autophagy inhibition of CP CML cells 
A number of investigations suggest that autophagy may act as a survival signal in 
tumour  cells  (164,  330)  and  that  the  inhibition  of  autophagy  can  lead  to  an 
increase in therapy-induced cell death (171, 331). Therefore, to determine whether 
autophagy acts as a protective mechanism in this system, it was thought to be 
critical to perform further experiments designed to modulate autophagic activity 
within TKI-treated CML cells. In order to inhibit autophagy, the pharmacological 
inhibitors, CQ and BAF were used. The lysosomotropic agent, CQ, is an inhibitor 
of lysosomal acidification, thus raises the pH within the lysosome. BAF acts by 
inhibiting  the  activity  of  the  H
+-ATPase  responsible  for  the  acidification  of 
autolysosomes.  Ultimately,  both  agents  inhibit  the  autophagosome-lysosome 
fusion  and  thus,  the  final  degradation  of  autophagic  material  within 
autolysosomes.  First,  the  committed  progenitor  cell  potential  following  TKI 
treatment of CML cells was tested. CD34
+ CP CML cells (n=3) were sorted into 
primitive (CD34
+38
-) and more mature progenitor (CD34
+38
+) populations, were 
cultured in SFM+5GF and left untreated or pretreated for 48 hours with either TKIs 
(IM  (0.5  and  2mM);  dasatinib  (10  and  150nM)  or  nilotinib  (2mM));  the  farnesyl 
transferase  inhibitor (FTI), lonafarnib (10 mM) (note:  lonafarnib inhibits the Ras-
pathway and was included to determine whether autophagy induction was specific 
to BCR-ABL inhibition) or autophagy inhibitors (CQ (10mM) or BAF (20nM)) alone 
or in the TKI/FTI/CQ/BAF combination. Following pre-treatment, aliquots of cells 
from each condition were taken for apoptosis measurement by annexin-V/viaprobe   221 
staining determined by flow cytometry (CD34
+38
+ cells only) and the remaining 
cells  were  added  to  methycellulose  for  CFC  analysis.  The  relevant  drug 
combinations from the pre-treatment were also added to the methylcellulose. The 
number of CFCs obtained for each sample was then compared with a baseline - 
cells which had no prior culture or treatment (100%). Figure 5-8A shows that there 
was a trend towards an increase in apoptotic cells following combination treatment 
with TKI/FTI and autophagy inhibitors, as compared to both untreated control cells 
and  TKI/FTI  alone,  with  the  greatest  increase  seen  with  150nM  dasatinib/CQ 
treatment (p=0.001 and 0.05 for 150nM dasatinib/CQ versus no drug and 150nM 
dasatinib  alone,  respectively).  Figure  5-8B  shows  that  within  the  CD34
+38
+ 
population,  the  untreated  cells  demonstrated  a  doubling  of  CFCs  over  the  48 
hours pre-treatment, consistent with stem/progenitor cell expansion in the culture 
medium. Neither CQ nor BAF alone had any effect on this expansion. However, 
consistent with previous studies (131, 226), the TKIs (IM, dasatinib (10nM) and 
nilotinib)  all  exhibited  an  anti-proliferative  effect,  which  prevented  any  CFC 
expansion  over  baseline.  Both  dasatinib,  at  the  highest  clinically  achievable 
concentration (150nM), and lonafarnib were able to reduce the number of CFCs to 
55  and 53% of baseline,  respectively, suggesting  some level of apoptosis  was 
achieved by these agents alone. This effect was dramatically increased following 
TKI or FTI/autophagy inhibitor combination treatment, with  80-98% reduction in 
CFC formation versus baseline, and even more impressive as compared to the no 
drug control. Interestingly, lonafarnib treatment combined with autophagy inhibition 
gave the greatest effect, with a 98% reduction in CFC as compared to baseline. 
Since  lonafarnib  inhibits  the  Ras  pathway,  this  finding  indicates  that  BCR-ABL 
inhibition  does  not  solely  and  directly  induce  autophagy  within  CML  cells  and 
thereby, corroborates the findings demonstrated in Figure 5-7.   222 
Consistent  with  the  CD34
+38
+  data,  within  the  more  primitive  CD34
+38
-  cell 
fraction  (Figure  5-8C),  the  untreated  cells  demonstrated  an  increase  in  CFC 
number  as  compared  to  baseline  and  this  remained  unchanged  following 
treatment with either CQ or BAF alone. TKI treatment alone also had a protective 
anti-proliferative  effect  on  CFC  expansion  over  baseline.  However,  for  these 
primitive  CML cells  which are consistently  resistant  to  TKI exposure, treatment 
with  TKI/autophagy  inhibitor  was  extremely  effective,  with  only  2%  CFCs 
remaining following 150nM dasatinib/CQ exposure.  
 
Notably, the combination treatment with TKI/BAF did not appear as effective as 
TKI/CQ treatment of these cells. Therefore it was decided that CQ should be used 
as an autophagy inhibitor for the subsequent primitive progenitor cell experiments. 
 
Overall, these data show that autophagy inhibition greatly potentiates the effect of 
either TKI or FTI treatment, on the reduction of committed progenitor cell potential 
of relatively mature CD34
+38
+ and primitive CD34
+38
- CML cell populations.  
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Figure 5-8 Analysis of committed progenitor cell potential following TKI/FTI 
treatment in combination with autophagy inhibition of CP CML cells 
CD34
+ CP CML cells (n=3) were sorted into progenitor (CD34
+38
+) (A+B) and 
stem (CD34
+38
-) (C) cell populations. Cells cultured in SFM ± 5GF and left 
untreated or pretreated for 48 hours with IM (0.5 and 2m m m mM), dasatinib (10 and 
150nM), nilotinib (2m m m mM) (CD34
+38
+ cells only) or lonafarnib (10m m m mM) (CD34
+38
+ 
cells only), either alone or in combination with CQ (10m m m mM) or BAF (20nM). 
Aliquots  of  cells  were  taken  for  apoptosis  measurement  by  annexin-V/ 
viaprobe staining (CD34
+38
+ cells only) (A) and the remaining cells were then 
plated in methylcellulose. Colonies were counted at 14 days and compared 
with  those  derived  from  cells  at  baseline  (cells  with  no  prior  culture  or 
treatment), which were taken as 100% (B:CD34
+38
+ and C:CD34
+38
-). 
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5.2.2  Analysis  of  committed  progenitor  cell  potential  following  TKI/FTI 
treatment in combination with autophagy inhibition of AP CML cells 
Although TKI treatment has revolutionised the management of CP CML, it is less 
effective  for  the  treatment  of  advanced  phases  of  CML.  ABL-kinase  domain 
mutations are more common in the advanced phases of CML than in CP CML 
(332).  Further,  the  acquisition  of  additional  chromosomal  abnormalities  in  the 
BCR-ABL clone, termed clonal evolution, is a criterion for the diagnosis of AP CML 
in the WHO guidelines for CML (333). These factors suggest that the advanced 
phase CML cells may develop BCR-ABL independent mechanisms of proliferation, 
which  would  thereby,  render  them  TKI-resistant.  The  results  in  Figure  5-8 
demonstrated that lonafarnib in combination with autophagy inhibition was highly 
effective at eliminating the CP CML cells with committed progenitor cell potential. 
Therefore, since lonafarnib acts on the Ras pathway rather than BCR-ABL itself, it 
was predicted that the lonafarnib/autophagy inhibitor combination would also be 
effective at targeting AP CML cells. The previous experiment, as demonstrated in 
Figure 5-8, was repeated using CD34
+ AP CML cells from one patient. Figure 5-
9A shows that the greatest increase in apoptotic cells was observed with both the 
lonafarnib  alone  and  lonafarnib/CQ/BAF  combination  (28.2,  26.6  and  28.2%, 
respectively, as compared to 12.1% for no drug control). As expected, Figure 5-9B 
shows  that  TKI  treatment,  both  alone  and  in  combination  with  autophagy 
inhibitors,  was  relatively  ineffective  at  targeting  AP  CML  cells  with  committed 
progenitor cell potential, with little or no effect as compared to both baseline and 
untreated control cells. However, combination treatment with lonafarnib/CQ/BAF 
gave the greatest effect, with a 98 and 97% reduction in CFC as compared to 
baseline, for lonafarnib/CQ and BAF, respectively. 
   226 
Although these experiments were performed on a single patient and therefore, no 
definitive conclusions can be drawn as yet, these data may be an early indicator 
that lonafarnib treatment in combination with autophagy inhibition is an effective 
therapy for patients with advanced phase CML. 
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Figure 5-9 Analysis of committed progenitor cell potential following TKI/FTI 
treatment in combination with autophagy inhibition of AP CML cells 
CD34
+ AP CML cells (n=1) were cultured in SFM + 5GF and left untreated or 
pretreated  for  48  hours  with  IM  (0.5  and  2m m m mM),  dasatinib  (10  and  150nM), 
nilotinib (2m m m mM) or lonafarnib (10m m m mM), either alone or in combination with CQ 
(10m m m mM) BAF (20nM). Aliquots of cells were taken for apoptosis measurement 
by annexin-V/viaprobe staining (A) and the remaining cells were then plated 
in methylcellulose. Colonies were counted at 14 days  and  compared with 
those derived from cells at baseline (cells with no prior culture or treatment), 
which were taken as 100% (B). 
 
 
 
b
a
s
e
l
i
n
e
n
o
 
d
r
u
g
 
M
)
m
I
M
 
(
0
.
5
M
)
m
I
M
 
(
2
D
a
s
a
t
i
n
i
b
 
(
1
0
n
M
)
D
a
s
a
t
i
n
i
b
 
(
1
5
0
n
M
)
N
i
l
o
t
i
n
i
b
 
L
o
n
a
f
a
r
n
i
b
C
Q
B
A
F
M
)
 
+
 
C
Q
m
I
M
 
(
0
.
5
M
)
 
+
 
B
A
F
m
I
M
 
(
0
.
5
M
)
 
+
 
C
Q
m
I
M
 
(
2
M
)
 
+
 
B
A
F
m
I
M
 
(
2
D
a
s
a
t
i
n
i
b
 
(
1
0
n
M
)
 
+
 
C
Q
D
a
s
a
t
i
n
i
b
 
(
1
0
n
M
)
 
+
 
B
A
F
D
a
s
a
t
i
n
i
b
 
(
1
5
0
n
M
)
 
+
 
C
Q
D
a
s
a
t
i
n
i
b
 
(
1
5
0
n
M
)
 
+
 
B
A
F
N
i
l
o
t
i
n
i
b
 
+
 
C
Q
N
i
l
o
t
i
n
i
b
 
+
 
B
A
F
L
o
n
a
f
a
r
n
i
b
 
+
 
C
Q
L
o
n
a
f
a
r
n
i
b
 
+
 
B
A
F 0
25
50
75
100
125
150
175
%
 
C
F
C
a
s
 
c
o
m
p
a
r
e
d
 
t
o
 
b
a
s
e
l
i
n
e  228 
5.2.3 Analysis of primitive progenitor cell potential following TKI treatment in 
combination with autophagy inhibition of CML cells 
Since  the  CFC  assay  measures  a  relatively  mature,  committed  progenitor  cell 
population,  LTC-IC  assays  were  also  carried  out  to  measure  the  effect  of 
autophagy  inhibition  on  the  functionality  of  more  primitive  CML  cells.  As  the 
presence of cytokines in the culture media may alter the requirement of autophagy 
for cell survival, the LTC-IC assays were carried out both in the presence and 
absence  of  a  5GF  cocktail.  CD34
+  CML  cells  (n=3)  were  left  untreated  or 
pretreated for 6 days with either TKIs (2mM IM or 150nM dasatinib); CQ alone or 
the TKI/CQ combination. It was noted that the presence of the drug combinations 
in the methylcellulose for the CFC assays (Section 5.2.1) may have exerted an 
anti-proliferative  effect  rather  than  the  elimination  of  functional  CML  progenitor 
cells.  Therefore,  following  the  pre-treatment,  the  cells  were  washed  twice  with 
PBS, to remove any drug, before being added to LTC-IC assays. As it was not 
known how long it would take for the inhibition of autophagy by CQ to have any 
effect on the cells, a pre-treatment time-point of 6 days was chosen as a median 
of the 12 day dasatinib treatment timecourse (described in Chapter 4). If primary 
cellular material had been more plentiful, it would have been useful to perform a 
TKI/CQ treatment timecourse, in order to determine the most effective treatment 
times for the drug combination.  
 
As with the CFC assay, the number of LTC-ICs obtained for each sample was 
then compared with a baseline. Figure 5-10A shows that in the presence of GFs, 
untreated and CQ-treated cells formed 67 and 47% fewer LTC-IC colonies than 
cells at baseline, respectively, suggesting that a large proportion of these cells had 
proceeded  towards  terminal  differentiation.  Consistent  with  the  CFC  data  and 
previous studies (131), treatment with IM or dasatinib was anti-proliferative, even   229 
in the presence of GFs, and therefore resulted in a protective effect on the number 
of  LTC-ICs  over  baseline.  Combination  treatment  with  TKIs  and  autophagy 
inhibitors  counteracted  this  protective  effect  and  resulted  in  an  impressive 
decrease in the number of LTC-ICs, with a significant reduction for treatments with 
IM/CQ  and  dasatinib/CQ  combinations  versus  TKI  alone  (p=  0.04  and  0.008, 
respectively). Figure  5-10B shows  that  untreated  and CQ-treated cells cultured 
without supplemental GFs also formed reduced numbers of colonies, as compared 
with  baseline  cells.  The  removal  of  GFs  combined  with  TKI  treatment  had  a 
dramatic  effect  on  the  number  of  LTC-IC  colonies  (6.5  and  4.1%  for  IM  and 
dasatinib,  respectively),  suggesting  that  cytokines  may  play  an  important 
protective role for the survival of TKI-treated CML cells, consistent with the results 
of a previous study  (235). Combination treatment  with CQ resulted in  an  even 
greater  decrease  in  LTC-IC  colony  numbers,  as  compared  to  TKI  alone  (1%; 
p=0.175 and 0.65%; p=0.04 for IM/CQ and dasatinib/CQ, respectively). 
 
Overall, these data show that autophagy inhibition greatly potentiates the effect of 
TKI treatment, on the reduction of primitive progenitor cell potential of CML cells. 
Furthermore, that TKI treatment combined with autophagy inhibition of GF-starved 
CML cells promotes the most effective elimination of primitive CML cells. 
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Figure 5-10 Analysis of primitive progenitor cell potential following TKI 
treatment in combination with autophagy inhibition of CML cells 
CD34
+ CML cells (n=3) were cultured in SFM with (A) and without GF (B) and 
left untreated or pretreated for 6 days with TKIs (IM 2m m m mM or dasatinib 150nM) 
or CQ (10m m m mM) alone or the TKI/CQ combination, before being added to LTC-
IC  stromal  feeder  layers.  Resulting  colonies  were  compared  with  those 
derived  from  cells  at  baseline  (cells  with  no  prior  culture  or  treatment), 
which were taken as 100%. Note: (B) is presented on a logarithmic scale due 
to the great differences between baseline and TKI/combination-treated arms. 
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5.3 Summary 
The  previous  results  chapter  demonstrated  that,  despite  culture  without 
exogenous GF support and full inhibition of BCR-ABL kinase activity via prolonged 
dasatinib  exposure,  a  small  proportion  CML  cells  survived.  This  indicated  that 
resistance  within these  cells may  be mediated  by  other survival  signals and/or 
pathways. Autophagy has previously been shown to provide survival signals for 
cancer  cells  against  chemotherapy.  Therefore,  the  purpose  of  the  work  in  this 
chapter was to investigate whether the biochemical changes within the cells which 
survived dasatinib treatment, were characteristic of the autophagic process and to 
determine whether these changes could be therapeutically exploited.  
 
Initial  experiments  found  that  CML  cells  were  decreased  in  size  following 
treatment with dasatinib, as compared to untreated control cells. This is a typical 
characteristic  of  cells  undergoing  autophagy,  as  the  lysosomal  degradation  of 
cellular components by the progressive autophagic process usually results in cell 
shrinkage due to self-consumption (164, 330). Further analysis by EM, revealed 
an  increase  in  cytoplasmic  vacuoles  following  GF  deprivation.  These  vesicular 
structures increased in size and number following treatment with dasatinib. Further 
treatment  with  lysosomal  protease  inhibitors,  which  prevent  the  degradation  of 
autophagic material, resulted in an increase in electron-dense inclusions within the 
vacuoles,  with  the  greatest  increase  observed  in  dasatinib-treated  CML  cells 
cultured without GFs. These morphological and intracellular changes served as 
early indicators that the autophagic process was occurring.  
 
Experiments designed to verify whether the initial intracellular changes observed 
were  indeed  due  to  the  induction  of  autophagy,  revealed  further  biochemical 
hallmarks of the autophagic process, following both GF-deprivation and dasatinib   233 
treatment.  These  included,  an  increase  in  LC3-positive  puncta  and  LC3-II 
accumulation,  with the greatest increase observed, again, within the CML cells 
which were treated with dasatinib and cultured without GFs. Mechanistic studies 
also demonstrated that the induction of autophagy caused by dasatinib treatment 
may be due to the indirect inhibition of the PI3K/Akt/mTOR pathway.  
 
These data suggest that autophagy may act as a survival mechanism within CML 
cells.  Therefore,  it  was  also  investigated  whether  autophagy  inhibition  would 
potentiate the TKI/FTI-induced cell death of CML cells. Remarkably, the inhibition 
of  autophagy  combined  with  TKI/FTI  treatment  caused  a  highly  significant 
elimination  of  CML  cells  with  both  committed  and  primitive  progenitor  cell 
potential.  Interestingly,  lonafarnib  treatment  in  combination  with  autophagy 
inhibition gave an impressive reduction in CFCs from both CP-CML and AP-CML 
cells. This could have important implications for the treatment of CML patients with 
advanced phase disease and/or TKI-resistant mutations, such as T315I. 
 
Overall, these data demonstrate that TKI/FTI treatment, results in the induction of 
the  BCR-ABL  independent  survival  mechanism,  autophagy,  in  CML  cells. 
Furthermore, the induction of autophagy could also explain the drug resistance 
demonstrated by the primitive CML cells treated with dasatinib (shown in Chapter 
4 of this thesis). Blocking of the autophagic process then enhances the TKI/FTI-
induced death of CML cells, including the inherently TKI-resistant primitive stem 
cell population (Figure 5-11).  
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Figure 5-11 Inhibition of autophagy potentiates cell death dasatinib-treated 
CML cells 
Following  dasatinib  treatment,  the  inhibition  of  BCR-ABL  results  in  the 
programmed cell death of all BCR-ABL kinase-dependent CML cells. Within 
the surviving BCR-ABL kinase-independent CML cells, autophagy is induced 
as  a  survival  mechanism.  Therefore,  treatment  with  autophagy  inhibitors 
results in increased cell death of dasatinib-treated CML cells. 
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6. DISCUSSION 
 
There is no doubt that IM treatment has revolutionised the management of CML. 
The remarkable activity of IM was first demonstrated in the pivotal phase III IRIS 
trial,  whereby  IM  treatment  significantly  improved  responses  and  survival 
outcomes compared with the previous standard therapy of IFNa and Ara-C (221). 
At the 5 year follow-up, the estimated cumulative rates of CHR, MCR, and CCR 
for  patients treated  with standard  dose IM  were 98, 92  and  87%, respectively. 
Moreover, the estimated freedom from progression and event free survival rates 
were an impressive 93 and 83%, respectively (222). The efficacy and safety of IM 
therapy was further confirmed by a recent update of the IRIS trial after a median 
follow up of 7 years, with an estimated overall survival rate of 86% (334). As a 
result,  IM  is  widely  considered  as  standard  front-line  therapy  for  patients  with 
CML. However, despite these unparalleled results, an obvious outcome from the 
follow-up analyses is that only a small group of patients achieves a CMR. Variable 
levels  of  BCR-ABL  mRNA  can  still  be  detected  by  RT-PCR  in  most  patients 
receiving IM therapy (222). Furthermore, responses to IM therapy in patients with 
advanced stage CML are rare and usually short-term (217). The elements which 
contribute to this phenomenon of IM resistance have been extensively studied and 
are briefly summarised in Figure 6-1. 
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Figure 6-1 Mechanisms of IM resistance 
 
Resistance  to  IM  and  other  TKIs  can  be  broadly  subdivided  into  BCR-ABL-
dependent and -independent mechanisms. Acquired resistance in Ph
+ leukaemias 
is  usually  BCR-ABL-dependent,  with  the  most  common  form  of  TKI  resistance 
attributed to the development of point mutations within the ABL-kinase domain of 
the BCR-ABL gene (238). These mutations confer structural changes whereby the 
ABL-kinase is unable to adopt the inactive conformation to which IM binds (206). 
This results in either a suboptimal response within the patient or in the worst case 
scenario, complete failure of therapy. The observation of IM resistance has led to 
the development of a second generation of TKIs such as nilotinib, a high-affinity 
ABL-kinase inhibitor and dasatinib, a dual SRC- and ABL-kinase inhibitor, which 
binds  to  the  ABL-kinase  in  both  its  active  and  inactive  conformations.  These 
agents have become essential for the management of resistant and advanced-
phase  CML  (254,  263).  Nevertheless,  neither  of  these  TKIs  have  significant 
clinical activity against the “gatekeeper” T315I mutation, which confers a tyrosine-
to-isoleucine substitution at position 315 and was detected in up to 15% of CML 
patients who failed IM therapy (335). However, the implication of BCR-ABL point 
mutations  as  the  sole  underlying  reason  for  TKI  resistance  remains  uncertain. 
Although, some investigators have detected mutations in CD34
+ cells from CML 
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patients both before (336) and after IM treatment (337), others have not detected 
any  ABL-kinase  mutations  within  the  TKI-resistant  CML  cell  population  in  vitro 
(131).  Furthermore,  it  is  also  worth  noting  that  the  presence  of  BCR-ABL 
mutations does not always explain clinical IM resistance (245) and in CD34
+ cells 
resistance mutations have not been present at high enough levels to explain the 
resistance of this population. 
 
Although less frequent than ABL-kinase domain mutations, BCR-ABL amplification 
has  also  been  described  as  a  potential  BCR-ABL  dependent  resistance 
mechanism. Upregulation of BCR-ABL mRNA and protein was first reported in IM-
resistant, BCR-ABL expressing cell lines, in the absence of ABL-kinase domain 
mutations  (237). BCR-ABL amplification has also  been documented  in  patients 
with advanced phase disease, who developed resistance to IM treatment (238). 
Further,  prolonged  IM  exposure  has  also  been  demonstrated  to  enhance 
oncogene amplification (236). However, in a subsequent screening of IM-resistant 
CML patients, only 2 out of 66 had BCR-ABL gene amplification as determined by 
D-FISH (132). This suggests that the phenomenon of point mutations within the 
ABL-kinase domain is a far more common mechanism of IM resistance. That said, 
it has been shown that CD34
+ CML cells expressing increased amounts of BCR-
ABL are less sensitive to IM and are prone to develop mutations faster than those 
that express low levels of BCR-ABL (338). Further, it has also been demonstrated 
that  very  primitive,  resistant  CD34
+  CML  cells  have  higher  transcript  levels, 
despite having just single copy BCR-ABL (131, 298). This suggests that the levels 
of protein are at least partially responsible for the rate at which IM-resistant clones 
emerge  (338)  and  that  this  increased  BCR-ABL  protein  level  still  plays  an 
important  role  in  the  propagation  of  disease,  but  possibly  not  as  a  result  of 
amplification of the gene.    238 
Although  these  mechanisms  have  been  well-documented  by  many  groups, 
resistance cannot solely be explained by oncogene mutation or amplification, as 
IM therapy does not eradicate all of the CML cells, even in those who respond 
well. For example, in patients who had achieved undetectable levels of BCR-ABL 
during IM treatment, molecular relapses were demonstrated in 50% of all cases 
when  IM  therapy  was  stopped  (339).  On  the  basis  of  these  observations,  it  is 
predicted that this constant MRD in IM-treated patients is the result of residual 
LSCs. These primitive, quiescent CML cells have been shown to be resistant to 
IM, even at concentrations 10 fold higher than those achievable in vivo (224, 226). 
Furthermore, subsequent in vitro investigations have shown that this population 
persists  in  the  face  of  treatment  with  the  more  potent  TKI,  nilotinib  (256)  and 
although  dasatinib  therapy  appears  to  target  a  population  of  CML  cells  which 
resides deeper within the stem cell compartment, the most  primitive, quiescent 
cells  still  remain  (131).  This  rare  population  of  quiescent  CML  cells,  which 
represent approximately 0.5% of the total CD34
+ cells (340), may be refractory to 
TKI  treatment  simply  by  virtue  of  their  dormant  status.  However,  quiescent 
primitive CML stem cells may also demonstrate other mechanisms of resistance. 
A variety of hypotheses have been suggested as the molecular basis for this TKI 
refractoriness. For example, optimal TKI plasma and intracellular concentrations 
within  the  cell  are  necessary  for  therapy  to  succeed.  Therefore,  it  has  been 
suggested that drug resistance may be induced by suboptimal intracellular TKI 
concentration. It has been hypothesised that TKI resistance in CML stem cells is 
as a result of reduced drug-influx and increased drug-efflux compared with more 
mature  cells.  Primitive  CML  CD34
+38
-  stem  cells  apparently  exhibit  high  level 
expression  or  activity  of  drug  efflux  proteins,  such  as  MDR-1,  and  reduced 
expression  or  activity  of  drug  influx  proteins,  such  as  the  organic  cation 
transporter-1,  as  compared  with  more  mature  cells  (298).    Therefore,  such   239 
mechanisms could possibly confer resistance against TKIs and other apoptosis-
inducing drugs. However, this notion remains controversial as more recent work in 
the field has shown that at least the MDR-1 (249) and ABCG2 (250) transporters 
are unlikely players in IM resistance. 
 
As  stated  previously,  one  important  finding  is  that  BCR-ABL  is  over-expressed 
within the quiescent CML stem cell population. Copland et al. showed that the IM-
resistant  CML  CD34
+38
-  cells  expressed  significantly  increased  BCR-ABL 
transcripts and BCR-ABL protein kinase than more mature CML cells. Additionally, 
phosphorylation of the direct downstream target, CrkL, was increased in the most 
primitive  CML  CD34
+38
-  cells,  as  compared  to  the  total  CD34
+  fraction  (131). 
These discoveries alone may explain why this population is so resistant to TKI 
treatment and suggest that BCR-ABL is still a relevant target for the treatment of 
CML. Following on from this, it is then necessary to ask the question: “why are the 
mature, proliferating CML cells targeted by TKI treatment, whereas the primitive 
quiescent  CML  cells  are  not?”  It  is  suggested  that  oncogenic  fusion  TK-
transformed cells are able to proliferate due to persistent survival signalling which 
counteracts  any  pro-apoptotic  signals  (341).  The  apparent  dependence  of  a 
tumour cell on a single mutationally activated oncoprotein or oncoprotein-mediated 
signalling pathway(s) for their proliferation and/or survival has been described as 
“oncogene addiction” (271). Sharma et al. proposed a hypothesis to explain the 
oncogene  addiction  phenomenon.  In  the  context  of  a  tumour  cell,  the  balance 
between  pro-survival  and  pro-apoptotic  signals  derived  from  the  activated 
oncoprotein  favour  a  survival  state.  However,  on  acute  inactivation  of  the 
oncoprotein, the pro-survival signals are decreased very rapidly as compared to 
the  pro-apoptotic  signals.  This  creates  a  temporal  window,  whereby  the  pro-
apoptotic signalling predominates, which lasts long enough for the cell to commit   240 
to  apoptotic  death  (342).  With  regards  to  the  fact  that  the  primitive  quiescent 
population is not targeted by TKI treatment, it is still currently unclear why they 
should be so insensitive. One could predict that they are not oncogene addicted to 
BCR-ABL TK activity. Studies, which have used transgenic mouse models for the 
inducible expression of BCR-ABL, have shown that multiple rounds of induction 
and reversion are possible. This thereby, indicates that the LSC population is able 
to persist long-term, even following BCR-ABL reversion (75, 275). Further support 
for  this  hypothesis  comes  from  investigations  which  demonstrated  that  despite 
inactivation of p190
BCR-ABL in a murine model of ALL,  there was a failure to rescue 
the malignant phenotype, thereby suggesting that p190
BCR-ABL is not required for 
the  maintenance  of  disease  in  mice  (343).  However,  this  notion  still  remains 
controversial in primary CML cells, as one critical question which remains to be 
answered is whether BCR-ABL activity is completely inhibited by TKI within this 
rare  primitive  population  of  LSCs.  If  BCR-ABL  was  found  to  be  incompletely 
inhibited within the stem cell population, then this would suggest that BCR-ABL is 
still a critical drug target for the management of CML. Therefore, efforts should be 
made to develop and use more potent TKIs, or manipulate drug transporters in 
order  to  increase  the  intracellular  TKI  concentrations  within  the  CML  stem  cell 
population and effectively inhibit BCR-ABL TK activity. However, if BCR-ABL was 
found to be completely inhibited within the resistant pool of CML stem cells, then 
one  could  definitively  say  that  this  cell  population  is  not  oncogene  addicted  to 
BCR-ABL TK activity. This would also then suggest that these resistant primitive 
CML cells are perhaps reliant on other non BCR-ABL TK-related mechanisms for 
their proliferation and/or survival. This thesis concentrated on determining whether 
primitive  CML  stem  cells  are  dependent  on  BCR-ABL  TK  activity  for  their 
proliferation  and/or  survival,  with  the  further  aim  of  characterising  the  resistant   241 
population  of  CML  cells  and  investigating  any  other  potential  cell  survival 
mechanisms. 
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6.1 Is BCR-ABL relevant for the survival of cancer stem cells in 
CML? 
 
Previous  studies  have  measured  BCR-ABL  TK  activity  as  an  indication  of  TKI 
response of CML cells, in a number of ways: total p-Tyr by FACS (291), p-CrkL 
measurement  by  Western  blot  (130,  131,  290,  294),  p-CrkL  by  flow  cytometry 
(130,  131).  Here  we  aimed  to  provide  an  alternative  technique  for  the 
measurement  of  BCR-ABL  TK  activity,  by  developing  a  novel  ELISA  method 
designed for the high throughput of samples. Although this technique was reliable 
against the other methods, it proved too costly in terms of cell numbers required to 
give an accurate read-out for stem cell work. Therefore, for the purposes of this 
thesis, where the quantity of samples and the cell number within each sample was 
low, we decided to use flow cytometry using a method developed in house (130) 
and other conventional methods. Nevertheless, the ELISA would perhaps prove to 
be more useful in a more clinical screening setting, where the sample numbers 
would be higher and material less limited. Even though Western blot has proven to 
be an extremely reliable technique for the assessment of kinase activity, it is not 
feasible when working with such rare populations of CML cells. Therefore, in order 
to accurately assess and characterise the CML cells which are undergoing drug 
treatment, the only reasonable option was found to be flow cytometry. One major 
advantage  of  flow  cytometry  over  the  other  methods  is  the  ability  to  measure 
multiple parameters simultaneously, within samples containing relatively low cell 
numbers.  This  was  absolutely  necessary  for  determining  BCR-ABL  TK  activity 
within specific subpopulations of CML stem cells. 
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Following the initial TKI timecourse studies, it was found that transient exposure to 
intermediate concentrations of TKI was as effective as continuous treatment with 
increased concentrations, which are clinically unachievable. This challenges the 
assumptions  based  on  early  studies  with  IM  (205,  207,  215),  where  it  was 
concluded  that  it  was  necessary  for  TKIs  to  achieve  continuous  BCR-ABL 
inhibition in order for CML cells to commit irreversibly to apoptosis. However, the 
results of this study are in keeping with more recent investigations (310, 316, 344), 
which have demonstrated that transient, potent inhibition of BCR-ABL TK activity 
is sufficient to commit both CML cell lines (310, 316) and primary CD34
+ CML 
cells  (316,  344)  irreversibly  to  apoptosis.  This  supports  the  “oncogenic  shock” 
model,  described  previously,  in  which  it  is  suggested  that  kinase  inhibitors  are 
effective  against  oncogene-addicted  tumour  cells  because  of  the  more  rapid 
reduction  of  oncogene-mediated  pro-survival  versus  pro-apoptotic  signals 
following inactivation of the oncoprotein’s TK activity. Here, these data suggest 
that once a specific threshold of kinase inhibition is exceeded within TKI-sensitive 
CML cells, following potent TKI exposure of up to only one hour, these cells will 
commit  irreversibly  to  apoptosis.  However,  within  the  TKI-resistant  CML  cells, 
neither dose escalation of TKI to concentrations which are clinically unachievable, 
nor  an  increase  in  the  drug  exposure  time  from  1  to  72  hours  led  to  an 
enhancement  of  cell  death.  This  suggested  that  the  cells  which  survived  the 
treatment were intrinsically resistant to BCR-ABL TK inhibition. The fact that drug-
sensitive  CML  cells  commit  to  apoptosis  following  potent  BCR-ABL  inhibition 
induced  by  transient  TKI  exposure  also  has  important  implications  for  the 
treatment of CML. This has particular significance for the clinical application of 
more  potent  TKIs  such  as,  dasatinib,  whereby  pulse-dosing  may  reduce  any 
associated toxicities. Indeed, data from a very recent trial suggests that potent and 
transient kinase inhibition of BCR-ABL with dasatinib (100mg/day) achieves rapid   244 
and  durable  cytogenetic  responses,  which  are  indistinguishable  from  those 
achieved  with  more  continuous  kinase  inhibition,  in  CP  CML  patients  with 
resistance, suboptimal response or intolerance to IM (345). 
 
An interesting finding from these studies was the fact that exogenous GF support 
gave a protective effect over the treatment of CML cells with TKI. In fact, treatment 
of CML cells with TKI in the presence of a high concentration of GFs gave the 
same effect as removing GFs from untreated control cells. This is perhaps, logical 
as  the  pathways  which  are  constitutively  activated  by  BCR-ABL 
autophosphorylation  are  also  activated  by  GF  stimulation.  Therefore,  in  this 
setting, the addition of exogenous GFs then negates the CML cells’ requirement 
for  BCR-ABL.  Previous  studies  have  shown  that  CML  cells  exhibit  BCR-ABL-
independent  IM  and nilotinib resistance, through activation of the anti-apoptotic 
JAK2/STAT5 pathway, as a result of adaptive autocrine and paracrine secretion of 
GM-CSF  (235).  Konig  and  colleagues  also  demonstrated  that  MAPK,  Akt  and 
STAT5 phosphorylation was inhibited in CML CD34
+ cells by nilotinib (346) and 
dasatinib  (347)  only  in the absence, but not the  presence  of GFs. Jiang  et al. 
showed  that  the  deregulated  growth  of  CD34
+  CML  cells  caused  by  BCR-ABL 
was, at least partially, dependent on the autocrine  production of IL-3 and G-CSF 
and a stimulation of STAT5 phosphorylation. Similarly, BCR-ABL was shown to 
require the IL-3 receptor and subsequent downstream JAK2/STAT5-signalling for 
the  oncogenic  transformation  of  BCR-ABL-expressing  fibroblasts  (348).  A  very 
recent study by the group led by Tim Hughes also confirms these findings, where 
CML cells remained viable in culture with additional cytokines following short-term 
exposure to dasatinib. Treatment with dasatinib in combination with JAK activity 
inhibition  then  re-sensitised  these  cells  to  BCR-ABL  TK  inhibition,  despite  the 
presence  of  exogenous  cytokine  support.  It  was  also  observed  that  short-term   245 
intense BCR-ABL TK inhibition commits CD34
+  CML cells to  death  only in the 
absence of GFs (344), further confirming the results of our study.  
 
Overall, these data highlight the importance of GF signalling in the survival of CML 
cells treated with TKI. Further, it suggests that primitive CML progenitor cells may 
not  be  entirely  dependent  on  BCR-ABL  for  proliferation  and/or  survival  in  the 
presence of GFs, due to the activation of cytokine-mediated signalling cascades, 
such as, JAK2/STAT5. This could have implications for the TKI treatment of CML 
patients,  where  cytokines  would,  of  course,  be  present  at  physiological 
concentrations.  Studies  have  demonstrated  that  the  IL-3  receptor,  CD123,  is 
highly expressed on CD34
+38
- LSCs in AML (349) and CML (350, 351) and has 
been shown to be an effective therapeutic target in pre-clinical AML models (352, 
353).  Groups  have  now  begun  to  investigate  the  therapeutic  potential  of 
recombinant IL-3-diphtheria toxin (DT) conjugates which target CD123, both in in 
vitro  and  in  vivo  CML  models  (354)  and  in  Ph
+  ALL  (355),  whereby  the  co-
treatment  with  TKI  and  DT  conjugate  was  more  effective  at  eliminating  Ph
+ 
progenitor  cells  than  either  agent  alone.  Furthermore,  a  Phase  I  study 
investigating the effects of an anti-CD123 monoclonal antibody (CSL360) in AML 
is  currently  ongoing  (356).  Therefore,  targeting  of  cytokine  signalling  in 
combination with BCR-ABL TK inhibition may represent an exciting new concept 
for therapeutic intervention in patients with CML and Ph
+ ALL.  
 
In this study, following a prolonged treatment timecourse of 12 days with 150nM 
dasatinib  in  the  absence  of  exogenous  cytokine  support,  10%  of  the  starting 
CD34
+ CML cells survived. Since no GFs were present in the culture media, the 
phenomenon  of  cytokine-mediated  mechanisms  of  BCR-ABL-independent   246 
resistance could be ruled out. Similarly, the other most common means of TKI 
resistance  in  CML  cells  (i.e.  oncogene  amplification  and  ABL-kinase  domain 
mutations)  were  also  found  to  be  irrelevant  in  this  TKI-resistant  CML  cell 
population. BCR-ABL TK inhibition was next measured by assessment of both p-
CrkL and p-STAT5. Previous studies which have used TKI to inhibit BCR-ABL TK 
activity have demonstrated incomplete levels of inhibition (131). To address the 
question of whether a CML stem cell is oncogene addicted, BCR-ABL TK activity 
must be fully inhibited and the cells tracked for survival. Here, it was concluded 
that maximal pharmalogical inhibition of BCR-ABL TK activity was achieved in the 
surviving dasatinib-treated CML cells, both in the bulk population of cells and the 
more problematic primitive stem cell population. As with previous studies (131), 
those cells which survived the dasatinib treatment were primitive, residing mainly 
in the undivided cell fraction and the very early cell divisions. Since these BCR-
ABL  TK-inhibited,  resistant  cells  were  also  able  to  grow  when  re-cultured  in 
cytokines and form LTC-IC colonies, these data suggest that ~10% of primitive 
CD34
+  CML  cells  are  not  addicted  to  BCR-ABL  TK  activity  for  their  survival. 
However, it would be presumptuous to say that these CML cells are not addicted 
to the BCR-ABL oncoprotein itself, since components in BCR-ABL, other than the 
kinase domain, could mediate resistance. Recent studies have identified Alox5 as 
a key gene that regulates the functions of LSCs, but not normal HSCs, in mice. It 
was demonstrated that Alox5 deficiency or inhibition prevented CML development 
initiated by BCR-ABL (357). Furthermore, Alox5 was also found to be regulated by 
BCR-ABL  oncoprotein,  but  was  unaffected  by  TKI  treatment  (358).  Therefore, 
Alox5 represents a potential BCR-ABL dependent, but BCR-ABL TK independent, 
target. Previous investigations have used si- and short hairpin (sh)RNA designed 
to target BCR-ABL itself, both in Ph
+ cell lines and primary CD34
+ CML cells (359-
361).  Such  a  strategy  should  block  all  BCR-ABL  activity  and  not  just  kinase   247 
activity.  Although  in  certain  cases,  BCR-ABL  knockdown  was  associated  with 
increased  apoptosis,  the  level  of  down-regulation  was  often  transient  and/or 
incomplete. Studies  performed  by our  own  lab  used shRNA  against BCR-ABL, 
delivered  by  either  electroporation  or  more  stable  lentiviral  transduction,  in 
combination with dasatinib treatment of CML cells. It was demonstrated that BCR-
ABL  oncoprotein  knockdown  and  inhibition  of  kinase  activity  resulted  in  a 
synergistic  induction  of  activated  caspase-3,  expression  of  annexin-V  and 
dramatic reduction in viable K562 cells (362).  However, since K562 are a BC 
CML cell line, they may prove to be more dependent on BCR-ABL expression for 
their survival. Therefore, further work is currently underway in this laboratory to 
use TKI to inhibit BCR-ABL TK activity, in combination with lentiviral shRNA to 
stably target BCR-ABL itself within the most primitive compartment of CML cells. If 
the  CML  cells  survive  both  complete  inhibition  of  BCR-ABL  TK  activity  and 
complete loss of the BCR-ABL oncoprotein, then it could be definitively said that 
this resistant population of CML cells are truly independent of BCR-ABL for their 
survival. 
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6.2 Analysis of the effects of autophagy on CML stem cell 
survival 
 
During the experiments which used dasatinib to inhibit BCR-ABL TK activity within 
CD34
+  CML  cells,  CFSE-staining  revealed  that  within  the  CML  cells  which 
survived the prolonged treatment timecourse, two populations existed; one which 
remained  undivided  and  another  which  was  able  to  divide  up  to  3  times.  This 
suggested  that  these  primitive,  resistant  CML  cells  appeared  to  survive  and 
proliferate  by  BCR-ABL-independent  mechanisms.  Therefore,  the  next 
experiments were then designed to investigate autophagy as a potential means of 
primitive  CML  cell  survival.  Autophagy  has  previously  been  shown  to  be  an 
important event for the megakaryocytic differentiation of the CML cell line, K562 
(363).  Furthermore,  since  the  induction  of  autophagy  has  previously  been 
demonstrated to provide tumour cells with a protective mechanism to survive in 
the face of irradiation (364), alkylating agents (365) or arsenic trioxide (366), it was 
hypothesised that resistant CML cells could also be employing such a mechanism 
to  survive  following  dasatinib  treatment,  especially  under  conditions  of  GF 
deprivation. In this study, analysis of the cellular properties of CD34
+ CML cells, 
which remained viable following the 12 days, revealed that the dasatinib-treated 
cells were significantly smaller in size as compared with control cells – a property 
of  cells  which  are  undergoing  autophagy.  EM  also  showed  that  both  GF 
deprivation of untreated CML cells and dasatinib treatment of CML cells induced 
the formation of cytoplasmic autophagic structures. Significantly increased LC3-
positive puncta and the autophagosome-asociated LC3-II were also observed in 
the CML cells treated with dasatinib, particularly in the cells cultured without GFs. 
Overall, these data suggested that autophagy is induced following GF deprivation   249 
of  CML  cells  and  is  significantly  increased  within  these  cells,  upon  BCR-ABL 
inhibition following dasatinib treatment. It was next hypothesised that autophagy 
was responsible for a condition by which primitive CML cells rely upon a state of 
metabolic inactivity, in order to survive following TKI treatment. Therefore, in order 
to test this hypothesis, it was assessed whether TKI-induced CML cell death could 
be enhanced by the chemical inhibition of autophagy by CQ or BAF. These agents 
act  by blocking  the last step of the autophagy  process  (i.e. the  degradation  of 
autophagosomes following fusion with lysosomes). Remarkably, it was found that 
the inhibition of autophagy greatly potentiates the effect of TKI treatment on the 
reduction of primitive CML progenitor cells, in terms of the effective eradication of 
functionally defined CFCs and LTC-ICs. Although CQ and BAF are relatively non-
specific  for  the  autophagy  process,  genetic  inhibition  of  autophagy  by  RNA 
interference-mediated  knockdown  of  either  ATG5  or  ATG7  yielded  comparable 
effects in CML cell lines (172). These data thereby demonstrate that the effects of 
CQ and BAF depend largely on the inhibition of autophagy. However, further work 
is currently underway in this laboratory to investigate ATG5 and ATG7 knockdown 
within  human  primary  CML  cells,  in  order  to  completely  verify  that  the 
enhancement of TKI-induced cell death caused by CQ or BAF treatment is a direct 
result of autophagy inhibition. Recent studies have also confirmed the importance 
of autophagy in CML cells, as inhibition of the autophagic process increased the 
effect of both the histone deacetylase inhibitor, SAHA (171), and the TKI, INNO-
406 (170), for the eradication of drug-resistant CML cells.  
 
Overall, the results of this study have provided a powerful rationale for the design 
and  implementation  of  a  Medical  Research  Council  TSCRC 
(www.mrc.ac.uk/Fundingopportunities/Grants/TSCRC/index.htm)  randomised 
phase II clinical called CHlOroquine Imatinib Combination to Eliminate Stem cells   250 
(CHOICES). The trial compares IM treatment versus HCQ in combination with IM, 
for patients with CML who have been on IM for 1-3 years and have achieved a 
MCR, with residual disease detectable by qRT-PCR (Figure 6-2).  
 
 
 
 
 
 
 
 
 
 
Figure 6-2 Schematic diagram of the protocol for the CHOICES trial 
 
 
Although  the  preliminary  in  vitro  data  have  shown  the  effectiveness  of  TKI 
treatment in combination with CQ for the eradication of primitive CML cells, CQ 
has been shown to be responsible for significant retinal toxicity in a number of 
patients (367). Therefore, for this trial it was replaced by HCQ, which has been 
used  extensively  in  rheumatology  and  is  well  tolerated  (368).  Furthermore, 
preliminary  in-house  in  vitro  data  indicated  that  HCQ  was  approximately 
equipotent  to  CQ  when  combined  with  TKI  treatment  in  terms  of  reduction  of 
functional CFCs from CD34
+ CML cells.  
 
The primary end-points of the study are to provide preliminary evidence that HCQ 
given in combination with IM is more effective than IM alone in terms of BCR-ABL 
levels in CML patients who are in MCR with residual BCR-ABL
+ 
cells after at least 
one year of IM treatment and to determine the safety and tolerability of HCQ given 
CML Start 
IM MCR Randomisation
Standard arm:
IM 400mg/day
Experimental arm:
HCQ 800mg/day
plus IM 400mg/day
Year 1  Year 2  251 
in combination with IM in these patients. The success criteria for the trial is defined 
as patients who have >0.5 log reductions in their 12 month PCR level of BCR-ABL 
transcripts  from  baseline.  Secondary  end-points  are  to  determine  whether  the 
introduction of HCQ influences IM plasma levels and to confirm that whole blood 
HCQ levels achieved on a continuous 800mg/day dose in combination with IM are 
in  the  expected  range.  Correlative  end-points  are  to  confirm  that  HCQ  at 
800mg/day  inhibits  autophagy  in  vivo  and  to  study  the  effect  of  HCQ  given  in 
combination with IM on residual BCR/ABL
+ 
primitive progenitors. 
 
Recruitment  for  the  trial  started  in  April  of  this  year,  with  33  patients  to  be 
randomised to each  treatment, making  a total  of 66 patients recruited in  3 UK 
centres. 
 
In  conclusion,  the  findings  from  this  study  clearly  demonstrate  that  autophagy 
provides a BCR-ABL independent survival mechanism for primitive primary CML 
cells which have been treated with TKIs. In-house micro-array data also further 
backs up this notion, as the autophagy genes ATG5 and ATG4 were found to be 
upregulated in dasatinib-treated CD34
+ CML cells as compared to control cells. 
Likewise, the genes which transcribe cathepsins B and L (hydrolases which are 
thought  to  be  important  for  the  degradation  of  autophagic  material  within 
autolysosomes) are also increased in dasatinib-treated cells. We have also shown 
that the inhibition of autophagy can greatly potentiate TKI-induced CML cell death, 
which ultimately resulted in the initiation of a UK-wide clinical trial to investigate 
the  benefits  of  the  use  of  autophagy  inhibitors  in  combination  with  TKI.  Most 
importantly, we have demonstrated that the combination of autophagy inhibition 
combined with TKI is able to target the TKI-resistant CML stem cell population. 
Previously, it was shown that dasatinib is a much more potent inhibitor of BCR-  252 
ABL TK activity than IM and is able to target BCR-ABL
+ cells deeper into the stem 
cell compartment (131). Here, we have shown that the combination of autophagy 
inhibition and BCR-ABL TK inhibition by TKI is able to target CML cells from even 
deeper within the stem cell compartment than dasatinib alone, as measured by the 
dramatic reduction in functional LTC-IC (Figure 6-3). Whether the truly quiescent 
CML  stem  cell  population  is  targeted  still  remains  to  be  seen.  However,  this 
strategy may  represent a novel  approach for the  improvement of responses in 
patients with CP CML by the more effective eradication of TKI-resistant CML cells. 
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Figure 6-3 Schematic diagram to show the  effects of either TKI treatment 
alone or in combination with autophagy inhibition on the different CML cell 
subpopulations 
(A) More mature haemopoietic cells and the majority of progenitor cells are 
sensitive to both IM and dasatinib. (B) More primitive progenitor cells are 
resistant to IM but targeted by dasatinib. (C)The CML stem cell compartment 
is resistant to both IM and dasatinib, but targeted by a combination of TKI 
plus autophagy inhibition. It is not yet known whether the truly quiescent 
LSC population is affected by treatment with TKI and autophagy inhibition. 
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6.3 Summary and future directions 
 
Overall, these findings suggest for the first time, that BCR-ABL targeting by TKI 
should no longer be the only focus of treatment for CML. Despite the success of 
both IM and the more potent second generation TKIs, such as dasatinib, in the 
treatment of CML, it is clear that quiescent stem cells still remain (131, 226). It was 
hypothesised that these resistant CML cells persist due to incomplete inhibition of 
BCR-ABL TK activity. However, here we have shown that despite maximal BCR-
ABL  TK  inhibition,  these  cells  are  still  able  to  survive.  To  attain  the  ultimate 
eradication of all CML cells, it is clear that combination therapies involving TKI and 
agents/therapies  with  activity  specifically  towards  the  cancer  stem  cell 
compartment  will  be  required.  In  previous  years,  there  were  less  well  defined 
mechanisms  for  quiescent  stem  cell  resistance  to  pro-apoptotic  agents  and 
therefore, no obvious molecular targets for therapeutic intervention. This prompted 
investigators to attempt to improve the effectiveness of TKI treatment by “waking 
up” the quiescent stem cell population, using cytokines to force them into cycle. It 
was demonstrated that a significant reduction of CML cells was observed following 
intermittent exposure to G-CSF compared to continuous treatment of IM alone, 
which was further enhanced when the cells were treated with a combination of IM 
and  intermittent  G-CSF  (369).  These  impressive  in  vitro  results  led  to  a  multi-
centre clinical trial that further investigated the potential clinical use of cytokines in 
combination  with  IM  to  improve  the  management  of  CP  CML.  However,  no 
significant  difference  was  observed  in  patients  treated  with  the  combination  as 
compared  to  continuous  IM  alone,  indicating  no  further  benefit  compared  to 
standard IM therapy (370). The group led by Andreas Trumpp has also used this 
approach in a mouse model. Here they first primed the quiescent stem cells into 
cycle with IFNa, which greatly sensitised these cells to the anti-proliferative agent   255 
5-FU (371). However, since this was not a CML model, these data may have no 
relevance for the clearance of human primary CML cells. 
 
In recent years, significant progress has been made in the objective for specific 
LSC-targeting in CML. A number of novel strategies for cancer stem cell therapy in 
CML are currently being investigated, with a few nearing the clinic and are briefly 
summarised in Table 6-1.  
 
 
Strategy  Treatment 
 
Reference 
 
 
PP2A activation via SET 
inhibition 
 
FTY720  (372) 
 
Self-renewal pathway 
(Smoothened) inhibition 
 
TKI and cyclopamine  (373),(374) 
 
PML protein degradation 
 
AraC and As2O3  (375) 
 
BCR-ABL and autophagy 
inhibition 
 
TKI and HCQ  (172) 
BCR-ABL and histone 
deacetylase inhibition  TKI and LBH589  (376) 
 
 
Table 6-1 Notable examples of LSC-targeted therapy in CML 
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In this study we have now shown that autophagy may also play a major role in the 
survival of LSCs following inhibition of critical oncogenic pathways. Little is known 
about the precise mechanism by which the autophagic process is induced by TKI 
in CML stem cells, therefore this remains to be elucidated by future investigations. 
Indeed, it is still not known why the primitive stem cell compartment is specifically 
able to survive through autophagy during conditions of stress. However, clues may 
come from the microenvironment in which they reside. The BM niche is a hypoxic 
tissue (377) and additionally, LSCs are more hypoxic than normal HSC in the BM, 
due  to  overcrowding  from  accelerated  growth  (378).  It  has  also  been 
demonstrated  that  CD34
+  human  primary  leukaemic  cells  populated  the  most 
hypoxic region of the BM (the epiphysis), when inoculated into immunodeficient 
mice (379). Recently, one study has suggested that a hypoxic microenvironment is 
important for the maintenance of CML stem cell quiescence (380). Therefore, it is 
likely  that  the  quiescent  CML  stem  cell  population  predominantly  resides  and 
thrives in a hypoxic BM environment. Since one of the processes which activate 
autophagy  is  prolonged  hypoxia  (381),  it  is  perhaps  possible  that  the  most 
primitive  CML  cells,  in  particular,  are  already  primed  to  use  the  autophagic 
process for survival. Therefore, understanding the hypoxic nature of LSCs and the 
importance  for  them  to  reside  in  such  a  microenvironment  may  be  a  further 
interesting avenue for future investigation. 
 
In  1999,  Holyoake  et  al.  highlighted  the  importance  of  quiescent  LSCs  for  the 
propagation of CML (224) and this population was subsequently found to persist in 
the face of TKI treatment (226). Significant progress has been made since then in 
terms  of  the  development  of  agents  which  are  able  to  specifically  target  this 
resistant cell population. However, little is known about why these primitive CML 
cells should remain quiescent? Here, we have shown that targeting autophagy is   257 
highly effective in the eradication of primitive CML cells. Yet, it is still not clear as 
to whether the truly quiescent cells are targeted by this strategy and whether this 
population would rely on autophagy for its survival at all? One interesting finding 
comes from in-house microarray data in which it was observed that the essential 
autophagy  genes,  ATG12,  ATG2,  ATG3  and  the  autolysosomal  hydrolases  - 
cathepsins  L and D,  were all decreased  in dividing CML  cells as  compared to 
quiescent CML cells in the G0 phase of cell cycle. Another important finding which 
may provide the connection between quiescence, the cell cycle arrest observed 
following TKI treatment and the induction of autophagy, was the observation that 
the  dasatinib-treated  cells  demonstrated  predominantly  nuclear  FoxO3a,  as 
compared to untreated control cells. Activation of the PI3K/Akt pathway, results in 
FoxO inactivation which leads to enhanced cell survival and proliferation. In the 
absence  of  GF  or  insulin-signalling,  or  in  the  presence  of  stress  stimuli,  FoxO 
members reside within the nucleus, where they are active as transcription factors 
involved  in  cellular  processes  such  as,  apoptosis,  cell-cycle  arrest  and  stress 
resistance  (382).  In  the  normal  HSC  compartment,  FoxOs  reside  within  the 
nucleus where they are thought to play a role in cellular quiescence through their 
transcriptional  activation  of  cell  cycle  regulators,  such  as  p21,  p27,  p130  and 
down-regulation of cyclin D (311). FoxOs are also thought to play an important 
role in protecting quiescent HSCs from oxidative stress. In FoxO-deficient stem 
cells, there is a marked increase in reactive oxygen species which leads to an 
increase  in  the  number  of  cycling  HSCs  and  eventual  HSC  exhaustion  (383). 
Recently, it was demonstrated that BCR-ABL inactivated the transcriptional activity 
of FoxOs in untreated CD34
+ CML cells. Furthermore, the TKI-mediated G1 arrest 
seen in CML cells was found to be induced by the reactivation of FoxOs. Finally, 
and most importantly, primitive CML stem cells retained sustained activation of 
FoxOs (314)  which presumably  regulated their  quiescence. Other studies  have   258 
also shown that FoxO3a was important for the maintenance of CML LSCs in a 
murine model (317). Therefore, within this study it is highly likely that the activation 
of  FoxO3a  played  some  part  in  the  cell  cycle  arrest  of  the  resistant  dasatinib-
treated CML cells.  
 
Interestingly, as another cellular regulation mechanism, it has been demonstrated 
that stimulation of the energy sensor pathway, which is activated by an increased 
adenosine monophosphate (AMP)/ATP ratio, results in the AMP-activated protein 
kinase (AMPK)-mediated activation of FoxO3a (384).  AMPK is a central metabolic 
switch which responds to low energy. It is found in all eukaryotes and governs 
glucose and lipid metabolism in response to changes in nutrients and intracellular 
energy levels. Furthermore, AMPK has been shown to be a direct downstream 
effector of the LKB1 tumour suppressor kinase and is involved in a mechanism 
representing the connection between energy metabolism and cell growth control 
(385). Recently, it has been reported that the conserved AMPK/FoxO3a energy 
sensor  pathway  is  inducible  in  human  tumour  cells  in  response  to  metabolic 
stress.  In  colorectal  and  ovarian  cancer  cells,  decreased  glycolysis  caused  by 
inhibition of the p38a/HIF1a pathway, led to the nuclear accumulation of FoxO3a 
and  the  subsequent  transcriptional  activation  of  target  genes  whose  protein 
products  promote  the  autophagic  process,  such  as,  ATG6,  ATG7  and  ATG12 
(386-388). In response to the acute energy demand that induced the autophagy 
process, the cells also exited the cell cycle and accumulated in the G1 phase, 
which also mirrors what we observed in the dasatinib-treated CML cells tested in 
this study. Taken together these data indicate that there may be an important link 
between the cell cycle arrest induced by the nuclear accumulation of FoxO3a and 
the  apparent  reliance  on  autophagy  for  survival  in  TKI-resistant  primitive  CML 
stem cells.    259 
Thus, it could be speculated that in response to acute energy depletion, caused by 
either  GF  deprivation  or  BCR-ABL  TK  inhibition,  AMPK  induces  FoxO3a  to 
accumulate in the nucleus of TKI-treated CML cells and triggers the transcription 
of target genes involved in both autophagy and cell cycle arrest. The cells would 
then induce autophagy and exit the cell cycle, arresting in G0/G1 in an attempt to 
retain energy for survival. The PI3K/Akt activation of mTOR has been shown to be 
an important negative regulator of autophagy. The known pathway by which Akt 
activates mTOR is via direct phosphorylation and inhibition of TSC2, which is a 
negative regulator of mTOR. It has also been demonstrated that Akt is a negative 
regulator  of  AMPK,  which  is  an  activator  of  TSC2  (389).  Therefore,  it  seems 
logical that activated AMPK would have an important role in the ultimate induction 
of autophagy. Interestingly, it was also shown that hypoxia induced autophagy in 
tumour cell lines via AMPK activity (390). Thus, this could be another indicator that 
the  very  quiescent  CML  stem  cells  rely  on  autophagy  for  survival  within  the 
hypoxic conditions of the BM niche. This may also mean that the AMPK/FoxO3a 
axis could represent a potential approach for therapeutic intervention in CML. Of 
course,  the  link  between  the  observation  of  nuclear  FoxO3a,  with  subsequent 
downregulation of cyclin D1 in dasatinib-treated primitive CML cells and the high 
level  of  autophagy  induction  within  this  resistant  cell  population  is  still  a  little 
tenuous.  Therefore,  further  work  should  be  carried  out  to  prove  that  this 
hypothesis is actually the case. However, this preliminary data may be an exciting 
early indicator of future insights in CML which are still to come. 
 
In 1990, George Daley and colleagues used murine models to establish BCR-ABL 
as  an  oncogene  to  induce  CML,  whereby  retroviral  transduction  of  BCR-ABL 
cDNA  into  the  BM  of  recipient  mice  was  sufficient  to  induce  a  CML-like 
myeloproliferative disease (74). In the subsequent years great efforts have been   260 
made  to  try  to  further  understand  the  key  signalling  pathways  and  molecular 
drivers of malignant transformation of CML stem cells. This has yielded a wealth of 
preliminary data from novel agents which have demonstrated impressive results 
both in vitro and in Phase I-III clinical trials. Many efforts have been made to direct 
therapy towards the kinase activity of BCR-ABL. However, this thesis has shown 
for  the  first  time  that  the  most  resistant  primitive  CML  cells  are  likely  to  be 
independent  of  BCR-ABL  TK  activity  for  their  survival.  Furthermore,  we  have 
shown  that  these  resistant  CML  stem  cells  rely  on  the  BCR-ABL  independent, 
autophagy process for survival in response to stressful conditions, such as, TKI 
treatment.  This  highlights  the  importance  for  further  work  directed  towards  the 
understanding of the complex biology of cancer stem cells and why they remain 
quiescent, both in CML and other haematological malignancies. Since the majority 
of  CP  CML  cells  appear  to  be  dependent  on  BCR-ABL  TK  activity  for  their 
survival; the use of TKI to remove the burden of the CML tumour load, combined 
with BCR-ABL independent therapies, targeted specifically towards the quiescent 
LSC  compartment  should  provide  more  effective  future  approaches  for  the 
ultimate eradication of CML. 
 
 
 
 
 
 
 
 
   261 
7. REFERENCES 
 
 
 
1.  Wu AM, Till JE, Siminovitch L, McCulloch EA. A cytological study of the 
capacity for differentiation of normal hemopoietic colony-forming cells. J Cell 
Physiol1967 Apr;69(2):177-84. 
2.  Wu AM, Till JE, Siminovitch L, McCulloch EA. Cytological evidence for a 
relationship between normal hemotopoietic colony-forming cells and cells of the 
lymphoid system. J Exp Med1968 Mar 1;127(3):455-64. 
3.  Eaves C, Glimm H, Eisterer W, Audet J, Maguer-Satta V, Piret J. 
Characterization of human hematopoietic cells with short-lived in vivo repopulating 
activity. Ann N Y Acad Sci2001 Jun;938:63-70. 
4.  Taichman RS. Blood and bone: two tissues whose fates are intertwined to 
create the hematopoietic stem-cell niche. Blood2005 Apr 1;105(7):2631-9. 
5.  Till JE, Mc CE. A direct measurement of the radiation sensitivity of normal 
mouse bone marrow cells. Radiat Res1961 Feb;14:213-22. 
6.  Kiel MJ, He S, Ashkenazi R, Gentry SN, Teta M, Kushner JA, et al. 
Haematopoietic stem cells do not asymmetrically segregate chromosomes or 
retain BrdU. Nature2007 Sep 13;449(7159):238-42. 
7.  Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization 
of mouse hematopoietic stem cells. Science1988 Jul 1;241(4861):58-62. 
8.  Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term 
lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic 
stem cell. Science1996 Jul 12;273(5272):242-5. 
9.  Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, et 
al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem 
cell. Cell2001 May 4;105(3):369-77. 
10.  Morrison SJ, Weissman IL. The long-term repopulating subset of 
hematopoietic stem cells is deterministic and isolatable by phenotype. 
Immunity1994 Nov;1(8):661-73. 
11.  Morrison SJ, Wandycz AM, Hemmati HD, Wright DE, Weissman IL. 
Identification of a lineage of multipotent hematopoietic progenitors. 
Development1997 May;124(10):1929-39. 
12.  Kondo M, Weissman IL, Akashi K. Identification of clonogenic common 
lymphoid progenitors in mouse bone marrow. Cell1997 Nov 28;91(5):661-72. 
13.  Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common 
myeloid progenitor that gives rise to all myeloid lineages. Nature2000 Mar 
9;404(6774):193-7. 
14.  Leary AG, Hirai Y, Kishimoto T, Clark SC, Ogawa M. Survival of 
hemopoietic progenitors in the G0 period of the cell cycle does not require early 
hemopoietic regulators. Proc Natl Acad Sci U S A1989 Jun;86(12):4535-8. 
15.  Leary AG, Zeng HQ, Clark SC, Ogawa M. Growth factor requirements for 
survival in G0 and entry into the cell cycle of primitive human hemopoietic 
progenitors. Proc Natl Acad Sci U S A1992 May 1;89(9):4013-7. 
16.  Lajtha LG. Stem cell concepts. Differentiation1979;14(1-2):23-34. 
17.  Schofield R. The relationship between the spleen colony-forming cell and 
the haemopoietic stem cell. Blood Cells1978;4(1-2):7-25. 
18.  Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat 
Rev Immunol2006 Feb;6(2):93-106. 
19.  Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interactions 
between hematopoietic and bone marrow stromal cells regulate human stem cell   262 
migration and development in NOD/SCID chimeric mice. Exp Hematol2006 
Aug;34(8):967-75. 
20.  Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. 
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice 
on CXCR4. Science1999 Feb 5;283(5403):845-8. 
21.  Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, et al. CXCR4 up-
regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration 
to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer 
Ther2008 Jan;7(1):48-58. 
22.  Nie Y, Han YC, Zou YR. CXCR4 is required for the quiescence of primitive 
hematopoietic cells. J Exp Med2008 Apr 14;205(4):777-83. 
23.  Scadden DT. The stem-cell niche as an entity of action. Nature2006 Jun 
29;441(7097):1075-9. 
24.  Caux C, Favre C, Saeland S, Duvert V, Mannoni P, Durand I, et al. 
Sequential loss of CD34 and class II MHC antigens on purified cord blood 
hematopoietic progenitors cultured with IL-3: characterization of CD34-, HLA-DR+ 
cells. Blood1989 Sep;74(4):1287-94. 
25.  Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and 
clinical utility. Blood1996 Jan 1;87(1):1-13. 
26.  Hao QL, Shah AJ, Thiemann FT, Smogorzewska EM, Crooks GM. A 
functional comparison of CD34 + CD38- cells in cord blood and bone marrow. 
Blood1995 Nov 15;86(10):3745-53. 
27.  Kung P, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies 
defining distinctive human T cell surface antigens. Science1979 Oct 
19;206(4416):347-9. 
28.  Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage 
engraftment potential from subfractions of human CD34+ cord blood cells 
transplanted into NOD/SCID mice. Proc Natl Acad Sci U S A2002 Jan 
8;99(1):413-8. 
29.  Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive 
human hematopoietic cells capable of repopulating immune-deficient mice. Proc 
Natl Acad Sci U S A1997 May 13;94(10):5320-5. 
30.  Miller JS, McCullar V, Punzel M, Lemischka IR, Moore KA. Single adult 
human CD34(+)/Lin-/CD38(-) progenitors give rise to natural killer cells, B-lineage 
cells, dendritic cells, and myeloid cells. Blood1999 Jan 1;93(1):96-106. 
31.  Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM. 
Characterization and partial purification of human marrow cells capable of initiating 
long-term hematopoiesis in vitro. Blood1989 Oct;74(5):1563-70. 
32.  Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et 
al. AC133, a novel marker for human hematopoietic stem and progenitor cells. 
Blood1997 Dec 15;90(12):5002-12. 
33.  Udomsakdi C, Eaves CJ, Sutherland HJ, Lansdorp PM. Separation of 
functionally distinct subpopulations of primitive human hematopoietic cells using 
rhodamine-123. Exp Hematol1991 Jun;19(5):338-42. 
34.  Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a 
multidrug efflux pump, in human hematopoietic stem cells. Cell1991 Jul 
12;66(1):85-94. 
35.  Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et 
al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells 
and is a molecular determinant of the side-population phenotype. Nat Med2001 
Sep;7(9):1028-34.   263 
36.  Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and 
functional properties of murine hematopoietic stem cells that are replicating in 
vivo. J Exp Med1996 Apr 1;183(4):1797-806. 
37.  Shapiro HM. Flow cytometric estimation of DNA and RNA content in intact 
cells stained with Hoechst 33342 and pyronin Y. Cytometry1981 Nov;2(3):143-50. 
38.  Gordon MY, Goldman JM, Gordon-Smith EC. 4-
Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-
macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor 
cells. Leuk Res1985;9(8):1017-21. 
39.  Sahovic EA, Colvin M, Hilton J, Ogawa M. Role for aldehyde 
dehydrogenase in survival of progenitors for murine blast cell colonies after 
treatment with 4-hydroperoxycyclophosphamide in vitro. Cancer Res1988 Mar 
1;48(5):1223-6. 
40.  Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM, et 
al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde 
dehydrogenase activity. Proc Natl Acad Sci U S A1999 Aug 3;96(16):9118-23. 
41.  Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic 
hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell 
characteristics? Proc Natl Acad Sci U S A2003 Sep 30;100 Suppl 1:11842-9. 
42.  Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic 
leukemia in man. Proc Natl Acad Sci U S A1967 Oct;58(4):1468-71. 
43.  Fialkow PJ, Singer JW, Adamson JW, Vaidya K, Dow LW, Ochs J, et al. 
Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood1981 
Jun;57(6):1068-73. 
44.  Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic 
leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, 
platelet and monocyte/macrophage. Am J Med1977 Jul;63(1):125-30. 
45.  Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: 
a primary cell culture assay. J Natl Cancer Inst1971 Feb;46(2):411-22. 
46.  Bruce WR, Van Der Gaag H. A Quantitative Assay for the Number of 
Murine Lymphoma Cells Capable of Proliferation in Vivo. Nature1963 Jul 
6;199:79-80. 
47.  Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat Med1997 
Jul;3(7):730-7. 
48.  Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of 
expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term 
proliferative ability in vitro and in vivo. Blood1997 May 1;89(9):3104-12. 
49.  Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, et al. 
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to 
committed murine hematopoietic progenitors. Cancer Cell2004 Dec;6(6):587-96. 
50.  Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. 
Similar MLL-associated leukemias arising from self-renewing stem cells and short-
lived myeloid progenitors. Genes Dev2003 Dec 15;17(24):3029-35. 
51.  Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. 
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-
AF9. Nature2006 Aug 17;442(7104):818-22. 
52.  Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, 
et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks 
the heterogeneity of leukemia-initiating cells. Blood2008 Aug 1;112(3):568-75. 
53.  Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous 
leukemia: biology and therapy. Ann Intern Med1999 Aug 3;131(3):207-19.   264 
54.  Rowley JD. Letter: A new consistent chromosomal abnormality in chronic 
myelogenous leukaemia identified by quinacrine fluorescence and Giemsa 
staining. Nature1973 Jun 1;243(5405):290-3. 
55.  Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, 
Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited 
region, bcr, on chromosome 22. Cell1984 Jan;36(1):93-9. 
56.  Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The 
chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl 
hybrid gene. Science1986 Jul 11;233(4760):212-4. 
57.  Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and 
transformation potency of bcr-abl oncogene products. Science1990 Mar 
2;247(4946):1079-82. 
58.  Sawyers CL. Chronic myeloid leukemia. N Engl J Med1999 Apr 
29;340(17):1330-40. 
59.  Lion T, Gaiger A, Henn T, Horth E, Haas OA, Geissler K, et al. Use of 
quantitative polymerase chain reaction to monitor residual disease in chronic 
myelogenous leukemia during treatment with interferon. Leukemia1995 
Aug;9(8):1353-60. 
60.  Vardiman JW, Harris NL, Brunning RD. The World Health Organization 
(WHO) classification of the myeloid neoplasms. Blood2002 Oct 1;100(7):2292-
302. 
61.  Laneuville P. Abl tyrosine protein kinase. Semin Immunol1995 
Aug;7(4):255-66. 
62.  Kipreos ET, Wang JY. Cell cycle-regulated binding of c-Abl tyrosine kinase 
to DNA. Science1992 Apr 17;256(5055):382-5. 
63.  McWhirter JR, Wang JY. An actin-binding function contributes to 
transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive 
human leukemias. EMBO J1993 Apr;12(4):1533-46. 
64.  Van Etten RA, Jackson PK, Baltimore D, Sanders MC, Matsudaira PT, 
Janmey PA. The COOH terminus of the c-Abl tyrosine kinase contains distinct F- 
and G-actin binding domains with bundling activity. J Cell Biol1994 
Feb;124(3):325-40. 
65.  Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene 
product is a nuclear protein, and activation of transforming ability is associated 
with cytoplasmic localization. Cell1989 Aug 25;58(4):669-78. 
66.  Reuther GW, Fu H, Cripe LD, Collier RJ, Pendergast AM. Association of 
the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. 
Science1994 Oct 7;266(5182):129-33. 
67.  Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences 
essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 
regulatory domain in a non-phosphotyrosine-dependent manner. Cell1991 Jul 
12;66(1):161-71. 
68.  McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain 
of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell 
Biol1993 Dec;13(12):7587-95. 
69.  Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. 
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 
domain of the GRB-2 adaptor protein. Cell1993 Oct 8;75(1):175-85. 
70.  Chan LC, Karhi KK, Rayter SI, Heisterkamp N, Eridani S, Powles R, et al. A 
novel abl protein expressed in Philadelphia chromosome positive acute 
lymphoblastic leukaemia. Nature1987 Feb 12-18;325(6105):635-7.   265 
71.  Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU. Expression 
of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood1987 
Nov;70(5):1584-8. 
72.  Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid 
leukaemia: the missing link with chronic myelomonocytic leukaemia? 
Leukemia1994 Jan;8(1):208-11. 
73.  Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al. 
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular 
marker (BCR/ABL with C3/A2 junction). Blood1996 Oct 1;88(7):2410-4. 
74.  Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous 
leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. 
Science1990 Feb 16;247(4944):824-30. 
75.  Koschmieder S, Gottgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, 
et al. Inducible chronic phase of myeloid leukemia with expansion of 
hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. 
Blood2005 Jan 1;105(1):324-34. 
76.  Teixido J, Hemler ME, Greenberger JS, Anklesaria P. Role of beta 1 and 
beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow 
stroma. J Clin Invest1992 Aug;90(2):358-67. 
77.  Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered 
adhesive interactions with marrow stroma of haematopoietic progenitor cells in 
chronic myeloid leukaemia. Nature1987 Jul 23-29;328(6128):342-4. 
78.  Verfaillie CM, Hurley R, Lundell BI, Zhao C, Bhatia R. Integrin-mediated 
regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function 
underlie the abnormal circulation and proliferation of CML progenitors? Acta 
Haematol1997;97(1-2):40-52. 
79.  Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC. Activation of 
phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell 
Biol1991 Feb;11(2):1107-13. 
80.  Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-alpha restores 
normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to 
bone marrow stroma by correcting impaired beta 1 integrin receptor function. J 
Clin Invest1994 Jul;94(1):384-91. 
81.  Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, 
et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice 
lacking the CXC chemokine PBSF/SDF-1. Nature1996 Aug 15;382(6592):635-8. 
82.  Geay JF, Buet D, Zhang Y, Foudi A, Jarrier P, Berthebaud M, et al. 
p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 
signaling and down-regulation of CXCR4 expression. Cancer Res2005 Apr 
1;65(7):2676-83. 
83.  Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of 
apoptosis by BCR-ABL in chronic myeloid leukemia. Blood1994 Apr 
15;83(8):2038-44. 
84.  Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, 
Choi JK, et al. Transformation of hematopoietic cells by BCR/ABL requires 
activation of a PI-3k/Akt-dependent pathway. EMBO J1997 Oct 15;16(20):6151-
61. 
85.  Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, 
et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid 
leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-
1 antisense oligonucleotides. Blood2005 Apr 15;105(8):3303-11. 
86.  Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, 
Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis:   266 
protection is correlated with up regulation of Bcl-xL. Oncogene1998 
Mar;16(11):1383-90. 
87.  Marley SB, Lewis JL, Scott MA, Goldman JM, Gordon MY. Evaluation of 
"discordant maturation' in chronic myeloid leukaemia using cultures of primitive 
progenitor cells and their production of clonogenic progeny (CFU-GM). Br J 
Haematol1996 Nov;95(2):299-305. 
88.  Smith DL, Burthem J, Whetton AD. Molecular pathogenesis of chronic 
myeloid leukaemia. Expert Rev Mol Med2003 Nov;5(27):1-27. 
89.  Carpino N, Wisniewski D, Strife A, Marshak D, Kobayashi R, Stillman B, et 
al. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in 
chronic myelogenous leukemia progenitor cells. Cell1997 Jan 24;88(2):197-204. 
90.  Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the 
major tyrosine-phosphorylated protein in neutrophils from patients with chronic 
myelogenous leukemia. J Biol Chem1994 Sep 16;269(37):22925-8. 
91.  Feller SM, Knudsen B, Hanafusa H. c-Abl kinase regulates the protein 
binding activity of c-Crk. EMBO J1994 May 15;13(10):2341-51. 
92.  Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, Griffin JD. Tyrosine 
phosphorylation of rasGAP and associated proteins in chronic myelogenous 
leukemia cell lines. Blood1992 May 1;79(9):2215-20. 
93.  Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, 
Miyazawa K, et al. Role of p21 RAS in p210 bcr-abl transformation of murine 
myeloid cells. Blood1993 Sep 15;82(6):1838-47. 
94.  Skorski T, Nieborowska-Skorska M, Szczylik C, Kanakaraj P, Perrotti D, 
Zon G, et al. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent 
and normal hematopoiesis. Cancer Res1995 Jun 1;55(11):2275-8. 
95.  de Jong R, ten Hoeve J, Heisterkamp N, Groffen J. Crkl is complexed with 
tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem1995 Sep 
15;270(37):21468-71. 
96.  Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, 
Zon G, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is 
required for the growth of Philadelphia chromosome-positive cells. Blood1995 Jul 
15;86(2):726-36. 
97.  Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding 
activity of signal transducers and activators of transcription (STAT) proteins in 
hematopoietic cell lines transformed by Bcr/Abl. J Exp Med1996 Mar 
1;183(3):811-20. 
98.  Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Cooperative and redundant 
effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. 
Oncogene2001 Sep 13;20(41):5826-35. 
99.  Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, et al. CRKL links 
p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol 
Chem1995 Dec 8;270(49):29145-50. 
100.  Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, 
et al. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) 
by BCR-ABL oncoprotein. Exp Hematol1995 Oct;23(11):1153-9. 
101.  Salgia R, Brunkhorst B, Pisick E, Li JL, Lo SH, Chen LB, et al. Increased 
tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing 
p210BCR/ABL. Oncogene1995 Sep 21;11(6):1149-55. 
102.  Gotoh A, Miyazawa K, Ohyashiki K, Toyama K. Potential molecules 
implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve 
GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 
3'-kinase. Leukemia1994 Jan;8(1):115-20.   267 
103.  Bassermann F, Jahn T, Miething C, Seipel P, Bai RY, Coutinho S, et al. 
Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of 
the Rac-1 pathway. J Biol Chem2002 Apr 5;277(14):12437-45. 
104.  Skorski T, Kanakaraj P, Ku DH, Nieborowska-Skorska M, Canaani E, Zon 
G, et al. Negative regulation of p120GAP GTPase promoting activity by 
p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive 
cell growth. J Exp Med1994 Jun 1;179(6):1855-65. 
105.  Gishizky ML, Cortez D, Pendergast AM. Mutant forms of growth factor-
binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci U 
S A1995 Nov 21;92(24):10889-93. 
106.  Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Grazia Borrello 
M, et al. Constitutive phosphorylation of Shc proteins in human tumors. 
Oncogene1995 Sep 7;11(5):899-907. 
107.  Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the 
transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J 
Exp Med1995 Jan 1;181(1):307-13. 
108.  Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements 
for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell 
Biol1995 Oct;15(10):5531-41. 
109.  Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals 
to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell1995 
Sep 22;82(6):981-8. 
110.  Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling 
through the JAK/STAT pathway, recent advances and future challenges. 
Gene2002 Feb 20;285(1-2):1-24. 
111.  Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and 
STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from 
leukemic patients. J Immunol1997 Nov 15;159(10):4720-8. 
112.  Ilaria RL, Jr., Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine 
phosphorylation and DNA binding activity of multiple specific STAT family 
members. J Biol Chem1996 Dec 6;271(49):31704-10. 
113.  de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. 
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia 
cells. Blood1999 Aug 1;94(3):1108-12. 
114.  Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene 
through STAT5. Blood2000 Sep 15;96(6):2269-76. 
115.  Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, 
Mora LB, et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks 
constitutive activation of Stat5 and growth of CML cells. Oncogene2002 Dec 
12;21(57):8804-16. 
116.  Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, 
Cantley LC. Purification and characterization of phosphoinositide 3-kinase from rat 
liver. J Biol Chem1990 Nov 15;265(32):19704-11. 
117.  Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, 
et al. Oncogenes and signal transduction. Cell1991 Jan 25;64(2):281-302. 
118.  Skolnik EY, Margolis B, Mohammadi M, Lowenstein E, Fischer R, Drepps 
A, et al. Cloning of PI3 kinase-associated p85 utilizing a novel method for 
expression/cloning of target proteins for receptor tyrosine kinases. Cell1991 Apr 
5;65(1):83-90. 
119.  Kapeller R, Cantley LC. Phosphatidylinositol 3-kinase. Bioessays1994 
Aug;16(8):565-76. 
120.  Shepherd PR, Reaves BJ, Davidson HW. Phosphoinositide 3-kinases and 
membrane traffic. Trends Cell Biol1996 Mar;6(3):92-7.   268 
121.  Divecha N, Irvine RF. Phospholipid signaling. Cell1995 Jan 27;80(2):269-
78. 
122.  Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, 
et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev 
Biochem2001;70:535-602. 
123.  Jain SK, Susa M, Keeler ML, Carlesso N, Druker B, Varticovski L. PI 3-
kinase activation in BCR/abl-transformed hematopoietic cells does not require 
interaction of p85 SH2 domains with p210 BCR/abl. Blood1996 Sep 1;88(5):1542-
50. 
124.  Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, et al. 
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell2002 
Jun;1(5):479-92. 
125.  ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine 
phosphorylation of CRKL in Philadelphia+ leukemia. Blood1994 Sep 
15;84(6):1731-6. 
126.  Reichman CT, Mayer BJ, Keshav S, Hanafusa H. The product of the 
cellular crk gene consists primarily of SH2 and SH3 regions. Cell Growth 
Differ1992 Jul;3(7):451-60. 
127.  de Jong R, ten Hoeve J, Heisterkamp N, Groffen J. Tyrosine 207 in CRKL 
is the BCR/ABL phosphorylation site. Oncogene1997 Feb 6;14(5):507-13. 
128.  Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. 
Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine 
phosphoprotein in chronic myelogenous leukemia cells. Blood1994 Nov 
1;84(9):2912-8. 
129.  Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, et al. The 
proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link 
c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase 
pathway. Oncogene1996 Feb 15;12(4):839-46. 
130.  Hamilton A, Elrick L, Myssina S, Copland M, Jorgensen H, Melo JV, et al. 
BCR-ABL activity and its response to drugs can be determined in CD34+ CML 
stem cells by CrkL phosphorylation status using flow cytometry. Leukemia2006 
Jun;20(6):1035-9. 
131.  Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. 
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in 
primary CML but does not eliminate the quiescent fraction. Blood2006 Jun 
1;107(11):4532-9. 
132.  Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. 
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) 
therapy. Leukemia2002 Nov;16(11):2190-6. 
133.  La Rosee P, Holm-Eriksen S, Konig H, Hartel N, Ernst T, Debatin J, et al. 
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-
resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients 
treated with nilotinib. Haematologica2008 May;93(5):765-9. 
134.  Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, 
differentiation, and transformation. Cell2004 May 14;117(4):421-6. 
135.  Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, Frangioni JV, et al. 14-3-3 
transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J 
Cell Biol2002 Mar 4;156(5):817-28. 
136.  Obsilova V, Vecer J, Herman P, Pabianova A, Sulc M, Teisinger J, et al. 
14-3-3 Protein interacts with nuclear localization sequence of forkhead 
transcription factor FoxO4. Biochemistry2005 Aug 30;44(34):11608-17.   269 
137.  Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate 
tumor necrosis factor-related apoptosis inducing ligand expression. Implications 
for PTEN mutation in prostate cancer. J Biol Chem2002 Dec 6;277(49):47928-37. 
138.  Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM, et al. 
The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim 
in response to IL-2. J Immunol2002 May 15;168(10):5024-31. 
139.  Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops 
GJ, Lam EW, et al. Cell cycle inhibition by FoxO forkhead transcription factors 
involves downregulation of cyclin D. Mol Cell Biol2002 Nov;22(22):7842-52. 
140.  Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. Cytokines and 
BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of 
forkhead FOXO3a transcription factor. Proc Natl Acad Sci U S A2003 May 
27;100(11):6523-8. 
141.  Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas 
NS, et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-
induced apoptosis in Bcr-Abl-expressing cells. Oncogene2005 Mar 
31;24(14):2317-29. 
142.  Fernandez de Mattos S, Essafi A, Soeiro I, Pietersen AM, Birkenkamp KU, 
Edwards CS, et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through 
a STAT5/BCL6-dependent mechanism. Mol Cell Biol2004 Nov;24(22):10058-71. 
143.  Reed JC. Bcl-2-family proteins and hematologic malignancies: history and 
future prospects. Blood2008 Apr 1;111(7):3322-30. 
144.  Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation 
of death agonist BAD in response to survival factor results in binding to 14-3-3 not 
BCL-X(L). Cell1996 Nov 15;87(4):619-28. 
145.  Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival 
function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent 
pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol2000 
Feb;20(4):1179-86. 
146.  Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway 
promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl 
Acad Sci U S A2001 Sep 25;98(20):11598-603. 
147.  Goetz AW, van der Kuip H, Maya R, Oren M, Aulitzky WE. Requirement for 
Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells. 
Cancer Res2001 Oct 15;61(20):7635-41. 
148.  Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the 
phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem1998 Aug 
7;273(32):19929-32. 
149.  Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-
3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev1998 
Nov 15;12(22):3499-511. 
150.  Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, et al. Loss of beta-
catenin impairs the renewal of normal and CML stem cells in vivo. Cancer 
Cell2007 Dec;12(6):528-41. 
151.  Richardson CJ, Schalm SS, Blenis J. PI3-kinase and TOR: PIKTORing cell 
growth. Semin Cell Dev Biol2004 Apr;15(2):147-59. 
152.  Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell2007 Apr;12(4):487-
502. 
153.  Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and 
metabolism. Cell2006 Feb 10;124(3):471-84. 
154.  Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science2005 Feb 
18;307(5712):1098-101.   270 
155.  Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer 
Cell2003 Nov;4(5):343-8. 
156.  Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates 
the translation regulators ribosomal protein S6 and 4E-BP1 in chronic 
myelogenous leukemia cells via the mammalian target of rapamycin. Cancer 
Res2003 Sep 15;63(18):5716-22. 
157.  Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, et al. 
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the 
treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A2004 
Mar 2;101(9):3130-5. 
158.  Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway 
in human disease. Nat Genet2005 Jan;37(1):19-24. 
159.  Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes 
Dev2004 Aug 15;18(16):1926-45. 
160.  Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, et al. S6K1(-/-
)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal 
oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-
dependent S6 kinase pathway. Mol Cell Biol2004 Apr;24(8):3112-24. 
161.  Levine B, Klionsky DJ. Development by self-digestion: molecular 
mechanisms and biological functions of autophagy. Dev Cell2004 Apr;6(4):463-77. 
162.  Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, et al. 
The role of autophagy during the early neonatal starvation period. Nature2004 Dec 
23;432(7020):1032-6. 
163.  Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential 
therapeutic applications of autophagy. Nat Rev Drug Discov2007 Apr;6(4):304-12. 
164.  Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T, et al. Growth 
factor regulation of autophagy and cell survival in the absence of apoptosis. 
Cell2005 Jan 28;120(2):237-48. 
165.  Xie Z, Klionsky DJ. Autophagosome formation: core machinery and 
adaptations. Nat Cell Biol2007 Oct;9(10):1102-9. 
166.  Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. 
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome 
membranes after processing. EMBO J2000 Nov 1;19(21):5720-8. 
167.  Cuervo AM. Autophagy: in sickness and in health. Trends Cell Biol2004 
Feb;14(2):70-7. 
168.  Jin S. Autophagy, mitochondrial quality control, and oncogenesis. 
Autophagy2006 Apr-Jun;2(2):80-4. 
169.  Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, et al. The 
anticancer drug imatinib induces cellular autophagy. Leukemia2007 
May;21(5):936-42. 
170.  Kamitsuji Y, Kuroda J, Kimura S, Toyokuni S, Watanabe K, Ashihara E, et 
al. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes 
of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ2008 
Nov;15(11):1712-22. 
171.  Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, et al. 
Targeting autophagy augments the anticancer activity of the histone deacetylase 
inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood2007 Jul 
1;110(1):313-22. 
172.  Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti 
M, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell 
death in Philadelphia chromosome-positive cells, including primary CML stem 
cells. J Clin Invest2009 May;119(5):1109-23.   271 
173.  Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E, et al. Cloning 
and genomic organization of beclin 1, a candidate tumor suppressor gene on 
chromosome 17q21. Genomics1999 Jul 1;59(1):59-65. 
174.  Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et 
al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature1999 
Dec 9;402(6762):672-6. 
175.  Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. Promotion of 
tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin 
Invest2003 Dec;112(12):1809-20. 
176.  Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene 
essential for early embryonic development, is a haploinsufficient tumor 
suppressor. Proc Natl Acad Sci U S A2003 Dec 9;100(25):15077-82. 
177.  Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, 
McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle 
progression and leukemogenesis. Leukemia2004 Feb;18(2):189-218. 
178.  Burgess AW, Metcalf D. Characterization of a serum factor stimulating the 
differentiation of myelomonocytic leukemic cells. Int J Cancer1980 Nov 
15;26(5):647-54. 
179.  Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not 
all! Growth Factors2005 Mar;23(1):33-41. 
180.  Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 
2000 update of recommendations for the use of hematopoietic colony-stimulating 
factors: evidence-based, clinical practice guidelines. American Society of Clinical 
Oncology Growth Factors Expert Panel. J Clin Oncol2000 Oct 15;18(20):3558-85. 
181.  Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. 
Effects of recombinant human granulocyte colony-stimulating factor on 
hematopoietic progenitor cells in cancer patients. Blood1988 Dec;72(6):2074-81. 
182.  Pan L, Delmonte J, Jr., Jalonen CK, Ferrara JL. Pretreatment of donor mice 
with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward 
type-2 cytokine production and reduces severity of experimental graft-versus-host 
disease. Blood1995 Dec 15;86(12):4422-9. 
183.  Sattler M, Salgia R. Activation of hematopoietic growth factor signal 
transduction pathways by the human oncogene BCR/ABL. Cytokine Growth 
Factor Rev1997 Mar;8(1):63-79. 
184.  Chang JM, Metcalf D, Lang RA, Gonda TJ, Johnson GR. Nonneoplastic 
hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF 
(IL-3) expression. Blood1989 May 1;73(6):1487-97. 
185.  Wong PM, Chung SW, Dunbar CE, Bodine DM, Ruscetti S, Nienhuis AW. 
Retrovirus-mediated transfer and expression of the interleukin-3 gene in mouse 
hematopoietic cells result in a myeloproliferative disorder. Mol Cell Biol1989 
Feb;9(2):798-808. 
186.  Just U, Katsuno M, Stocking C, Spooncer E, Dexter M. Targeted in vivo 
infection with a retroviral vector carrying the interleukin-3 (multi-CSF) gene leads 
to immortalization and leukemic transformation of primitive hematopoietic 
progenitor cells. Growth Factors1993;9(1):41-55. 
187.  Hariharan IK, Adams JM, Cory S. bcr-abl oncogene renders myeloid cell 
line factor independent: potential autocrine mechanism in chronic myeloid 
leukemia. Oncogene Res1988;3(4):387-99. 
188.  Sirard C, Laneuville P, Dick JE. Expression of bcr-abl abrogates factor-
dependent growth of human hematopoietic M07E cells by an autocrine 
mechanism. Blood1994 Mar 15;83(6):1575-85. 
189.  Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG, Van Etten RA. 
Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not   272 
required for induction of chronic myeloid leukemia-like myeloproliferative disease 
in mice by BCR/ABL. Blood2001 Mar 1;97(5):1442-50. 
190.  Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and 
action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid 
leukemia. Proc Natl Acad Sci U S A1999 Oct 26;96(22):12804-9. 
191.  Strife A, Lambek C, Wisniewski D, Wachter M, Gulati SC, Clarkson BD. 
Discordant maturation as the primary biological defect in chronic myelogenous 
leukemia. Cancer Res1988 Feb 15;48(4):1035-41. 
192.  Geary CG. The story of chronic myeloid leukaemia. Br J Haematol2000 
Jul;110(1):2-11. 
193.  Galton DA. Myleran in chronic myeloid leukaemia; results of treatment. 
Lancet1953 Jan 31;264(6753):208-13. 
194.  Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic 
myelogenous leukemia: a concise update. Blood1993 Aug 1;82(3):691-703. 
195.  Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, 
et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N 
Engl J Med1986 Jan 23;314(4):202-7. 
196.  Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, 
et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, 
interferon, and allogeneic bone marrow transplantation in treating the chronic 
phase of chronic myeloid leukemia: developed for the American Society of 
Hematology. Blood1999 Sep 1;94(5):1517-36. 
197.  Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, 
et al. Risk assessment for patients with chronic myeloid leukaemia before 
allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of 
the European Group for Blood and Marrow Transplantation. Lancet1998 Oct 
3;352(9134):1087-92. 
198.  Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-
analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' 
Collaborative Group. J Natl Cancer Inst1997 Nov 5;89(21):1616-20. 
199.  Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman 
JU. Hematologic remission and cytogenetic improvement induced by recombinant 
human interferon alpha A in chronic myelogenous leukemia. N Engl J Med1986 
Apr 24;314(17):1065-9. 
200.  Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, 
et al. Interferon alfa-2b combined with cytarabine versus interferon alone in 
chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. 
N Engl J Med1997 Jul 24;337(4):223-9. 
201.  Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A. Tyrphostin-induced 
inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. 
Blood1993 Dec 15;82(12):3524-9. 
202.  Okabe M, Uehara Y, Miyagishima T, Itaya T, Tanaka M, Kuni-Eda Y, et al. 
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-
associated cell proliferations: abrogative effect on the transformation of murine 
hematopoietic cells by transfection of a retroviral vector expressing oncoprotein 
P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth. 
Blood1992 Sep 1;80(5):1330-8. 
203.  Honma Y, Matsuo Y, Hayashi Y, Omura S. Treatment of Philadelphia-
chromosome-positive human leukemia in SCID mouse model with herbimycin A, 
bcr-abl tyrosine kinase activity inhibitor. Int J Cancer1995 Mar 3;60(5):685-8. 
204.  Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, et al. 
Novel oxime derivatives of radicicol induce erythroid differentiation associated with 
preferential G(1) phase accumulation against chronic myelogenous leukemia cells   273 
through destabilization of Bcr-Abl with Hsp90 complex. Blood2000 Sep 
15;96(6):2284-91. 
205.  Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. 
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl 
positive cells. Nat Med1996 May;2(5):561-6. 
206.  Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. 
Science2000 Sep 15;289(5486):1938-42. 
207.  Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, et al. 
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-
phenylaminopyrimidine derivative. Cancer Res1996 Jan 1;56(1):100-4. 
208.  Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon 
NB, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells 
expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood1997 Dec 
15;90(12):4947-52. 
209.  Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, et al. Selective 
inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic 
leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase 
inhibitor (CGP-57148). Clin Cancer Res1998 Jul;4(7):1661-72. 
210.  Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML 
therapeutics. Biochim Biophys Acta2001 Aug 31;1551(1):M11-8. 
211.  Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase 
inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. 
Blood1997 Nov 1;90(9):3691-8. 
212.  Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, 
Marchesi E, et al. Inhibition of the ABL kinase activity blocks the proliferation of 
BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis1997 
Dec;23(3):380-94. 
213.  Kasper B, Fruehauf S, Schiedlmeier B, Buchdunger E, Ho AD, Zeller WJ. 
Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; 
activity on lineage-committed and primitive chronic myelogenous leukemia 
progenitors. Cancer Chemother Pharmacol1999;44(5):433-8. 
214.  Marley SB, Deininger MW, Davidson RJ, Goldman JM, Gordon MY. The 
tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the 
capacity for amplification of granulocyte-macrophage progenitors from patients 
with chronic myeloid leukemia. Exp Hematol2000 May;28(5):551-7. 
215.  le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, et 
al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL 
kinase inhibitor. J Natl Cancer Inst1999 Jan 20;91(2):163-8. 
216.  Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. 
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in 
chronic myeloid leukemia. N Engl J Med2001 Apr 5;344(14):1031-7. 
217.  Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. 
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of 
chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia 
chromosome. N Engl J Med2001 Apr 5;344(14):1038-42. 
218.  Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-
Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in 
chronic myelogenous leukemia. N Engl J Med2002 Feb 28;346(9):645-52. 
219.  Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann 
OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with 
chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. 
Blood2002 May 15;99(10):3530-9.   274 
220.  Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, 
Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses 
in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 
study. Blood2002 Mar 15;99(6):1928-37. 
221.  O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, 
et al. Imatinib compared with interferon and low-dose cytarabine for newly 
diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med2003 Mar 
13;348(11):994-1004. 
222.  Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann 
N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid 
leukemia. N Engl J Med2006 Dec 7;355(23):2408-17. 
223.  Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et 
al. Frequency of major molecular responses to imatinib or interferon alfa plus 
cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med2003 Oct 
9;349(15):1423-32. 
224.  Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent 
subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood1999 
Sep 15;94(6):2056-64. 
225.  Holyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, Laird C, et al. 
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia 
spontaneously initiate factor-independent growth in vitro in association with up-
regulation of expression of interleukin-3. Blood2001 Feb 1;97(3):720-8. 
226.  Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, 
et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with 
chronic myeloid leukemia are insensitive to STI571 in vitro. Blood2002 Jan 
1;99(1):319-25. 
227.  Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib 
mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic 
myelogenous leukemia through reversal of abnormally increased proliferation. 
Blood2002 May 15;99(10):3792-800. 
228.  Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, et al. 
Persistence of malignant hematopoietic progenitors in chronic myelogenous 
leukemia patients in complete cytogenetic remission following imatinib mesylate 
treatment. Blood2003 Jun 15;101(12):4701-7. 
229.  Jorgensen HG, Allan EK, Mountford JC, Richmond L, Harrison S, Elliott 
MA, et al. Enhanced CML stem cell elimination in vitro by bryostatin priming with 
imatinib mesylate. Exp Hematol2005 Oct;33(10):1140-6. 
230.  Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. 
Dynamics of chronic myeloid leukaemia. Nature2005 Jun 30;435(7046):1267-70. 
231.  Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum 
F, et al. Evolving concepts in the management of chronic myeloid leukemia: 
recommendations from an expert panel on behalf of the European LeukemiaNet. 
Blood2006 Sep 15;108(6):1809-20. 
232.  Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, et al. 
Imatinib mesylate resistance through BCR-ABL independence in chronic 
myelogenous leukemia. Cancer Res2004 Jan 15;64(2):672-7. 
233.  Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-
ABL independence and LYN kinase overexpression in chronic myelogenous 
leukemia cells selected for resistance to STI571. Blood2003 Jan 15;101(2):690-8. 
234.  Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, et al. Lyn regulates 
BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in 
imatinib-resistant chronic myelogenous leukemia cells. Blood2008 Apr 
1;111(7):3821-9.   275 
235.  Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, et al. Adaptive 
secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) 
mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-
2/STAT-5 pathway activation. Blood2007 Mar 1;109(5):2147-55. 
236.  le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. 
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells 
through gene amplification. Blood2000 Mar 1;95(5):1758-66. 
237.  Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman 
JM, et al. Selection and characterization of BCR-ABL positive cell lines with 
differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms 
of resistance. Blood2000 Aug 1;96(3):1070-9. 
238.  Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. 
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation 
or amplification. Science2001 Aug 3;293(5531):876-80. 
239.  Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High 
frequency of point mutations clustered within the adenosine triphosphate-binding 
region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute 
lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood2002 May 
1;99(9):3472-5. 
240.  Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. 
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the 
tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic 
myeloid leukemia. Cancer Cell2002 Aug;2(2):117-25. 
241.  Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et 
al. Crystal structures of the kinase domain of c-Abl in complex with the small 
molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res2002 Aug 
1;62(15):4236-43. 
242.  O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug 
resistance, and the road to a cure for chronic myeloid leukemia. Blood2007 Oct 
1;110(7):2242-9. 
243.  Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-
571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell2003 Mar 
21;112(6):831-43. 
244.  Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. 
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: 
review and recommendations for harmonizing current methodology for detecting 
BCR-ABL transcripts and kinase domain mutations and for expressing results. 
Blood2006 Jul 1;108(1):28-37. 
245.  Khorashad JS, Anand M, Marin D, Saunders S, Al-Jabary T, Iqbal A, et al. 
The presence of a BCR-ABL mutant allele in CML does not always explain clinical 
resistance to imatinib. Leukemia2006 Apr;20(4):658-63. 
246.  Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-
571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp 
Ther2003 Mar;304(3):1085-92. 
247.  Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, et 
al. MDR1 gene overexpression confers resistance to imatinib mesylate in 
leukemia cell line models. Blood2003 Mar 15;101(6):2368-73. 
248.  Ferrao PT, Frost MJ, Siah SP, Ashman LK. Overexpression of P-
glycoprotein in K562 cells does not confer resistance to the growth inhibitory 
effects of imatinib (STI571) in vitro. Blood2003 Dec 15;102(13):4499-503. 
249.  Hatziieremia S, Jordanides NE, Holyoake TL, Mountford JC, Jorgensen 
HG. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia 
CD34+ cells to imatinib. Exp Hematol2009 Jun;37(6):692-700.   276 
250.  Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional 
ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib 
mesylate. Blood2006 Aug 15;108(4):1370-3. 
251.  Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, 
Ray A, et al. Characterization of AMN107, a selective inhibitor of native and 
mutant Bcr-Abl. Cancer Cell2005 Feb;7(2):129-41. 
252.  O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In 
vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically 
relevant imatinib-resistant Abl kinase domain mutants. Cancer Res2005 Jun 
1;65(11):4500-5. 
253.  Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, et 
al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity 
against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res2005 Jul 
1;11(13):4941-7. 
254.  Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. 
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N 
Engl J Med2006 Jun 15;354(24):2542-51. 
255.  Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et 
al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase 
inhibitor, is effective in patients with Philadelphia chromosome-positive chronic 
myelogenous leukemia in chronic phase following imatinib resistance and 
intolerance. Blood2007 Nov 15;110(10):3540-6. 
256.  Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. 
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce 
apoptosis in CD34+ CML cells. Blood2007 May 1;109(9):4016-9. 
257.  Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor 
signaling. Exp Cell Res2000 Jan 10;254(1):1-13. 
258.  Stanglmaier M, Warmuth M, Kleinlein I, Reis S, Hallek M. The interaction of 
the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding 
domains. Leukemia2003 Feb;17(2):283-9. 
259.  Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. 
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. 
Cancer Res1996 Aug 1;56(15):3589-96. 
260.  Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, 
a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent 
antiproliferative agent against chronic myelogenous leukemia cells in culture and 
causes regression of K562 xenografts in nude mice. Cancer Res2003 Jan 
15;63(2):375-81. 
261.  Cortes J, Kantarjian HM, Baccarani M, Brummendorf TH, Liu D, 
Ossenkoppele G, et al. A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and 
Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) 
Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) 
Relapsed, Refractory or Intolerant of Imatinib. Blood (ASH Annual Meeting 
Abstracts)2006;108: Abstract 168. 
262.  Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic 
myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase 
inhibitor SKI-606. Blood2008 Feb 15;111(4):2329-38. 
263.  Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. 
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N 
Engl J Med2006 Jun 15;354(24):2531-41. 
264.  Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. 
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-
yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual   277 
Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med 
Chem2004 Dec 30;47(27):6658-61. 
265.  Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, et al. 
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain 
elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer 
Res2006 Jun 1;66(11):5790-7. 
266.  Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg 
SL, et al. Dasatinib induces durable cytogenetic responses in patients with chronic 
myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. 
Leukemia2008 Jun;22(6):1200-6. 
267.  Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et 
al. Dasatinib induces significant hematologic and cytogenetic responses in 
patients with imatinib-resistant or -intolerant chronic myeloid leukemia in 
accelerated phase. Blood2007 May 15;109(10):4143-50. 
268.  Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, et al. 
Dasatinib induces complete hematologic and cytogenetic responses in patients 
with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. 
Blood2007 Apr 15;109(8):3207-13. 
269.  Weinstein IB, Begemann M, Zhou P, Han EK, Sgambato A, Doki Y, et al. 
Disorders in cell circuitry associated with multistage carcinogenesis: exploitable 
targets for cancer prevention and therapy. Clin Cancer Res1997 Dec;3(12 Pt 
2):2696-702. 
270.  Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: 
the role of homeostasis. Carcinogenesis2000 May;21(5):857-64. 
271.  Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. 
Science2002 Jul 5;297(5578):63-4. 
272.  Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. 
Analysis of lung tumor initiation and progression using conditional expression of 
oncogenic K-ras. Genes Dev2001 Dec 15;15(24):3243-8. 
273.  Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. 
Essential role for oncogenic Ras in tumour maintenance. Nature1999 Jul 
29;400(6743):468-72. 
274.  Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in 
hematopoietic lineages. Mol Cell1999 Aug;4(2):199-207. 
275.  Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-
cell leukaemia induced by BCR-ABL1. Nat Genet2000 Jan;24(1):57-60. 
276.  Colomer R, Lupu R, Bacus SS, Gelmann EP. erbB-2 antisense 
oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 
oncogene amplification. Br J Cancer1994 Nov;70(5):819-25. 
277.  Zhou P, Jiang W, Zhang YJ, Kahn SM, Schieren I, Santella RM, et al. 
Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of 
human esophageal cancer cells. Oncogene1995 Aug 3;11(3):571-80. 
278.  Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M. 
Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer 
cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol 
Carcinog1997 Oct;20(2):251-8. 
279.  Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small 
interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo 
growth of colon cancer cells. Clin Cancer Res2003 Apr;9(4):1291-300. 
280.  Lyons AB, Parish CR. Determination of lymphocyte division by flow 
cytometry. J Immunol Methods1994 May 2;171(1):131-7.   278 
281.  Li X, Dancausse H, Grijalva I, Oliveira M, Levi AD. Labeling Schwann cells 
with CFSE-an in vitro and in vivo study. J Neurosci Methods2003 May 30;125(1-
2):83-91. 
282.  Coulombel L, Eaves AC, Eaves CJ. Enzymatic treatment of long-term 
human marrow cultures reveals the preferential location of primitive hemopoietic 
progenitors in the adherent layer. Blood1983 Aug;62(2):291-7. 
283.  Sutherland HJ, Eaves CJ, Lansdorp PM, Thacker JD, Hogge DE. 
Differential regulation of primitive human hematopoietic cells in long-term cultures 
maintained on genetically engineered murine stromal cells. Blood1991 Aug 
1;78(3):666-72. 
284.  Hogge DE, Lansdorp PM, Reid D, Gerhard B, Eaves CJ. Enhanced 
detection, maintenance, and differentiation of primitive human hematopoietic cells 
in cultures containing murine fibroblasts engineered to produce human steel 
factor, interleukin-3, and granulocyte colony-stimulating factor. Blood1996 Nov 
15;88(10):3765-73. 
285.  Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle 
analysis of a cell proliferation-associated human nuclear antigen defined by the 
monoclonal antibody Ki-67. J Immunol1984 Oct;133(4):1710-5. 
286.  Jordan CT, Yamasaki G, Minamoto D. High-resolution cell cycle analysis of 
defined phenotypic subsets within primitive human hematopoietic cell populations. 
Exp Hematol1996 Sep;24(11):1347-55. 
287.  Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano 
MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem1985 
Oct;150(1):76-85. 
288.  Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, 
et al. Standardization and quality control studies of 'real-time' quantitative reverse 
transcriptase polymerase chain reaction of fusion gene transcripts for residual 
disease detection in leukemia - a Europe Against Cancer program. Leukemia2003 
Dec;17(12):2318-57. 
289.  Hayette S, Michallet M, Baille ML, Magaud JP, Nicolini FE. Assessment 
and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide 
appropriate therapeutic decision making in CML patients. Leuk Res2005 
Sep;29(9):1073-7. 
290.  White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, et al. In vitro 
sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of 
molecular response in patients with de novo CML. Blood2005 Oct 1;106(7):2520-
6. 
291.  Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo JV. Analysis of total 
phosphotyrosine levels in CD34+ cells from CML patients to predict the response 
to imatinib mesylate treatment. Blood2005 Jun 15;105(12):4893-4. 
292.  Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding 
imatinib resistance with a novel ABL kinase inhibitor. Science2004 Jul 
16;305(5682):399-401. 
293.  Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several 
Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance 
remain sensitive to imatinib. Blood2003 Jun 1;101(11):4611-4. 
294.  Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, Kubista E, et al. 
Active (p)CrkL is overexpressed in human malignancies: potential role as a 
surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep2006 
Feb;15(2):353-9. 
295.  Patel H, Marley SB, Gordon MY. Conventional Western blotting techniques 
will not reliably quantify p210BCR-ABL1 levels in CML mononuclear cells. 
Blood2007 Feb 1;109(3):1335; author reply 6.   279 
296.  Patel H, Marley SB, Gordon MY. Detection in primary chronic myeloid 
leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, 
CRKL, and GRB2. Genes Chromosomes Cancer2006 Dec;45(12):1121-9. 
297.  Maxwell SA, Kurzrock R, Parsons SJ, Talpaz M, Gallick GE, Kloetzer WS, 
et al. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of 
Philadelphia chromosome-positive cells from chronic myelogenous leukemia 
patients. Cancer Res1987 Mar 15;47(6):1731-9. 
298.  Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, et al. Chronic 
myeloid leukemia stem cells possess multiple unique features of resistance to 
BCR-ABL targeted therapies. Leukemia2007 May;21(5):926-35. 
299.  Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, et 
al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia 
by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S 
A2002 Aug 6;99(16):10700-5. 
300.  Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. 
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-
crisis CML. N Engl J Med2004 Aug 12;351(7):657-67. 
301.  Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, et al. Association 
between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent 
activation of LYN kinase. J Natl Cancer Inst2008 Jul 2;100(13):926-39. 
302.  O'Hare T, Eide CA, Deininger MW. Persistent LYN signaling in imatinib-
resistant, BCR-ABL-independent chronic myelogenous leukemia. J Natl Cancer 
Inst2008 Jul 2;100(13):908-9. 
303.  Dorsey JF, Cunnick JM, Lanehart R, Huang M, Kraker AJ, Bhalla KN, et al. 
Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from 
apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia2002 
Sep;16(9):1589-95. 
304.  Barber DL, Mason JM, Fukazawa T, Reedquist KA, Druker BJ, Band H, et 
al. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and 
association with CRK adaptor proteins. Blood1997 May 1;89(9):3166-74. 
305.  Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H, et al. Crkl is 
constitutively tyrosine phosphorylated in platelets from chronic myelogenous 
leukemia patients and inducibly phosphorylated in normal platelets stimulated by 
thrombopoietin. Blood1996 Dec 1;88(11):4304-13. 
306.  Reedquist KA, Fukazawa T, Panchamoorthy G, Langdon WY, Shoelson 
SE, Druker BJ, et al. Stimulation through the T cell receptor induces Cbl 
association with Crk proteins and the guanine nucleotide exchange protein C3G. J 
Biol Chem1996 Apr 5;271(14):8435-42. 
307.  Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV, et al. 
Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a 
complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol 
Chem1997 Apr 11;272(15):10248-53. 
308.  Sattler M, Salgia R, Shrikhande G, Verma S, Uemura N, Law SF, et al. 
Differential signaling after beta1 integrin ligation is mediated through binding of 
CRKL to p120(CBL) and p110(HEF1). J Biol Chem1997 May 30;272(22):14320-6. 
309.  Smit L, van der Horst G, Borst J. Sos, Vav, and C3G participate in B cell 
receptor-induced signaling pathways and differentially associate with Shc-Grb2, 
Crk, and Crk-L adaptors. J Biol Chem1996 Apr 12;271(15):8564-9. 
310.  Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, et al. 
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid 
leukemia cells irreversibly to apoptosis. Cancer Cell2008 Dec 9;14(6):485-93. 
311.  Burgering BM. A brief introduction to FOXOlogy. Oncogene2008 Apr 
7;27(16):2258-62.   280 
312.  Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes 
cell survival by phosphorylating and inhibiting a Forkhead transcription factor. 
Cell1999 Mar 19;96(6):857-68. 
313.  Komatsu N, Watanabe T, Uchida M, Mori M, Kirito K, Kikuchi S, et al. A 
member of Forkhead transcription factor FKHRL1 is a downstream effector of 
STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J Biol Chem2003 
Feb 21;278(8):6411-9. 
314.  Pellicano F, Cilloni D, Helgason GV, Messa F, Panuzzo C, Arruga F, et al. 
FOXO transcription factor activity is partially retained in quiescent CML stem cells 
and induced by tyrosine kinase inhibitors in CML progenitor cells. Blood2009 Dec 
1. 
315.  Rangatia J, Bonnet D. Transient or long-term silencing of BCR-ABL alone 
induces cell cycle and proliferation arrest, apoptosis and differentiation. 
Leukemia2006 Jan;20(1):68-76. 
316.  Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ, et al. Acute 
dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood2009 Oct 
15;114(16):3459-63. 
317.  Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. 
TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid 
leukaemia. Nature2010 Feb 4;463(7281):676-80. 
318.  Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell 
survival in the land of plenty. Nat Rev Mol Cell Biol2005 Jun;6(6):439-48. 
319.  Eskelinen EL. To be or not to be? Examples of incorrect identification of 
autophagic compartments in conventional transmission electron microscopy of 
mammalian cells. Autophagy2008 Feb 16;4(2):257-60. 
320.  He H, Dang Y, Dai F, Guo Z, Wu J, She X, et al. Post-translational 
modifications of three members of the human MAP1LC3 family and detection of a 
novel type of modification for MAP1LC3B. J Biol Chem2003 Aug 1;278(31):29278-
87. 
321.  Tanida I, Ueno T, Kominami E. Human light chain 3/MAP1LC3B is cleaved 
at its carboxyl-terminal Met121 to expose Gly120 for lipidation and targeting to 
autophagosomal membranes. J Biol Chem2004 Nov 12;279(46):47704-10. 
322.  Cantley LC. The phosphoinositide 3-kinase pathway. Science2002 May 
31;296(5573):1655-7. 
323.  Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-
kinases as regulators of growth and metabolism. Nat Rev Genet2006 
Aug;7(8):606-19. 
324.  Kaur H, Park CS, Lewis JM, Haugh JM. Quantitative model of Ras-
phosphoinositide 3-kinase signalling cross-talk based on co-operative molecular 
assembly. Biochem J2006 Jan 1;393(Pt 1):235-43. 
325.  Arico S, Petiot A, Bauvy C, Dubbelhuis PF, Meijer AJ, Codogno P, et al. 
The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the 
phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem2001 Sep 
21;276(38):35243-6. 
326.  Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular 
degradation. Science2000 Dec 1;290(5497):1717-21. 
327.  Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian 
cells. Int J Biochem Cell Biol2004 Dec;36(12):2445-62. 
328.  Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer 
Cell2007 Jul;12(1):9-22. 
329.  Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et 
al. Guidelines for the use and interpretation of assays for monitoring autophagy in 
higher eukaryotes. Autophagy2008 Feb 16;4(2):151-75.   281 
330.  Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. 
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and 
tumorigenesis. Cancer Cell2006 Jul;10(1):51-64. 
331.  Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, et al. 
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model 
of lymphoma. J Clin Invest2007 Feb;117(2):326-36. 
332.  Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. 
Contribution of ABL kinase domain mutations to imatinib resistance in different 
subsets of Philadelphia-positive patients: by the GIMEMA Working Party on 
Chronic Myeloid Leukemia. Clin Cancer Res2006 Dec 15;12(24):7374-9. 
333.  Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, et 
al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the 
World Health Organization proposal. Cancer2006 Mar 15;106(6):1306-15. 
334.  O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, 
et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year 
Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of 
Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic 
Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM) Blood 
(ASH abstracts)2008;Abstract: 186. 
335.  Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, et al. 
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after 
sequential treatment with multiple tyrosine kinase inhibitors. Blood2007 Dec 
1;110(12):4005-11. 
336.  Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in 
primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst2007 
May 2;99(9):680-93. 
337.  Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, et al. 
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous 
leukemia patients in complete cytogenetic remission on imatinib mesylate 
treatment. Blood2005 Mar 1;105(5):2093-8. 
338.  Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, 
Wong A, et al. Bcr-Abl expression levels determine the rate of development of 
resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res2005 Oct 
1;65(19):8912-9. 
339.  Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. 
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia 
in complete molecular remission for more than 2 years. Blood2007 Jan 
1;109(1):58-60. 
340.  Jorgensen HG, Allan EK, Graham SM, Godden JL, Richmond L, Elliott MA, 
et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to 
imatinib mesylate in vitro. Leukemia2005 Jul;19(7):1184-91. 
341.  Turner SD, Alexander DR. Fusion tyrosine kinase mediated signalling 
pathways in the transformation of haematopoietic cells. Leukemia2006 
Apr;20(4):572-82. 
342.  Sharma SV, Fischbach MA, Haber DA, Settleman J. "Oncogenic shock": 
explaining oncogene addiction through differential signal attenuation. Clin Cancer 
Res2006 Jul 15;12(14 Pt 2):4392s-5s. 
343.  Perez-Caro M, Gutierrez-Cianca N, Gonzalez-Herrero I, Lopez-Hernandez 
I, Flores T, Orfao A, et al. Sustained leukaemic phenotype after inactivation of 
BCR-ABLp190 in mice. Oncogene2007 Mar 15;26(12):1702-13. 
344.  Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, et al. 
Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces 
apoptosis in primary CML progenitors. Leukemia2010 Feb 4.   282 
345.  Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, et al. 
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid 
and durable cytogenetic responses and high transformation-free survival rates in 
chronic phase chronic myeloid leukemia patients with resistance, suboptimal 
response or intolerance to imatinib. Haematologica2010 Feb;95(2):232-40. 
346.  Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, et al. 
Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of 
downstream signaling pathways or increased growth suppression in CML 
progenitors. Leukemia2008 Apr;22(4):748-55. 
347.  Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R. Effects of 
dasatinib on SRC kinase activity and downstream intracellular signaling in 
primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res2008 
Dec 1;68(23):9624-33. 
348.  Tao WJ, Lin H, Sun T, Samanta AK, Arlinghaus R. BCR-ABL oncogenic 
transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene2008 
May 15;27(22):3194-200. 
349.  Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew 
AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human 
acute myelogenous leukemia stem cells. Leukemia2000 Oct;14(10):1777-84. 
350.  Neering SJ, Bushnell T, Sozer S, Ashton J, Rossi RM, Wang PY, et al. 
Leukemia stem cells in a genetically defined murine model of blast-crisis CML. 
Blood2007 Oct 1;110(7):2578-85. 
351.  Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr 
WR, et al. Detection of molecular targets on the surface of CD34+/CD38-- stem 
cells in various myeloid malignancies. Leuk Lymphoma2006 Feb;47(2):207-22. 
352.  Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, et al. 
Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, 
eliminates human acute myeloid leukemic stem cells. Cell Stem Cell2009 Jul 
2;5(1):31-42. 
353.  Feuring-Buske M, Hiddemann W, Buske C. [Pathogenesis and biology of 
leukemias]. Internist (Berl)2002 Oct;43(10):1179-89. 
354.  Frolova O, Wang RY, Korchin B, Watt JC, Cortes J, Frankel AE, et al. 
Targeting IL3 Receptor in Chronic Myeloid Leukemia. Blood (ASH 
abstracts)2009;Abstract: 2172. 
355.  Kim HP, Frankel AE, Hogge DE. A diphtheria toxin interleukin-3 fusion 
protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors 
from BCR/ABL positive acute leukemia. Leuk Res2010 Feb 4. 
356.  Roberts AW, He S, Bradstock KF, Hertzberg MS, Durrant STS, Ritchie D, 
et al. A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in 
AML Blood (ASH abstracts)2008;Abstract: 2956. 
357.  Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs 
leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet2009 
Jul;41(7):783-92. 
358.  Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting 
multiple kinase pathways in leukemic progenitors and stem cells is essential for 
improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A2006 Nov 
7;103(45):16870-5. 
359.  Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M. Specific 
inhibition of bcr-abl gene expression by small interfering RNA. Blood2003 Feb 
15;101(4):1566-9. 
360.  Li MJ, McMahon R, Snyder DS, Yee JK, Rossi JJ. Specific killing of Ph+ 
chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small 
hairpin RNA. Oligonucleotides2003;13(5):401-9.   283 
361.  Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, 
Duyster J, et al. Inhibition of bcr-abl gene expression by small interfering RNA 
sensitizes for imatinib mesylate (STI571). Blood2003 Sep 15;102(6):2236-9. 
362.  Myssina S, Helgason GV, Serrels A, Jorgensen HG, Bhatia R, Modi H, et 
al. Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib 
augments induction of apoptosis in Philadelphia-positive cells. Exp Hematol2009 
Feb;37(2):206-14. 
363.  Colosetti P, Puissant A, Robert G, Luciano F, Jacquel A, Gounon P, et al. 
Autophagy is an important event for megakaryocytic differentiation of the chronic 
myelogenous leukemia K562 cell line. Autophagy2009 Nov;5(8):1092-8. 
364.  Ito H, Daido S, Kanzawa T, Kondo S, Kondo Y. Radiation-induced 
autophagy is associated with LC3 and its inhibition sensitizes malignant glioma 
cells. Int J Oncol2005 May;26(5):1401-10. 
365.  Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of 
autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell 
Death Differ2004 Apr;11(4):448-57. 
366.  Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic 
cell death in malignant glioma cells by arsenic trioxide. Cancer Res2003 May 
1;63(9):2103-8. 
367.  Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of 
hydroxychloroquine and chloroquine use and the development of retinal toxicity. J 
Rheumatol1985 Aug;12(4):692-4. 
368.  Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. 
Hydroxychloroquine concentration-response relationships in patients with 
rheumatoid arthritis. Arthritis Rheum2002 Jun;46(6):1460-9. 
369.  Jorgensen HG, Copland M, Allan EK, Jiang X, Eaves A, Eaves C, et al. 
Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to 
granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib 
mesylate. Clin Cancer Res2006 Jan 15;12(2):626-33. 
370.  Heaney NB, Holyoake TL. Therapeutic targets in chronic myeloid 
leukaemia. Hematol Oncol2007 Jun;25(2):66-75. 
371.  Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal 
MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. 
Nature2009 Apr 16;458(7240):904-8. 
372.  Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al. 
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia 
and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin 
Invest2007 Sep;117(9):2408-21. 
373.  Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, et 
al. Hedgehog signalling is essential for maintenance of cancer stem cells in 
myeloid leukaemia. Nature2009 Apr 9;458(7239):776-9. 
374.  Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P, et al. Expansion 
of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway 
activation. Cancer Cell2008 Sep 9;14(3):238-49. 
375.  Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, et al. PML 
targeting eradicates quiescent leukaemia-initiating cells. Nature2008 Jun 
19;453(7198):1072-8. 
376.  Bhatia R, Snyder DS, Lin A, Arceo J, Seymour L, Deininger M, et al. A 
Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for 
Patients with CML in Cytogenetic Remission with Residual Disease Detectable by 
Q-PCR Blood (ASH abstracts)2009;Abstract: 2194.   284 
377.  Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of 
hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc 
Natl Acad Sci U S A2007 Mar 27;104(13):5431-6. 
378.  Jensen PO, Mortensen BT, Hodgkiss RJ, Iversen PO, Christensen IJ, 
Helledie N, et al. Increased cellular hypoxia and reduced proliferation of both 
normal and leukaemic cells during progression of acute myeloid leukaemia in rats. 
Cell Prolif2000 Dec;33(6):381-95. 
379.  Ninomiya M, Abe A, Katsumi A, Xu J, Ito M, Arai F, et al. Homing, 
proliferation and survival sites of human leukemia cells in vivo in immunodeficient 
mice. Leukemia2007 Jan;21(1):136-42. 
380.  Takeuchi M, Kimura S, Kuroda J, Ashihara E, Kawatani M, Osada H, et al. 
Glyoxalase-I is a novel target against Bcr-Abl(+) leukemic cells acquiring stem-like 
characteristics in a hypoxic environment. Cell Death Differ2010 Feb 5. 
381.  Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive 
oxygen species are essential for autophagy and specifically regulate the activity of 
Atg4. EMBO J2007 Apr 4;26(7):1749-60. 
382.  Greer EL, Brunet A. FOXO transcription factors at the interface between 
longevity and tumor suppression. Oncogene2005 Nov 14;24(50):7410-25. 
383.  Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, et al. 
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic 
oxidative stress. Cell2007 Jan 26;128(2):325-39. 
384.  Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, et al. The 
energy sensor AMP-activated protein kinase directly regulates the mammalian 
FOXO3 transcription factor. J Biol Chem2007 Oct 12;282(41):30107-19. 
385.  Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and 
growth control in tumour suppression. Nat Rev Cancer2009 Aug;9(8):563-75. 
386.  Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, et 
al. p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a 
switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ2009 
Sep;16(9):1203-14. 
387.  Chiacchiera F, Simone C. Inhibition of p38alpha unveils an AMPK-FoxO3A 
axis linking autophagy to cancer-specific metabolism. Autophagy2009 
Oct;5(7):1030-3. 
388.  Matrone A, Grossi V, Chiacchiera F, Fina E, Cappellari M, Caringella AM, 
et al. p38alpha is required for ovarian cancer cell metabolism and survival. Int J 
Gynecol Cancer Feb;20(2):203-11. 
389.  Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay 
N. Akt activates the mammalian target of rapamycin by regulating cellular ATP 
level and AMPK activity. J Biol Chem2005 Sep 16;280(37):32081-9. 
390.  Papandreou I, Lim AL, Laderoute K, Denko NC. Hypoxia signals autophagy 
in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell 
Death Differ2008 Oct;15(10):1572-81. 
 
 